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ii 
Abstract 
 
 
Hepatitis C Virus (HCV) is a global health problem, with over 170 million 
infected individuals worldwide. 70-80% of infected individuals develop 
progressive disease, and approximately 2% of these acquire hepatocellular 
carcinoma (HCC). HCV entry is dependent on tetraspanin CD81, scavenger 
receptor BI, and tight junction proteins claudin-1 and occludin.  
 
Tetraspanins are involved in multiple biological functions including cell-ECM 
adhesion and motility. An actin polymerization-dependent cell spread was 
observed upon ligation of CD81 on hepatoma cells. Importantly, HCV infection 
perturbed CD81-dependent cell spread, suggesting HCV infection may 
modulate CD81 function in hepatoma cells.  
 
Functional assays demonstrated that CD81 expression and HCV infection 
promote hepatoma cell motility. These findings allude to a link between HCV 
infection and associated HCC development. 
 
Establishment of a chronic infection demonstrates that HCV can escape from 
the host adaptive immune responses. We developed an in vitro cell culture 
system to monitor viral transmission in the presence of neutralizing antibodies 
(nAb). Separation of producer and target cells ablated nAb resistant 
transmission, suggesting that cell-cell contact was essential. Furthermore nAb 
resistant transmission was dependent upon all four co-receptors. These 
observations confirm HCV immune evasion by cell-to-cell transfer and have 
major implications for anti-glycoprotein targeted therapies. 
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1. Introduction  
 
1.1 History and Epidemiology of HCV 
 
During the 1970’s scientific advances were made enabling serological detection of 
hepatitis A and B virus infection (35, 136), it quickly became apparent that at least 
one other agent was responsible for hepatitis arising from blood transfusion, this was 
commonly referred to as non-A non-B hepatitis (NANBH) (137). Despite a large 
amount of research it wasn’t until over a decade later that Hepatitis C Virus (HCV) 
was formerly identified. Choo and colleagues constructed a cDNA library from serum 
containing the NANBH agent isolated from infected chimpanzee plasma and 
successfully isolated a clone that specifically hybridized with RNA found only in 
NANBH infected chimpanzees and encoded a protein that bound antibodies from 
NANBH infected patients (206, 259). These findings enabled the establishment of 
assays to screen for HCV in blood, and since introducing these tests in the early 90’s 
the risk of transmission through blood transfusion in the developed world is now 
extremely low (62).  
 
HCV is endemic worldwide and according to figures from the WHO there are an 
estimated 170 million people infected making up approximately 3% of the worlds 
population.  Prevalence varies greatly depending on geographical location. Areas 
with the highest recorded prevalence are in Africa and Asia; Egypt for example has a 
prevalence of 22% (148). Prevalence in North America, Japan and Western Europe 
are lower ranging from 0.6% in Germany (363) to 2.2% in Italy (11, 430). It is likely 
that these values under estimate the burden especially in the developing world where 
 
 
2 
there is less data available. In some areas the true burden may not yet be realized 
due to the asymptomatic nature of the disease during both the acute and early 
chronic phases of infection, preventing detection until late in disease progression (11, 
430). Interestingly in different geographical locations the range in prevalence 
determined by age varies considerably. In North America for example the highest 
prevalence is among people between the age of 30 and 49 (12), this differs from 
Japan and Italy where the highest prevalence is among the over 50’s (11). These 
differences are consistent with young adults in North America being at greatest risk 
around 20 years ago whilst in Japan the greatest risk was many years before this.  
Like Japan, in Egypt the highest prevalence is in the over 50’s age group, however 
unlike Japan the prevalence in the younger age groups is also extremely high (1, 11). 
 
HCV is the sole member of the genus Hepacivirus within the Flaviridae family. This 
family includes yellow fever and classical swine fever viruses, all of which are 
enveloped viruses containing a single stranded positive sense RNA genome. HCV is 
genetically very diverse with 7 major genotypes and many different subtypes (166, 
442). Subtypes vary between 20 and 25% whilst genotypes can vary by 30% at the 
nucleotide level (440, 443). The geographical prevalence and diversity of the 
genotypes differ giving clues as to the origin of the virus (441).  Genotype 1a, 1b and 
3a are the most prevalent genotypes in the western world (440). Genotypes found in 
Africa and South-East Asia associate with specific geographical areas and are much 
more diverse. The genetic diversity of these viral strains suggest that the virus has 
been present in human populations in these areas for a long time and that it is only in 
recent history that the virus has transmitted to the western world (323).  Genotypes 1, 
2 and 4 are found specifically in sub Saharan Africa and genotypes 3 and 6 found in 
 
 
3 
South-East Asia (445). As for the origin of the 6 genotypes there is no evidence of 
HCV or HCV-like virus in old world ape or monkey species as observed for HBV 
(301). Interestingly though a distantly related virus named GB virus B has been 
reported to infect tamarins and other new world primate species (441, 447). Further 
studies are needed to understand the origin of HCV and its relation to GB virus B. 
 
Risk factors of infection vary geographically and have altered over time. In the 
developed world a major source of transmission was through increased use of blood 
products in medical practices, as previously explained this is no longer a risk due to 
routine screening of donated blood (62). Since the 1960’s injection drug abuse has 
become the primary route of transmission (12). Other lower risk factors associated 
with HCV transmission include perinatal, sexual and occupational transmission. 
There is little evidence for risk associated with sexual transmission and the data from 
occupational transmission suggests a low risk (11). Perinatal transmission occurs in 
approximately 2.7-8.4% of cases, interestingly this value increases significantly in 
mothers co-infected with HIV (139, 477). However in the developing world the picture 
is very different with major risk associated with contaminated blood products a result 
of financial constraints limiting screening (11). Another major risk factor in the 
developing world is through vaccination(s) with contaminated needles. Two studies in 
India demonstrated an association between HCV infection and visits to unlicensed 
medical practitioners (86, 305). In Egypt the majority of HCV infections are 
associated with a nationwide vaccination program against Schistosomiasis that was 
carried out between 1960 and 1987 (148).  Contaminated needles in vaccination 
programs are likely to be the cause of infection in some developed countries where 
prevalence is highest in older populations (430). As for transmission of the virus in 
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Africa and Southern East Asia before the use of modern medicine it is hypothesized 
that transmission was and may still occur through tribal scarification practices or 
through insect vectors such as mosquito’s or ticks. However, to date there is no 
substantial evidence to support these theories (430).  
1.2 Disease progression and current treatment 
 
1.2.1 Disease progression 
 
HCV is unusual compared to other flaviviruses due to its capability to persist in 
infected individuals. Between 75 and 85% of individuals infected with HCV develop a 
persistent infection (204).  
 
Due to the asymptomatic nature of early infection there is little data on acute 
infection, most of our current knowledge has been acquired from prospective studies 
of transfusion patients, chimpanzee studies or though a number of acute cohorts 
largely consisiting of injection drug users (IDUs) or health care workers (HCWs) (361, 
392, 413, 492). Acute resolving infection typically lasts between 10 and 12 weeks. 
RNA can be detected within the first two weeks post exposure and rises to a peak of 
between 10^5 and 10^7 IU/ml at 6 to 10 weeks post infection, this often comes 
shortly before a peak in serum alanine aminotransferase (ALT) levels, a marker for 
liver injury (8, 135, 300, 476). The production of anti-HCV antibodies is more 
variable, with most patients developing anti-HCV between 7 and 8 weeks post 
infection (349, 369). The presence of neutralizing antibodies (nAbs) is critical in 
ensuring successful clearance of many viruses (61). Although there are a few 
examples where a nAb response during acute HCV infection has associated with 
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viral clearance (29, 268, 326, 377), the majority of studies show nAbs appearing after 
acute infection indicating a more dominant role for nAbs in controlling chronic 
infection (290). In contrast a cellular immune response is essential to ensure viral 
clearance. HCV specific T-cell responses are detectable between 4 to 8 weeks post 
infection. A correlation has been demonstrated on many occasions between a robust 
CD8+ and CD4+ T-cell response and viral clearance (97, 242, 271, 437, 476). In 
non-resolvers the response is often weak or not detected at all.  Although most 
patients do not exhibit any symptoms, evidence suggests that when symptoms do 
occur there is an increased likelihood for successful viral clearance (9, 159).  
 
The acute stage of a chronic infection with respect to antibody response, RNA level 
and ALT levels cannot be distinguished from the acute stage of resolving patients 
(204). If after 6 months HCV RNA levels are still detectable the patient is reported to 
have developed a chronic infection (204). RNA levels in the blood remain stable 
although they can vary greatly between donors and are not predictive of disease 
outcome (544). ALT levels decrease after the initial boost during acute infection and 
in the majority of cases levels remain elevated above normal and fluctuate during the 
course of chronic infection, again ALT was found not to be a good predictor of liver 
disease status (178). Some patients with a chronic infection have a mild non-
progressive disease whilst 20-30% develop complications including cirrhosis and end 
stage liver disease, 2.5% of these patients develop hepatocellular carcinoma (HCC) 
(6, 10, 71). HCV associated liver damage is explored in more depth in chapter 4. 
Given the diversity of HCV it is surprising that large variations in clinical outcomes do 
not occur, in fact all genotypes are capable of initiating a chronic infection that can 
eventually lead to the development of liver disease and HCC. Although, as more 
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clinical data is collected differences between genotypes are becoming apparent. A 
number of studies looking at European cohorts have revealed that genotype 1 is 
more likely than genotypes 2 and 3 to firstly establish a persistent infection and 
secondly once a persistent infection is established to cause a greater degree of liver 
disease (311, 395, 542). A strong association between development of liver steatosis 
and genotype 3 infection has also been demonstrated (2, 405). It is believed that a 
block in lipoprotein secretion from hepatocytes causes this phenotype (426). More 
work is needed to validate and determine the mechanism of these observed 
differences.  
 
Although the primary disease symptoms are liver related, chronic infection is also 
associated with other extra-hepatic conditions suggesting the liver is not the only 
reservoir for infection. Examples of which include auto-immune diseases such as 
cryoglobulineimia and glomerulonephritis (129) as well as B-cell non-Hodgkin 
lymphoma (562) and neurological conditions including cognitive disorders (193). Our 
laboratory has previously demonstrated HCV association with B-lymphocytes aiding 
infectivity in vitro (455) and we are currently investigating brain tissue as a further 
reservoir for HCV  (142)(Nicola Fletcher, submitted).  
1.2.2 HCV immune escape  
 
HCV employs a number of mechanisms to hinder both the innate and adaptive 
immune responses allowing a persistent chronic infection within the host (48, 182). 
Briefly the intracellular innate immune response to viral infection is as follows; upon 
viral entry into host cells Pathogen Recognition Receptors (PRR) present in the 
cytoplasm identify signatures of viral infection such as single and double stranded 
RNA, these are termed Pathogen Associated Molecular Patterns (PAMPs) (409). In 
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hepatocytes the predominant PRRs associated with HCV infection are Toll-like 
receptor 3 (TLR-3) and RIG-I (276, 461, 548). Both of these PRR’s recognize HCV 
double stranded RNA and induce a signaling cascade leading to the activation of 
latent cellular transcription factors Interferon regulatory factor IRF (3) and nuclear 
factor NFκB (280, 397). These transcription factors induce Interferon-beta (IFNβ) 
gene transcription. IFNβ is then secreted from the infected cells and functions in an 
autocrine and paracrine manner by engaging type I IFN receptors on the cell surface 
eliciting the Jak-STAT pathway (412).  This pathway results in the formation of 
Interferon stimulated gene factor-3 (ISGF3) that enhances transcription of Interferon 
stimulated genes (ISGs). ISGs are responsible for antiviral actions within the cell 
(113, 153). Predominant anti-viral effecter genes include Protein kinase receptor 
(PKR) that inhibits translation of viral RNA (512) and 2’-5’ oligoadenylate synthetase 
(OAS) that cleaves HCV genomic RNA into non-functional products, inhibiting viral 
replication (185). Other ISGs include p56, IRF7 and IRF3 (48). IRF7 and 3 induce 
transcription of IFNα gene leading to a positive feedback loop increasing IFN 
response (20). IFNα is also responsible for influencing the adaptive immune 
response (412).  For HCV to successfully persist in its host it needs to be able to 
overcome these innate immune response.  A number of HCV proteins including 
Core, NS3/4A protease and NS5A, are implicated in hindering stages of this immune 
response. NS3/4A for example blocks the RIG-I signaling pathway and completely 
ablate TLR-3 signaling (147, 276). Core protein has been shown to induce SOCS1 
and SOCS3 expression; that are negative regulators of the Jak-STAT pathway (49). 
NS5A protein and glycoprotein E2 have both been implicated in inhibiting anti-viral 
effecter genes. For example E2 can bind PKR inhibiting its function (367, 472) and 
NS5A has been shown to inhibit PKR function (378) whilst also repressing OAS 
 
 
8 
functions (464). NS5A expression has also been shown to induce IL-8 expression; an 
inhibitor of IFNα induced ISG expression (387).  
 
HCV has also evolved to escape from cellular and adaptive immune responses. For 
example HCV core protein has been implicated as an agent capable of inhibiting 
immune cells directly. An in vitro study reported that HCV core protein inhibits T-cell 
activation by interacting with complement factor gG1qR (244, 509). Of note core 
protein from genotype1a virus was used in this study and the results could not be 
repeated in a separate study with core from genotype 1b, indicating a possible 
genotype specific function (182, 289). As yet this effect has not been confirmed in 
vivo.  As will be explained later HCV glycoprotein E2 binds co-receptor tetraspanin 
CD81 (384). NK cell cytopathic function is inhibited upon engagement of cell surface 
expressed CD81 with recombinant E2 protein, suggesting a possible mechanism for 
HCV to perturb the host immune response (105, 486). Controversy over whether 
these studies can be re-produced when E2 is expressed on a viral particle is 
currently under debate (549). A further example is the induction of escape mutants to 
nAb’s and T cell epitopes. A single infected host contains a quasispecies (closely 
related species of virus subjected to genetic mutations, competition and selection) 
population of HCV (117). A quasispecies population develops for two main reasons; 
firstly HCV replicates rapidly allowing many opportunities for mutations to occur and 
secondly HCV has a single strand positive sense genome that is replicated by an 
RNA dependent RNA polymerase (RdRp). RdRp does not have proof reading ability 
and permits rapid evolution of the virus (37). Neutralizing antibodies have been 
shown to target the hypervariable region 1 (HVR-1) of glycoprotein E2 and mutations 
have been detected in this region in human and chimpanzee studies that confer 
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escape from immune pressures (434, 450, 497). Mutations in regions inhibiting CTL 
CD8+ T cell responses have also been detected in both chimpanzees and humans 
suggesting another possible mechanism of viral escape (73, 131, 500, 505). As will 
be discussed later HCV particles associate with lipoproteins (14, 351). This has been 
suggested as an additional mechanism employed by HCV to disguise the virion from 
the immune system reducing the effectiveness of nAb’s. Lastly recent work published 
from our laboratory demonstrates that HCV can transmit in co-culture in the presence 
of nAbs capable of neutralizing cell free virus, suggesting that HCV may transmit 
from cell-to-cell via a novel route reducing exposure to the host immune system 
(480). This is discussed in Chapter 5.  
1.2.3 Treatments 
 
Standard treatment for HCV infection is a course of pegylated Interferon (IFN) and 
Ribavarin. This can be extremely effective (up to 90%) if treatment is started within 
the acute phase of infection (221, 510). After onset of chronic infection efficacy drops 
and varies considerably depending on the infecting genotype. 70-80% of individuals 
with genotypes 2 and 3 respond to Interferon based therapy compared to only 40-
50% of patients infected with genotype 1 (181, 267, 303). The mechanism of action 
of IFN and Ribavarin based therapy is not fully understood. IFN is likely to reduce 
infection at both the viral level by inducing Interferon stimulated genes (ISGs) that 
have direct anti-viral functions as well as promoting the innate and adaptive immune 
response (38, 425, 479). Ribavarin is a synthesized guanosine that has previously 
been demonstrated to inhibit other RNA and DNA virus infections (138). It is thought 
that its main mechanism of action against HCV may be through increasing 
mutagenesis of viral RNA and thereby reducing specific infectivity (550). Limitations 
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in efficacy and severity of side effects associated with the current therapy make it 
increasingly important to find new more effective therapies.  
 
Many alternative therapies are being explored and some of which have/are currently 
undergoing clinical trials with promising results (109, 428). Examples of these include 
drugs targeting viral enzymes including the NS3-4A viral protease and NS5B RNA 
polymerase (109, 261, 265, 394), these became promising targets after there 
structures were defined in 1996 and 1999 respectively (4, 56, 243).  NS3-4A is a 
particularly attractive target not only because of its important role in the HCV lifecycle 
but also because of its role as an inhibitor of the innate immune response as 
previously described (147, 276).  Our laboratory is currently working with a small 
molecular inhibitor of SR-BI, a co-receptor for HCV entry, this compound is soon to 
be trialed here in Birmingham. More information on this inhibitor is presented later in 
chapter 5. Further immuno-modulating agents have also been considered as 
therapeutics including TLR-7 and TLR-9 antagonists. Toll-like receptors are present 
on a number of immune cells and recognize microbial agents inducing an immune 
response primarily involving the induction of IFN whilst also priming an adaptive 
immune response (465). TLR-7 and TLR-9 in particular recognize single stranded 
RNA (50). Antagonists to TLR-7 have been trialed against HCV infection with 
promising results (520). Complications have arisen with many of the more potent 
anti-replicase agents including a rapid induction of viral escape mutants (258, 279, 
329). It is therefore hypothesized that a combination of therapies targeting both virus 
and host will be required to overcome this problem in the future (109).   
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As yet there is no effective vaccine available against HCV, this has been due 
predominantly to the lack of knowledge on mechanisms of viral clearance, the 
evidence for re-infection of both humans and chimpanzees as well as lack of 
definitive evidence on the efficacy of neutralizing antibodies in vivo. Recent studies 
have given more hope into the eventual production of an effective vaccine. Firstly 
over time increasingly more information has become available on patients with 
resolving infection increasing our understanding of what constitutes an effective 
immune response (101, 271, 437). Secondly patients that are re-infected with HCV 
are often protected against the development of a chronic infection (266, 322). Lastly 
neutralizing antibodies have been detected that can cross-neutralize across different 
genotypes suggesting that a broad spectrum vaccine may be possible and 
furthermore a small number of studies have reported a correlation between the 
induction of neutralizing antibodies in the early stages of infection and viral clearance 
(29, 268, 326, 377). Supporting observations in humans, chimpanzee studies using 
an E1E2 peptide vaccine, although unable to stop re-infection, were able to prevent 
progression to a chronic infection in the majority of subjects tested (84). Chronic 
infections create the greatest burden of HCV disease both financially and to the host 
therefore the ability to reduce this occurrence would be extremely beneficial. More 
recent studies are looking at methods to develop a vaccine that will elicit both the 
production of cross neutralizing antibodies as well as inducing a broad cellular 
response, responses that have previously been associated with viral clearance (65, 
207, 282). Although trials in animal models have been relatively successful, human 
trials are needed to determine their true efficacy. The use of vaccines as a 
therapeutic treatment is also being investigated in the field, the theory behind this is 
that a vaccine may be able to boost the immune system and therefore increase 
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efficacy of IFN based therapies (207). This theory is based on evidence that 
increased immune response prior to treatment increases the likelihood of success 
(34, 103, 347).  
 
The absence of an effective prophylactic or vaccine for HCV together with the virus’s 
propensity to cause considerable liver damage after long term infection makes it 
absolutely crucial that more research is done to fully understand HCV infection.  
 
1.3 Tools available to study HCV in vitro 
 
An in vitro system to study the full viral life cycle, from entry through to release of 
infectious viral particles has only recently become available. Although a partial 
sequence of HCV was identified in 1989 (85), it wasn’t until 1996 that the full HCV 
genome sequence was completed using sequences isolated from patient H 
(Huchinson 1977), a patient infected with a genotype 1a virus (249). With this 
knowledge a model cDNA template was constructed (H77), and delivery of the 
transcribed RNA into the liver of chimpanzee’s resulted in viral replication (248, 526). 
This became a model system allowing the study of immune response and viral 
evolution during infection (58). Unfortunately these clones were unable to replicate 
and assemble infectious particles in cell culture. 
 
Although a number of techniques have been used to study HCV entry the most 
effective and widely used system is the retroviral pseudoparticle system (HCVpp). 
Pseudoparticles comprise of an HIV capsid with HCV glycoproteins. HCVpp allow 
glycoprotein dependent entry to be studied and have allowed considerable advances 
to be made in determining host cell entry receptors (30, 121, 208). These 
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pseudoparticles can only undergo one round of replication and cannot transmit to 
other cells.  
 
A critical development in the race to find an in vitro culture system to study the full 
viral lifecycle was made by Lohmann et al., in 1999. Lohman and colleagues 
demonstrated replication of sub-genomic replicons in cell culture (292). The 
development of the replicon system has been a critical tool for increasing our 
understanding of HCV genome replication and a screening tool for the discovery of 
new anti-viral agents (26, 47, 381). Although full-length replicons replicated efficiently 
no infectious viral particles were produced and it was feared that Huh-7 cells may be 
unable to assemble or release virus particles (382). Cell culture adapted mutations 
were identified allowing increased replication efficacy in vitro but unfortunately the 
mutations severely reduced infection in vivo (283, 291). 
 
It wasn’t until 2005 that a full-length virus with no cell culture adaptive mutations was 
identified and demonstrated to replicate and assemble virus particles in cell culture 
(283, 499, 560). This was termed HCVcc, cc representing cell culture.  JFH-1 
(genotype 2a) was isolated from a Japanese patient with fulminant hepatitis and had 
previously been shown to replicate in the form of a sub-genomic replicon without any 
amino acid changes (237). Wakita and colleagues were the first to demonstrate that 
the full length JFH-1 genome could replicate in Huh-7 hepatoma cells and importantly 
also in the chimpanzee model (499). Chimera’s of JFH-1 consisting of core to NS2 of 
J6 (genotype 2b) or H77 (genotype 1a) with the remaining non-structural proteins of 
JFH-1 were developed and were reported to be infectious in chimpanzees and uPA-
SCID mice containing human liver grafts. Importantly the virus remained infectious in 
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cell culture after in vivo propagation (284, 545). The JFH-1 HCVcc system is the 
basis for much of our research today and recent advances have led to the production 
of numerous JFH-1 chimeric viruses representating the 7 major HCV genotypes 
allowing genotype specific comparisons to be made (166).  
 
HCVcc replicates most efficiently in the Huh-7 hepatoma cell line (47). Hepatocytes 
in the liver are highly polarized and tight junction proteins claudin-1 and occludin 
have been identified as critical co-receptors for HCV entry (133, 385). Huh-7 cells do 
not polarize and therefore may not be the most appropriate representative model to 
use. Our laboratory is currently working with a polarised hepatoblastoma cell line 
HepG2, these cells exhibit hepatocyte polarity and support viral replication but have a 
low permissivity to HCV infection making them challenging to use (319, 320). To 
further in vitro studies a highly permissive cell line that exhibits hepatocyte polarity is 
needed. A model system utilizing primary hepatocytes would be ideal but because of 
difficulties in accessing and processing human liver tissue very little work has been 
reported with primary cells. Recent developments in this area have involved the 
establishment of new techniques to propagate primary hepatocytes for longer periods 
of time before de-differentiation (229, 241). This is an area of research that is still in 
its preliminary stages and needs to be developed in the future to allow greater 
accessibility for more laboratories to use these techniques.   
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1.4 HCV lifecycle 
 
1.4.1 Genome and replication  
 
HCV contains a 9.6kb genome consisting of a long Open Reading Frame (ORF) 
flanked by Non Translational Regions (NTR’s) (285). A highly conserved region of 
the 5’NTR represents the internal Ribosome Entry Site (IRES) and mediates a CAP 
independent translation of the ORF (57, 357, 488). The ORF encodes a polyprotein 
of 3011 amino acids long consisting of a structural and a non-structural region 
(Fig.1.1). Host cell signal peptidases cleave the structural proteins and also p7/NS2 
junction, whereas the non-structural proteins (NS2 to NS5B) are cleaved by two viral 
enzymes, NS2-3 and NS3-4A (285). 
Figure 1.1: HCV genome and gene products.  
The top image depicts the genome organization. Translation of the polyprotein is 
dependent on the IRES located in the 5’UTR. The polyprotein contains structural 
(gold) and non-structural (green) proteins. Host and viral proteases cleave the 
polyprotein producing 10 viral proteins. The lower image depicts the proteins within a 
membrane in the Endoplasmic reticulum (ER).  Image based on (285, 374). 
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The structural region comprises the highly basic core protein and two glycoproteins 
E1 and E2 (285). Core protein has a hydrophilic N terminal (Domain I) that is able to 
bind RNA and is believed to be important in the packaging of the nucleocapsid, this 
domain is also responsible for homotypic interactions between core proteins allowing 
the formation of larger multimeric structures of core resembling nucleocapsid like 
structures in vitro (257, 316). Regions of the hydrophobic C terminal (Domain II) 
anchor core into the ER and allow interactions with lipid droplets (LD) (128, 165, 395, 
404). This region also contains a cystein (Cys 128) that has been identified to have a 
role in particle production and has most recently been shown to form a disulphide 
bond between core monomers, allowing stabilization of the capsid (260, 339). As well 
as being structurally important for the virus, core protein also functions in many other 
aspects of the viral lifecycle including immune evasion strategies as previously 
described and viral assembly through the modulation of lipid droplets as will be 
described in more detail later on (49, 263). 
 
Post translation, the E1E2 glycoproteins (consisting of c-terminal transmembrane 
and N-terminal ectodomains) are trans-located to the ER where they are cleaved 
from the poly-protein by host signal proteases and retained in the ER by restriction 
signals located in their transmembrane domains (92, 94, 123, 143). The 
transmembrane domains also function to initiate formation of stable non-covalent 
heterodimers (94, 110). A number of N-linked glycosylation sites have been identified 
on the E1E2 proteins. Glycosylation is thought to occur post translation to insure 
correct protein folding (124, 125, 162, 327). Viral glycoproteins have two major 
functions in the viral lifecycle. Firstly they are involved in viral attachment and have 
been shown to directly interact with co-receptors CD81 (384) and SR-BI (418). 
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Secondly they are thought to function as membrane fusion proteins coordinating pH 
dependent fusion of the viral and cell membranes in the early endosome permitting 
release of the viral genome into the cytoplasm of the host cells (208, 485, 496). 
Sequence comparison with other flaviviruses revealed that HCV E2 glycoprotein was 
likely to contain a class II fusion peptide (522) and a number of laboratories have 
since identified the C-terminus of E2 as being important for cell fusion (144, 286). 
Furthermore a number of regions in E1 have been discovered that are important for 
cell fusion (156, 275). A recent study showed evidence for a functional role of E1 in 
membrane fusion by measuring biophysical changes in membranes after interaction 
with an E1 peptide representative of a previously identified fusion domain (375).  It is 
now widely believed that a number of regions are required for HCV-cell fusion events 
and this is likely to involve both E1 and E2 proteins, although the mechanism is still 
under debate (120, 130, 269, 371). 
 
p7 is an integral membrane protein that is primarily located in the ER (67), it consists 
of two hydrophobic transmembrane domains connected by a short basic loop that is 
highly conserved between genotypes (173, 456). p7 forms oligomers and electron 
microscopy studies have revealed the structure of p7 hexamers (172, 296) and 
heptamers (91). These oligomeric structures form cation selective ion channels in 
lipid bilayers (172, 368). As such p7 has been categorized as a member of a group of 
viral permeability altering proteins called viroproteins; other examples include M2 
from Influenza, vPu from HIV-1 and M from dengue virus (90). A number of in vitro 
studies have demonstrated an essential role for p7 in virus assembly and release this 
is supported by work showing that p7 is essential for infection in chimpanzees (230, 
410, 456). Woznik and colleagues demonstrated that intracellular virus particles have 
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greater acid sensitivity compared to extra-cellular virions, suggesting a role for p7 in 
protecting maturing virions from acidic conditions by removing H+ ions from 
intracellular membranes (518).  Inhibitors for p7 ion channel have been effective in in 
vitro studies making p7 an attractive therapeutic target for the future (170, 171, 457).  
 
NS2 has been shown to have multiple functions in the viral life cycle and like p7 has 
been demonstrated to be critical for viral assembly (112, 225, 230). NS2 is a 
hydrophobic protein with several transmembrane domains in the N-terminal region 
(414, 525). NS2 is stimulated by cofactor NS3 and NS2-3 cysteine protease 
(Comprising of the C-terminal of NS2 and the N terminal of NS3 (364, 475)) cleaves 
the NS2/3 junction allowing NS3-4A serine protease to cleave all the downstream 
sites (364, 475). The cleavage of the NS2/3 junction is required for replication of full-
length replicons (506) and also replication in chimpanzees (250). The N-terminal 
transmembrane domain of NS2 is necessary for virus assembly (225) and the C 
terminal protease domain but not its catalytic ability has also been demonstrated to 
be necessary for virus assembly (230). 
 
NS3 to NS5B proteins are all required for viral replication although due to the small 
size of the viral genome it is likely that most viral proteins are multifunctional (338). 
RNA viruses replicate their genome associated with altered cytoplasmic membranes 
or membrane webs. Replication of HCV has been demonstrated to occur in 
association with cytoplasmic membranous webs in a distinct subcellular replication 
complex (RC) compartment (5, 165, 332). The positive sense RNA is translated to 
make new viral proteins as well as acting as a template for an intermediate negative 
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RNA strand that forms the template for the production of multiple sense genomes 
that are packaged into new virus particles (285).  
 
NS4A is a cofactor for NS3, the presence of NS4A increases the stability of NS3 as 
well as allowing the cleavage of NS4B-NS5A junction (516). The C terminal region of 
NS4A is required for cleavage of the NS3-NS4A and NS5A-NS5B junctions (134). 
Membrane anchorage of NS3-NS4A has been shown to occur through the N 
terminus of NS4A (516). As previously discussed the NS3-NS4A protease also 
functions in immune evasion by blocking the RIG-I and TLR-3 signaling pathways 
(147, 276). Recent work has discovered that NS4A is also involved in recruiting 
creatine kinase B (ATP generating enzyme) to the replication complex (186). The 
initiation of the membrane web formation is down to NS4B protein (128). NS4B is an 
integral membrane protein that is thought to contain four transmembrane domains 
and interacts with other non-structural proteins as well as viral RNA (167). Recent 
work implies that NS4B may also play a role in viral assembly (231). 
 
NS5A is a three domain protein that is found in hypo and hyper phosphorylated forms 
(469). This protein is involved in a number of stages of the viral lifecycle, the 
multifunctional capacity of NS5A is most likely down to its ability to interact with 
numerous host proteins (81, 82, 473, 474). NS5A is a critical member of the 
replication complex and all three domains are able to bind viral RNA, it has been 
suggested that part of its role in replication is to enhance NS5B activity (82, 146). As 
previously discussed NS5A is also important for HCV immune evasion strategies by 
effecting IFN sensitivity (378, 387, 464). Recently NS5A has also been shown to be 
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involved in viral particle assembly as discussed later on (473). The remaining 
nonstructural domain, NS5B codes for the RNA dependent RNA polymerase (393).  
1.4.2 Particle assembly and egress. 
The exact mechanism by which viral particles are formed and released from the cell 
is currently not well understood. Clues into the assembly process of HCV came from 
observations that virus isolated from either in vitro studies or from serum of infected 
patients contained particles of varying densities (74, 234, 285, 351).  Andre et al., 
proposed that low density HCV particles associate with lipoproteins, he termed these 
lipoviral particles (LVP) and likened them to very low density lipoprotein (VLDL) (14). 
LVPs are enriched with high levels of triglycerides and both apolipoprotein B (Apo B) 
and apolipoprotien E (Apo E) have been detected in the viral RNA containing low 
density fractions (14, 215, 351). Recently Merz et al., established a high affinity 
purifaction assay using flag tagged viral particles, permiting further investigation of 
cell culture derived viral particle compostion.  The lipid compositon of the viral 
particles was found to be distinct from the host cell membrane, predominantly 
consisting of Cholesteryl esters as well as high levels of Apo E and detectable levels 
of cholesterol (324).  
 
Particle assembly is believed to occur on/near lipid droplet associated membranes 
that are derived from the ER (27, 331, 429).  Nucleic acid association with core is 
vital for nucleo-capsid formation and this association may initiate viral particle 
formation (257). The C terminal region of HCV core protein is responsible for core 
proteins association with lipid droplets and ER membranes (128, 165, 404). 
Extensive work by McLauchlan and colleagues has demonstrated that core is 
released from the ER and loaded onto lipid droplets during HCV infection and 
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importantly this correlates with virion production (53, 315, 317). Furthermore, core 
protein induces the accumulation of lipid droplets and modulates their distribution in 
infected cells (52). Lipid droplets move through the cytoplasm and interact with the 
ER facilitating lipid and protein transport between organelles. Miyanari et al., 
demonstrated that core recruits non-structural proteins and replication complexes to 
lipid droplets associated with the ER, facilitating particle assembly (331).  
 
We have previously acknowledged that non-structural proteins p7, NS2 and NS5A 
are involved in viral assembly. Work on p7 predominantly focused on protein 
structure (91, 172, 296) however, recent research has demonstrated that p7 
modulates the pH of membrane structures involved in viral production, most likely 
providing protection for the immature virus from acidic conditions (518). As yet the 
mechanism of NS2 function in assembly is not well understood (225, 230).  
 
NS5A like core can be found on lipid droplets in infected cells. NS5A and core are 
reported to interact with one another; importantly elimination of this association by 
mutations in domain III of NS5A reduces particle assembly (16, 331). Furthermore 
NS5A domain III also associates with Annexin A2 (phospholipid binding protein with 
multiple functions including endosome trafficking), this interaction has been shown to 
be important for viral assembly (21).  
 
Proteins involved in the VLDL (Very low-density lipoproteins) secretion pathway have 
been identified in membranous web compartments containing the HCV replication 
complex, these include Apo E and ApoB (209).  VLDLs are found only in the liver and 
inhibition of VLDL secretion limits HCV release from Huh-7 cells suggesting this 
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process is closely linked to the VLDL assembly and secretion pathway (209). 
Dependence on the VLDL secretion pathway for viral assembly and egress has been 
proposed as an explanation for hepatic tropism (157, 209). There is controversy over 
this data set as Jaing et al., were not able to repeat these observations and found 
only the VLDL associated protein Apo-E and not Apo-B or microsomal transfer 
protein (MTP) was important for viral assembly (223).  
 
The important role of Apo E in viral assembly has been confirmed in a number of 
studies. Recent studies have demonstrated that silencing Apo E reduces viral 
assembly and egress, interestingly partial silencing was reported to permit viral 
assembly but inhibit release resulting in an accumulation of vius particles in the 
cytoplasm, indicating Apo E may be involved in two separate steps of viral assembly 
and release (40). Furthermore Apo E associates with NS5A (40). Cun et al., has 
recently confirmed that a specific alpha helix domain in the C terminal third of Apo E 
is responsible for this association and most importantly blocking this specific 
interaction using an ApoE deletion mutant protein inhibited viral production (108). It 
has been hypothesized that the interaction of NS5A with Apo E may provide a link 
between virus production and secretion (40).  
 
In summary HCV assembly is likely to occur near lipid droplets that are associated 
with membranous vesicles containing the replication complex, key viral proteins 
involved in this process comprise NS5A and core protein and key host cell factors 
include lipid droplets and Apo-E protein.  
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The area of research covering HCV egress is to date quite limiting. As previously 
discussed the host cell protein Apo E is likely to be involved in egress as well as viral 
assembly (40) and the specifics of the involvement of the VLDL secretion pathway in 
viral egress is currently under debate (209, 223). Processing from high mannose to 
complex-type sugars of N-linked glycans on envelope proteins of HCVpp indicates 
post -translational modification in the Golgi a step that may support a link with VLDL 
secretion pathway (355). Recent work has implicated the involvement of late 
endosomes in viral release, a process completely separate from the endosomal 
pathway utilsed by the virus for cell entry (263). Lai et al., demonstrated that viral 
egress was dependent on the motility of early to late endosomes and hypothesized 
that following assembly, virus particles are transported through early and late 
endosomes to the plasma membrane where they are released (98, 263). This is 
supported by recent findings that the endosomal sorting complex required for 
transport (ESCRT) machinery in particular ESCRTIII and VSP4 permits HCV release 
(98). Briefly ESCRT machinery is required by the cell to incorporate ubiquitinated 
proteins into intra luminal vesicles within a multivesicular body (MVB) / late 
endosome and to traffic these vesicles for degradation by the lysosome, it is also 
used in cytokinesis and budding of enveloped viruses (517). ESCRT III and VSP4 
are the most highly conserved of the ESCRT machinery; VSP4 is an AAA ATP that 
enables recycling of ESCRT III protein (517). It is hoped that a greater understanding 
of HCV viral egress will increase the availability of possible drug targets for the 
future.  
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1.4.3 Attachment and entry 
 
 HCV initially attaches to the host cell membrane through non-specific interactions 
with low affinity receptors (3, 28, 31, 155). Successful entry into the cell requires four 
essential co-receptors or entry factors. These are Tetraspanin CD81, Scavenger 
receptor BI (SR-BI), and tight junction proteins Claudin-1 and Occludin (Fig.1.2) (133, 
384, 385, 418). HCV is thought to enter the host cell through a clathrin-mediated 
endocytosis followed by a low pH dependent fusion event within the early endosome 
allowing release of the genome into the cytoplasm. Indeed inhibitors of both clathrin 
endocytosis and early endosome acidification block entry of HCVcc and HCVpp in 
vitro (45, 208).  
 
 
 
 
Figure 1.2: Schematic drawing of HCV co-receptors 
SR-BI consists of a large extra-cellular loop and two transmembrane domains as 
opposed to CD81, Claudin-1 and Occludin that have four transmembrane domains 
and two extra-cellular loops. 
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Attachment factors 
 
Low affinity receptors are thought to be important in the initial binding of the virion to 
the host cell prior to interaction with high affinity receptors. Glycosaminoglycan’s 
(GAG’s) are linear polysaccharides ubiquitously expressed on eukaryotic cell 
membranes; highly sulfated GAG’s such as heparin sulphate (HS) are implicated in 
the attachment and subsequent entry of a number of viruse for example other 
flaviviridae including Dengue virus type 2 utlise HS as a viral receptor (80, 199). In 
2003 Barth et al., demonstrated that sE2 binds HS suggesting it could be involved in 
attachment of HCV (28). Furthermore treatment with heparinase an enzyme that 
degrades heparin sulfate or heparin an analogue of HS, reduces HCVcc infection in 
vitro indicating that HS is indeed important for initial attachment of HCV to the host 
cell (31, 252). Interestingly upon formation of the E1E2 heterodimer E2 is no longer 
able to bind to HS, indicating the binding site is no longer visible and that the 
lipoproteins associated with HCV may be the factor mediating HCV attachment to HS 
and not the glycoproteins (60, 63).  
 
Other low affinity receptors implicated in HCV attachment include the C-type lectin 
DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin) and the liver related molecule L-SIGN (Liver and Lymph node specific 
DC-SIGN). DC-SIGN regulates the interaction between T-cells and dendritic cells 
and is important for the binding, uptake and antigen processing of multiple pathogens 
via the recognition of high mannose residues on the pathogens surface. L-SIGN has 
also been identified as a capture receptor for pathogens and was proposed as a 
capture receptor that could transmit virus to neighbouring cells (264, 293, 386). Both 
DC-SIGN and L-SIGN have been demonstrated to interact with HCV envelope 
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glycoproteins (155). HCVpp and sE2 have been shown to bind to both molecules on 
sinusoidal endothelial cells (264), and sE2 has also been found to bind DC-SIGN on 
mature human monocyte-derived dendritic cells (386). This led to the proposition that 
DC-SIGN and L-SIGN may capture and deliver HCV via dendritic cells to the liver, in 
fact Lozach et al., demonstrated that HCVpp bound to L-SIGN and DC-SIGN positive 
cells could be transmitted to Huh-7 cells in co-culture (293).  
 
As previously described HCV has been isolated in low density fractions of plasma 
and is believed to associate with low-density lipoproteins, indeed recent research has 
identified Apo E, a component of low density lipoproteins, to be associated with 
virions exhibiting peak infectivity (14, 358). It is therefore no surprise that low-density 
lipoprotein receptor (LDL-R) was an obvious choice for an HCV receptor (3, 60). 
LDL-R is the most important receptor for LDL in plasma. LDL binds to the receptor 
and is endocytosed via clathrin dependent endocytosis. LDL-R is recycled to the cell 
surface whilst LDL is released from the endosome via a pH dependent process 
followed by degradation in lysosomes resulting in the release of cholesterol into the 
cytoplasm (406). The first indirect evidence of HCV entry via LDL was shown by 
Agnello et al., in 1999, where HCV uptake into cells correlated with low density 
lipoprotein receptor activity and a reduction in uptake was observed in the presence 
of LDL receptor antibodies (3). More recent work has demonstrated that antibodies 
specific for LDL-R inhibit serum derived virus replication in primary hepatocyte 
cultures, suggesting a role for LDL-R in HCV replication (333). Owen et al., silenced 
LDL-R expression and demonstrated a reduction in HCV entry, these results were 
substantiated by a rescue of infection following re-expression of LDL-R (358). Further 
to this Owen et al., demonstrated the specific involvement of Apo E in LDL-R 
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mediated HCV entry by firstly inhibiting entry using Apo E specific antibodies and 
secondly identifying that Apo E is associated with highly infectious virions that have a 
high dependence on LDL-R (358). As yet there has been no direct evidence of an 
association between HCVpp/HCVcc with LDL-Rs however this may reflect the 
differential lipid association of particles propagated in vitro (60).  
 
Receptors 
CD81 is a member of the tetraspanin superfamily. It has two small intracellular 
domains, four transmembrane domains and two extra cellular loops, a large extra 
cellular loop (EC1) and a small extra cellular loop (EC2) (Fig.1.2). Tetraspanins form 
networks at the cell surface and are reported to be involved in cell adhesion, motility, 
cell activation, metastasis, and signal transduction (274). In the liver CD81 has been 
demonstrated to regulate cell proliferation and more recently to regulate 
hepatocellular carcinoma cell migration (42, 66, 312, 313).  Chapter 3 and 4 of this 
study further investigate the function of CD81 in hepatoma cells. 
 
Pileri et al. demonstrated an interaction between HCV E2 glycoprotein and CD81 in 
1999 (384). The large extra cellular loop of CD81 was demonstrated to bind soluble 
E2 and subsequent experiments with both HCVpp and HCVcc validated the essential 
role of CD81 in viral entry (99, 145, 314, 555). Zhang et al., 2004 reported that 
monoclonal antibodies to CD81 and small interfering RNA’s to silence CD81 inhibited 
HCVpp infection in vitro. McKeating et al., 2004 demonstrated the infection of diverse 
HCV genotypes was dependent on CD81 expression. HCVcc and HCVpp only infect 
the hepatoma cell line, HepG2 when engineered to express CD81, confirming the 
critical role of CD81 in viral entry (555). Recently an in vivo study showed that 
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treatment with anti-CD81 antibodies prior to HCV infection of liver-uPA-SCID mice 
provided complete protection from HCVcc infection but treatment after infection had 
no effect (325).  A number of studies have demonstrated that CD81 is a co-receptor 
for HCV entry and functions post attachment of HCV to the cell membrane (5, 99, 
335). Tan et al., 2003 showed that CD81 is involved in HCV internalisation and that 
HCV particles can bind to the cell surface in the absence of CD81 but could only be 
internalised when cell surface CD81 was present. Cormier et al., 2004 demonstrated 
that an anti-CD81 monoclonal antibody inhibits HCV entry post attachment, further 
supporting this conclusion. 
 
Regions of E2 important for E2/CD81 binding have been identified by antibody 
blocking experiments of E2 and structural modeling of E1E2 (360, 401). Owsianka et 
al., 2006 demonstrated conserved regions of E2 that were critical for CD81 binding 
for all genotypes. Specific residues on CD81 have been identified as critical for E2 
binding. Four amino acid residues on the large extracellular loop of human CD81 
were identified to differ from that of African green monkey CD81 that does not bind 
E2. One of these residues 186 was subsequently identified as being critical for E2 
binding by mutagenesis studies (197). Drummer et al., 2002 used random 
mutagenesis to determine specific residues 182, 186, 184 and 162 on CD81 large 
extracellular loop that were critical for E2 binding (122). The above studies used E2 
to assess binding specific residues on CD81 important for virus entry. Since then 
Flint et al., 2006 successfully infected HepG2 cells that expressed full length CD81 
derived from a broad range of species and showed that sE2 binding and recombinant 
CD81 blocking of HCVpp infection were not good predictors for successful HCVcc 
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infection (145). Implying that some of the previous work that identified residues 
critical for E2 binding may not predict successful entry of HCV.  
 
CD81 is closely associated with immunoglobulin like proteins EWI-2 and EWI-F. 
These proteins are members of a novel family of immunoglobulin proteins that are 
directly linked to actin linking ezrin-radixin-moesin (ERM) (411, 458). A cleavage 
product of EWI-2, EWI-2 wint (without its N terminus) that is not present in 
hepatocytes and was recently shown to inhibit HCV-CD81 interaction and reduce 
HCV infection in Huh-7 cells (402), suggesting that inhibitor proteins may contribute 
to the non-permissive nature of some cell types (194). 
 
SR-BI is a lipoprotein receptor that binds HDL and oxidized LDL (oxLDL). It functions 
by mediating cholesteryl ester uptake from HDL and controlling cholesterol efflux 
(222). It is expressed highly in the liver although it can also be found in steroidogenic 
tissue and macrophages (235).  SR-BI is a cell membrane protein that has two 
cytoplasmic terminal domains and a large extra cellular domain (Fig.1.2). The SR-BI 
gene gives rise to at least three isoforms, SR-BI, SR-BII and SR-BIII (127) The 
mechanism of SR-BI internalisation is unknown, however, SR-BII has been shown to 
endocytose via a clathrin dependent pathway (126). 
 
Scarselli et al., 2002 was the first to identify that SR-BI could interact with HCV E2. 
Since this discovery further work has been carried out to characterize the role of SR-
BI as a HCV receptor (70, 174, 175). Initial work focused on the effect of lipoproteins 
(SR-BI ligands) on HCV entry. Lavillette et al., 2005 found that human sera could 
increase HCVpp infectivity and hypothesised that an agent in the serum was 
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responsible for the increased infectivity (268). As previously described lipoproteins in 
serum have been found to associate with HCV in vivo (14, 351, 478) and to increase 
HCV glycoprotein E2 cell binding (519). Treatment of cells with high density 
lipoproteins (HDL) increased HCVpp infectivity, this was abrogated in the presence of 
inhibitors of SR-BI selective cholesterol uptake (BLT-2, BLT-4) suggesting that HCV 
entry may be dependent on the cholesterol uptake by SR-BI (495).  
 
Grove et al., reported that both plasma and cell culture derived J6/JFH had increased 
infectivity for Huh-7.5 cells transduced to over-express SR-BI and SR-BII (174). 
Antibodies specific for SR-BI inhibited HCVcc infectivity, demonstrating a specific role 
for this receptor in HCV entry and replication (70). Kinetic studies have shown that 
SR-BI may have a role post viral attachment, as antibodies neutralized cell bound 
virus (553). However, work by Catanese et al., 2009 contradicted these findings, 
demonstrating that anti-SR-BI antibodies blocked vius attachment.  
 
It is only very recently that the direct interaction of E2 with SR-BI has been 
demonstrated to be important for HCV entry (69). Catanese et al., produced mutant 
SR-BI proteins containing specific mutations required for sE2 binding and used them 
to show that firstly they were unable to restore infectivity after SR-BI knockdown 
treatment, suggesting that direct SR-BI E2 binding is important for virus infection. 
Secondly they demonstrated that HDL binding and cholesterol efflux was maintained 
in the mutant SR-BI expressing cells indicating that HDL and HCV E2 binding are 
distinct (69).  
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Dreux et al., 2009 expressed SR-BI in SR-BI negative cell lines, SK-hep1 (human 
liver endothelial cell) and BRL3A (rat hepatocarcinoma cell line), and demonstrated 
permisivity to HCVpp and HCVcc infection. These results for the first time defined 
SR-BI as an essential co-receptor.  By expressing mutant SR-BI proteins in the SR-
BI negatie cell lines Dreux et al., concluded that intracellular domains of SR-BI were 
important for HCV infection (118).  
 
Kapadia et al., demonstrated the potential cooperation of CD81 and SR-BI in HCVcc 
infection with monoclonal antibodies to CD81 and SR-B1 (235). Huh-7 cells were 
incubated with both CD81 and SR-BI antibodies alone or in combination and 
screened for their ability to support JFH-1 infection. Treatment of cells with antibodies 
to both co-receptors simultaneously had a synergistic effect suggesting cooperation 
between the two receptors. Grove et al., demonstrated that both CD81 and SR-BI 
dependency could be altered by a single amino acid change in glycoprotein E2. 
Mutation at amino acid 451 reduced SR-BI dependency and rendered the particle 
more sensitive to neutralisation by glycoprotein antibodies and soluble CD81 as well 
as altering particle density: infectivity relationship (175). These findings suggest a 
co-coperation between HCV receptors. 
 
Some cell lines that express CD81, SR-BI and LDL receptors are non-permissive 
cells to HCV infection, implying that at least one other liver specific receptor was 
needed. In 2007 Evans et al., screened a complementary DNA library from Huh-7.5 
cells for genes that were able to confer HCVpp entry into non-permissive 293T cells. 
These studies identified the tight junction protein claudin-1 (CLDN-1) as a critical 
factor defining HCV entry (133). Claudin-1 is highly expressed within the liver and 
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recent evidence from our laboratory suggests that the protein localises to junctional 
and non-junctional regions of the plasma membrane (396). Claudin-1 consists of four 
transmembrane regions with two extra cellular loops (Fig. 1.2). The first extracellular 
loop (EL1) of claudin-1 was found to be essential for HCV entry, however, there is so 
far no evidence for a direct association between claudin-1 and HCV E1E2. Evans et 
al., reported that claudin-1 plays a role downstream of CD81 and is required for HCV 
glycoprotein mediated cell fusion (133). Furthermore Evans et al., identified two 
residues in EL1 essential for virus entry, I32 and E48 (133). Cukierman et al., 
identified by mutational studies a further 7 residues (6 highly conserved resdues, 
W30, GLW-51, C54 and C64 as well as a further residue D38) in EL1 that were 
critical for HCV entry (107). Claudin-1 is part of a family of claudin proteins. It has 
recently been shown that further family members, claudin-6 and claudin-9 can also 
permit HCV entry into the claudin-1 negative hepatocellular carcinoma cell line 
Bel7402 (321, 559). 
 
A further tight junction protein occludin was recently implicated as an important entry 
factor(288, 385). Ploss et al., showed that expression of human occludin in murine 
cells rendered the cells permissive for infection with HCVpp and HCVcc. It is hoped 
that this knowledge may help to provide a mouse model for HCV infection by 
expressing human occludin.  Occludin like claudin-1 has two extra-cellular loops EL1 
and EL2 (Fig.1.2). Work by Benedicto et al., using shRNA to silence occludin 
expression confirmed a role for occludin in virus entry and eliminated the possibility 
of a role in replication. Furthermore Benedicto et al., established that occludin was 
not involved in attachment of the virion and demonstrated a possible role in 
glycoprotein dependent cell fusion, a later step in entry (39). Since then occludin EL2 
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has been identified by a number of studies to be important for mediating HCV entry 
(286, 328). Liu et al., expressed deletion mutant occludin proteins in 786-0 cells, 
(human renal carcinoma cells that are naturally occludin deficient) and demonstrated 
that deletion of EL2 abolished HCVpp and HCVcc infection whilst still exhibiting 
comparable cell surface expression to wild type (287). Mitcha et al., further confirmed 
the importance of EL2 by expressing occludin from different species in 786-0 cells 
and comparing permissivity to HCVpp, they were able to further define the area of 
importance to the second half of EL2 (328). A number of different splice variants of 
occludin have been identified (302). Kohaar et al., investigated the diversity of 
occludin present in normal human liver and compared activity when expressed in 
786-0 cells (245). Some of the splice variants were not expressed at the cell surface 
and were unable to support infection, suggesting that the variability in splice variants 
identified across different human livers may contribute towards partly explaining the 
differences in disease outcome between patients and may also help to explain tissue 
tropism (245). Importantly expression of CD81, SR-BI, claudin-1 and occludin in non-
liver derived cells (786-0(renal carcinoma cell line), TZM (HeLa cell-derived cervical 
carinoma cell line) and NIH3T3 (Mouse embroyo fibroblast cell line)) renders the cells 
permissive to HCV infection indicating that these four entry factors are the minimal 
requirement for viral entry (385).  
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Receptor complex and endocytosis 
 
 
The involvement of many receptors in HCV entry suggests a complex process 
that is only now beginning to be investigated. Preliminary studies addressed receptor 
localization in liver tissue and investigated protein co-localisation by confocal 
imaging. To fully interpret this data it is important to appreciate the liver architecture 
(Figure 1.4A).  The liver is a complex organ that is fed by both the portal vein and the 
hepatic artery. Blood is discharged from the portal vein and hepatic artery into 
sinusoids. Blood then travels through the sinusoids that weave around the 
hepatocytes until it reaches the central vein where it leaves the liver (433). Bile ducts 
are integrated throughout the structure and act to remove bile from hepatocytes and 
take it to the duodenum via the common hepatic bile duct (490). The liver is made up 
primarily of polarised parenchyma hepatocytes (493, 502) and other non 
parenchymal cells, examples of which include; Kupffer cells (resident macrophages), 
stellate / fat storing cells, and liver sinusoidal endothelial cells (LSEC) that form a 
permeated barrier between hepatocytes and the sinusoidal blood flow (493) 
(Fig.1.4B). The gap between the sinusoidal endothelium and the hepatocytes is 
termed the space of Disse and is where tissue fluid flows outward towards the 
lymphatics and is also where stellate cells can be found (433). Hepatocytes are 
highly polarised and their membrane can be split into three different surfaces: the 
sinusoidal / basolateral membrane faces the sinusoids and space of Disse and has 
irregular sized and spaced microvilli; the apical / canalicular membrane faces the bile 
and is separated from the other surfaces by the presence of tight junctions and 
desmosomes; finally, the third side faces other hepatocytes (433). 
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Reynolds et al., demonstrated the co-localisation of CD81 and claudin-1 at the 
sinusoidal (basolateral) and canalicular (apical) domains of polarized hepatocytes 
and the co-localisation of SR-BI and claudin-1 only at the sinusoidal domain (396). It 
is the sinusoidal domain of the hepatocytes that will be exposed to the sinusoidal 
blood and the site that we presume will come into contact with the virus.  Evidence as 
to occludin localization in the liver is limited; investigations in our laboratory suggest 
localization predominantly at the bile canalicular, this is significantly different to 
expression in diseased livers where it is expressed at both the sinusoidal and 
canalicular membranes (Wilson, unpublished data).  
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Figure 1.3: Liver organisation and hepatic polarity 
A) The top image represents a liver lobule whilst the lower image represents a more 
detailed illustration of a segment of a liver lobule. B) Cartoon of polarized 
hepatocytes illustrating the sinusoidal/basolateral (red) and canalicular/apical (blue) 
membrane surfaces. 
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To understand whether the receptors form a complex, specific interactions between 
the co-receptors need to be determined. To date interactions between CD81, CLDN 
and occludin have been investigated (188, 189). Work from our laboratory has 
investigated these associations using FRET (Fluorescence resonance energy 
transfer), a technique that allows distances of very closely associated fluorescently 
tagged proteins to be measured (less than 10nm). FRET occurred between 
fluorescent tagged CD81 and claudin-1 in permissive and non-permissive cells 
suggesting co-localization and formation of a co-receptor complex (189). Further 
work by Harris & Davis et al., demonstrated that receptor active claudins (Claudin-1, 
6 and 9) exhibit a 1 to 1 stoichiometry with co-receptor CD81. Furthermore disruption 
of claudin-1-CD81 association ablated HCV entry demonstrating that this complex 
defines HCV entry. Of equal importance claudin-1 - occludin interactions were not 
found to define HCV entry (188). 
 
Since the identification of tight junction proteins claudin-1 and occludin as receptors 
for HCV entry there has been much speculation as to whether HCV may utilize a 
cellular receptor to traffic to tight junctions where claudin-1 and occludin reside to 
permit entry. A similar mechanism has previously been observed for group B 
coxsackievirus (CVB) infection that utilzes a cellular receptor, decay accelerating 
factor (DAF) to co-ordinate the movement of virus particles from the apical surface of 
polarized epithelial cells to reach a further receptor, cosackievirus and adenovirus 
receptor (CAR) that is a component of the tight junction (102). These speculations 
were hightened by research carried out by Brazzoli et al., showing a re-organisation 
of CD81 to tight junctions following sE2 engagement (54). Importantly our laboratory 
has been unable to repeat these results  (Michelle Farquar, unpublished data). 
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Benedicto et al., 2009 suggested that occludin may be responsible for re-localisation 
of the virus to sites of entry, as yet there is no evidence for a direct association 
between extra-cellular occludin and HCV glycoprotein’s making this hypothesis 
unlikely (39, 287). Work in our laboratory would argue against the need for re-
localization of the virion to tight junctions as the CD81-claudin-1 complexes are 
predominantly at the basolateral membrane of polarised HepG2 cells (Cell line that 
exhibits hepatic polarity (319) and not tight junctions (188). Furthermore Coller et al., 
recently published data showing the movement of fluorescent labeled HCV particles 
along filopodia and across the cell body followed by internalization at sites that were 
predominantly not cell junctions (96).  
 
Liu et al., recently demonstrated that dynamin is important for HCV entry, this is no 
surprise as dynamin is a large GTPase that functions in the scission of vesicles from 
the cell membrane including clathrin mediated endocytosis, which has previously 
been shown to be involved in HCV entry in vitro (45, 208). Indeed our laboratory has 
recently shown that dynamin is important for HCV entry (Farquar, submitted). Liu et 
al., demonstrated that occludin association with dynamin is important for entry, 
suggesting that this association may be involved in coordinating HCV endocytosis 
HCV (287). This is particularly interesting as recent work in our laboratory has shown 
that CD81 engagement by either anti-CD81 or sE2 promotes a clathrin and dynamin 
dependent co-endocytosis of CD81 and claudin-1 to early endosomes, arguing that 
HCV glycoprotein engagement with CD81 may mediate endocytosis of the virus-
receptor complex. Our data supports previous observations by Coller et al., that 
visualized internalization of fluorescently labeled virions after association with 
claudin-1 and CD81 (96). The lack of an endocytic motif on CD81 and the knowledge 
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that CD81 lacking the N or C terminus is still endocytosed suggests that this process 
may be coordinated by an associated protein and that the previously identified CD81-
claudin-1 interaction may be important in facilitating this process (Farquar, 
submitted), (188, 189).  
 
The final stages of virus entry into the cell involve viral-cell fusion inside the early 
endosome allowing the release of the viral genome into the cytoplasm. Our 
laboratory has shown that antibodies to CD81 are able to block entry at late time 
points post infection suggesting that CD81 might be involved in these later stages of 
entry as well as attachment (Farquar, submitted). Claudin-1 (133) and occludin (39, 
287) have also been implicated to function in these later stages of entry. Taken 
together these studies indicate that CD81, claudin-1 and occludin will need to be 
present inside the early endosome for the final stages of viral entry, whether they get 
there in association with one another and / or in association with the virus remains 
unknown. Evidently further work is needed to understand the complex nature of HCV 
entry. A cartoon depicting a possible route for HCV entry is shown in Figure 1.4.  
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Figure 1.4: A possible pathway for HCV entry.  
 
1.4.4 Viral transmission  
  
 
An estimated 10^12 HCV particles are released into the serum of infected individuals 
everyday (350) and new viral hosts become infected through exposure to 
contaminated blood (11) suggesting that viral transmission between hosts is 
dependent on the release of infectious viral particles from infected hepatocytes.   
Transmission of virions within the host is not so easy to decipher. A humoral and 
cellular response to infection is observed following HCV infection and the existence 
of escape mutants directed against these responses demonstrates that selective 
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pressure occurs in vivo (73, 131, 434, 450, 497, 500, 505). However, HCV infection 
is able to persist in the presence of neutralizing antibodies suggesting a direct cell-to-
cell route of transmission may also be occurring (290).  The ability to transmit directly 
from cell-to-cell without the release of infectious viral particles is often an advantage 
for the virus, it enables a more efficient mode of transmission and furthermore helps 
to protect the virion from the host immune system. Our laboratory has recently 
developed an assay to determine in vitro transmission. Timpe et al., 2008 used this 
assay to demonstrate that HCV can transmit efficiently in the presence of nAbs 
suggesting the presence of a novel direct cell-to-cell route of HCV transmission 
(480). This is investigated further in chapter 5 of this study.   
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1.5 Project aims 
 
This project focuses on three areas. HCV entry requires glycoprotein engagement of 
tetraspanin CD81 (384), and a number of studies using immune cells have 
demonstrated that engagement of CD81 by antibody or recombinant sE2 protein 
induces a rearrangement of the actin cytoskeleton and alters cell function(s) (95, 104, 
486). Our first goal focuses on the role of CD81 engagement on hepatoma cell 
morphology using a panel of anti-CD81 antibodies that recognize novel CD81 
epitopes.  
 
In a small but significant proportion of patients, HCV infection leads to the 
development of hepatocellular carcinoma (6, 10, 71). Tetraspanins have been 
reported to alter the metastatic potential of a number of different cancers (561). 
Therefore our second goal investigates a role for tetraspanin CD81 in hepatoma-
ECM adhesion and migration and whether HCV infection modulates CD81 
dependent function and/or CD81 independent hepatoma adhesion and migration 
potential.  
 
Recent work in the HCV field suggests that HCV infection may transmit within a host 
in a neutralizing antibody resistant manner involving a direct cell-to-cell route of 
transmission (480). In the final chapter we characterized the receptor dependency of 
neutralizing antibody resistant transmission of HCV in vitro. 
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2. Materials and Methods 
2.1 Basic techniques 
2.1.1 Tissue culture 
All cell lines used in this study are detailed in Table 2.1. All cells were propagated in 
Dulbecco’s modified medium (DMEM) (Gibco) with 10% fetal bovine serum (FBS) 
(Gibco, CA, USA), 1% non-essential amino acids (Gibco), 1% L-Glutamine (Gibco) 
and 50units/ml penicillin and 50µg/ml streptomycin (P/S) (Gibco), Cells were 
maintained in tissue culture flasks (Becton Dickinson, NJ, USA) and grown at 37°C in 
5%CO2.  
 
Table 2.1: Cell lines used 
Name Species:Tissue Growth media Source
Huh-7.5 Human hepatoma DMEM
Dr. R.C Rice, rockerfeller 
University, New York
Huh-7.5/SR-BI Human hepatoma DMEM In house
Huh-7 Lunet parental Human hepatoma DMEM
Dr. T. Pietschmann, 
TWINCORE, Hanover
Huh-7 Lunet/CD81 Human hepatoma DMEM
Dr. T. Pietschmann, 
TWINCORE, Hanover
Huh-7 Lunet/CD81 WT Human hepatoma DMEM
In house (See Retrovirus 
Phoenix cell  Delivery)
Huh-7 Lunet/CD81 delta N Human hepatoma DMEM
In house (See Retrovirus 
phoenix cell Delivery)
Huh-7 Lunet/CD81 delta C Human hepatoma DMEM
In house (See Retrovirus 
phoenix cell Delivery)
Huh-7 CD81 nul Human hepatoma DMEM Dr. Y.T Tan, Singapore
Huh-7 CD81 Human hepatoma DMEM
In house (see 
Retrovirus/Trip Delivery)
HepG2 Human hepatocellular carcinoma DMEM
American type culture 
collection
HepG2/CD81 Human hepatocellular carcinoma DMEM
In house (See 
Retrovirus/TRIP Delivery)
HepG2/CD81 WT Human hepatocellular carcinoma DMEM
In house(See Retrovirus 
Phoenix cell  Delivery)
HepG2/CD81 delta N Human hepatocellular carcinoma DMEM
In house(See Retrovirus 
Phoenix cell  Delivery)
HepG2/CD81 delta C Human hepatocellular carcinoma DMEM
In house(See Retrovirus 
Phoenix cell  Delivery)
293T Human embryonic kidney DMEM
American type culture 
collection
Phoenix cells Human embryonic kidney DMEM American type culture 
Cell lines
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 2.1.2 Antibodies 
 
All antibodies used in this study detailed in Table 2.2. 
 
 
 
 
 
Table 2.2: Antibodies used 
Antibody name Antigen Type Specificity Species Source
9E10 HCV NS5A Hybridoma SN Monoclonal Mouse Dr. C. M. Rice, The Rockefeller University, NY
9/27 HCV E2 Purified IgG Monoclonal Rat In house
10/76b HIV gp 120 Purified IgG Monoclonal Rat In house
3/11 HCV E2 Purified IgG Monoclonal Rat In house
11/20 HCV E2 Purified IgG Monoclonal Rat In house
CBH2 HCV E2 Purified IgG Monoclonal Human Dr. S. Foung, University of Stanford, California
CBH4G HCV E2 Purified IgG Monoclonal Human Dr. S. Foung, University of Stanford, California
2.s131 Human CD81 Purified IgG Monoclonal Mouse
In house, K.Hu and M.Goodall (See Table 3.1 for all 
other anti-CD81 in house antibodies) 
PF72 Human SR-BI Purified IgG Monoclonal Human Pfizer Ltd.
Anti-Claudin Human Claudin-1 Purified IgG Monoclonal Rabbit Invitrogen
Anti-Claudin-1 Human Claudin-1 Hybridoma SN Polyclonal Rat
Dr. T. Baumert, University hospital Strasbourg, 
France
Anti-Occludin Human Occludin Purified IgG Monoclonal Rabbit Invitrogen
VG67e Human VEGF Purified IgG Monoclonal Mouse
Prof.R.Bicknell, University of Birmingham, 
Birmingham
Anti-P-ERM Human P-ERM Purified IgG Monoclonal Rabbit Cell signalling
Anti-CD9 (IAA2) Human CD9 Purified IgG
Monoclonal
Mouse
Dr. M. Tomlinson, Univeristy of Birmingham, 
Birmingham
Anti-CD151 (11B1) Human CD151 Ascites Polyclonal Mouse
Dr. M. Tomlinson, Univeristy of Birmingham, 
Birmingham
Anti-EWI-2 (8A12) Human EWI-2 Purified IgG
Monoclonal
Mouse
Dr. M. Tomlinson, Univeristy of Birmingham, 
Birmingham
Anti-Beta1 Human Beta-1 Purified IgG Monoclonal Mouse R&D systems
Anti-Beta2 Human Beta-2 Purified IgG Monoclonal Mouse R&D systems
Anti-Beta3 Human Beta-3 Purified IgG Monoclonal Mouse BD-pharmaceuticals
Anti-Beta4 Human Beta-d Purified IgG Monoclonal Mouse Chemicon
Anti-alpha1 Human alpha-1 Purified IgG Monoclonal Mouse Chemicon
Anti-alpha2 Human alpha-2 Purified IgG Monoclonal Mouse Immunotech
Anti-alpha4 Human alpha-4 Purified IgG Monoclonal Mouse Chemicon
Anti-alpha5 Human alpha-5 Purified IgG Monoclonal Mouse BD-pharmaceuticals
Anti-alpha6 Human alpha-6 Purified IgG Monoclonal Mouse Serotech
Anti-alphaVBeta3 Human alphaVBeta3 Purified IgG Monoclonal Mouse Chemicon
Anti-alphaV-Beta5 Human alphaVBeta5 Purified IgG Monoclonal Mouse Chemicon
Anti-alphaVBeta6 Human alphaVBeta6 Purified IgG Monoclonal Mouse Chemicon
Anti-Fibronectin Human Fibronectin Ascites Monoclonal Mouse Sigma-Aldrich,MO
Anti-Collagen I Human Collagen I Ascites Monoclonal Mouse Sigma-Aldrich,MO
Anti-Collagen IV Human Collagen IV Ascites Monoclonal Mouse Sigma-Aldrich,MO
Anti-Beta-actin (AC-15) Human Beta-actin Purified IgG Monoclonal Mouse Sigma-Aldrich,MO
Anti-Mouse Alexa fluor -488 Mouse (IgG2a) Purified IgG Polyclonal Goat Molecular Probes, Invitrogen, CA
Anti-Mouse Alexa fluor-488 Mouse (H+L) Purified IgG Polyclonal Goat Molecular Probes, Invitrogen, CA
Anti-Mouse Alexa fluor-RPE Mouse (IgG2a) Purified IgG Polyclonal Goat Molecular Probes, Invitrogen, CA
Anti-Mouse Alexa fluor-594 Mouse (IgG2a) Purified IgG Polyclonal Goat Molecular Probes, Invitrogen, CA
Anti-Rabbit Alexa fluor-594 Rabbit (H+L) Purified IgG Polyclonal Goat Molecular Probes, Invitrogen, CA
Anti-Mouse-HRP Mouse Purified IgG Polyclonal Donkey Jackson ImmunoResearch laboratories
Anti-Human-HRP Human Purified IgG Polyclonal Donkey Jackson ImmunoResearch laboratories
Anti-Mouse-HRP Mouse Purified IgG Polyclonal Sheep Amersham, Biosciences, PA
Anti-Rabbit-HRP Rabbit Purified IgG Polyclonal Sheep Amersham, Biosciences, PA
Primary antibody
Secondary antibody
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2.1.3 Plasmids and proteins 
 
All plasmids and proteins used in this study detailed in Table 2.3 
 
 
 
Table 2.3 Plasmids and proteins used 
 
Name Source
HCVcc JFH-1 Dr. T. Wakita, National Institute of infectious diseases, Tokyo
HCVcc J6/JFH-1 Dr. C.M Rice, The Rockefeller University, New York
HCVcc  JFH-1 G451R Dr, F. Chisari, Dr. J Zhong, The Scripps Research Institute, La Jolia
HCVcc JFH-1 W529A Dr. A.H. Patel,University of Glasgow, Glasgow
HCVcc J6/JFH del B Dr. T Tellinghuissen, The Scripps Research Institue, Florida
HCVcc H77/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc J4/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc J6/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc J8/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc S52/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc ED43/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc SA13/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc HK6a/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
HCVcc QC69/JFH-1 Dr. J. BuKh, Copenhagen University hospital, Denmark
Lifeact-Ruby Dr. R Wedlich-Söldner, Max Planck Institute of Biochemistry, Germany
Moesin-GFP Dr. M. Yanez-Mo, University hospital La Princesa, Madrid
N-Moesin-GFP Dr. M. Yanez-Mo, University hospital La Princesa, Madrid
CD81 WT Dr. M. Hemler, Dana-Farber Cancer Institute, Boston
CD81 Delta N Dr. M. Hemler, Dana-Farber Cancer Institute, Boston
CD81 Delta C Dr. M. Hemler, Dana-Farber Cancer Institute, Boston
TRIP SR-BI In house
TRIP CD81.GFP In house
HIV gagpol 8.2 Aaron Diamond AIDS Research Centre
VSV-G Aaron Diamond AIDS Research Centre
shRNA Occludin RHS4533-NM_002538 Open Biosystems
shRNA SR-BI RHS4533-NM_005505 Open Biosytems
JFH HCV sE2-10/76b In house
VEGF-165 Peprotech
 Plasmids
Proteins
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2.1.4 HCVcc generation 
All HCVcc viruses used in this study were constructed around the non-structural 
regions of JFH-1, a unique genome that was identified to assemble HCV particles in 
cell culture and is predominantly used throughout the HCV field of research (166, 
283, 499, 560). RNA was transcribed from a plasmid containing the RNA genome 
(Table 2.3) and introduced into Huh-7.5 cells by electroporation.  
RNA synthesis 
• 5µg of the plasmid containing a cDNA clone of the HCV genome was linearized 
using Xba-1 digest (Promega)  
• 1µg of the RNA was used as a template for RNA transcription using the 
megascript T7 kit (Ambion, Austin, TX), the reaction mixture was incubated at 
37°C for 2hrs after which the RNA was purified using the RNeasy MinElute Kit 
(Qiagen, NL) according to manufacturer’s instructions.  
• RNA quality was assessed by gel electrophoresis on a 1% agarose gel (Bioline, 
UK). Typical yields as measured by UV spectrophotometry (Amersham), were 
250-1500ng/µl. 
Electroporation 
• Huh-7.5 cells were grown to 60-80% confluence.  Trypsin was used to remove the 
cells from the tissue culture plastic. 
• Cells were washed twice by centrifugation at 1200rpm for 3min at 1°C and re-
suspension in 50ml ice-cold phosphate buffered saline (PBS).  
• 1.5x107 cells were re-suspended in 1ml of ice-cold PBS and placed on ice.   
• 400µl of cell suspension was then mixed with 4ng of transcribed RNA in a cuvette 
and electroporated under the following conditions; 5x100uS(820V) pulses with 1.1 
second delay between pulses.  
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• Electroporated cells were then left for 5min at room temperature to rest prior to 
suspension in 10ml Iscove’s modified dulbecco’s medium (IMDM) (plus10% 
human serum, 1% non essential amino acids, 1% pen strep). 8ml of re-
suspended cells were placed into a T75 flask, and the remainder put into 2 wells 
of a 24 well tissue culture plate to allow the monitoring of HCV protein expression. 
Cells incubated at 37°C at category three containment level. Media was replaced 
with DMEM (3% FBS) the following day.  
• 72hrs post electroporation cells in the 24 well plates were fixed with ice-cold 
methanol and stained for HCV non-structural protein, NS5A (As described in 
section  2.1.7).  
• Electroporated cells were used in assays at 72hrs or 96hrs post electroporation. 
In this scenario no viral particles were harvested.  
• Where HCV particles were harvested to use in cell free infection assays the 
following procedure was followed; HCVcc particles were harvested between 4 
and 14 days post EP, after which the cells were discarded. To harvest, infected 
cells were cultured in a minimal volume of DMEM (3% FBS) and media containing 
secreted virions collected every 8-14hrs. Harvested virus was frozen prior to 
titration using the standard infection assay.  
Standard infection assay 
All infection assays in this study were performed as follows. 
• 0.75x104 cells were seeded per well into a 96 well tissue culture plate. 
• The following day cells were infected with virus diluted in DMEM (3% FBS) in a 
total volume of 100µl per well. 
• The virus was left on overnight and media replaced the following day. 
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• 48hrs post infection cells were fixed with ice-cold methanol and stained for HCV 
non-structural protein, NS5A (As described in section 2.1.7).  
• Infected cells were counted as individual cells or foci of cells using a fluorescent 
microscope, Nikon TE2000.  Infectious units (IU) or foci forming units (FFU) per 
ml were then determined.  
2.1.5 Retrovirus delivery 
TRIP retrovirus gene delivery  
The TRIP system is a retrovirus gene expression vector developed by Zennou et. al. 
(554). It produces virus vector particles, formed around a replication deficient HIV 
gag-pol core, that bear the envelope glycoprotein of vesicular stomatitis virus 
(VSVG). These particles can package a gene of interest as an RNA transcript, 
subsequent transduction of a cell line with the TRIP system results in reverse 
transcription of the target gene and its insertion into the genomic DNA. In this study 
transduced cells were not under selection, however they maintained exogenous gene 
expression for around 1 month, after which they were discarded. The following 
plasmids were delivered by TRIP retrovirus delivery CD81.GFP / SR-BI / shRNA 
Occludin and shRNA SR-BI. 
• TRIP particles were produced by Fugene (Roche, Switzerland) transfection of 
293T cells. 
• Fugene/plasmid complex was made up as follows;   
o Following amounts of plasmids (400ng VSVG envelope, 600ng TRIP gag-
pol and 600ng target gene) added to 6µl Fugene dissolved in 100µl 
Optimem (Gibco). 
o This was incubated at room temperature for 20min to allow formation of 
complex. 
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• Cells were transfected in 6 well tissue culture plates for 8hrs, after which the 
culture media was changed to DMEM (3% FBS + P/S).  
• Transfection efficiency was monitored by the inclusion of a TRIP plasmid 
encoding enhanced green fluorescent protein as a target gene (TRIP EGFP).  
• Culture media containing TRIP particles was harvested at 48 and 72hrs post 
transfection and passed through a 0.2µM filter to remove any contaminating 293T 
cells. Transduction of target cells was performed immediately.  
• Target cells were seeded at 4x105cells/well in a 6 well tissue culture plate 24hrs 
prior to transduction. To transduce, cells were incubated overnight with harvested 
TRIP culture media diluted 1:1 in DMEM (3% FBS + P/S). After which the media 
was changed to DMEM (10% FBS + P/S). 
• Transduction efficiency was assessed after 48hrs by monitoring expression of 
TRIP EGFP and flow cytometric detection of target gene(s).  
Phoenix cell retrovirus gene delivery  
Pheonix cells are 293T cells that have been engineered to express gag-pol and 
envelope protein. Upon transient transfection with a plasmid containing LTR’s (Long 
terminal repeats), cells produce retrovirus containing the required DNA. This system 
was used in this study in the production of CD81 mutant expressing Huh-7 Lunet and 
HepG2 cells.  Like the TRIP retroviral system, subsequent transduction of a cell line 
with the retrovirus results in reverse transcription of the target gene and its insertion 
into the genomic DNA. Transduced cells were maintained under Zeosin selection 
(Invitrogen). HepG2 cells under 400µg/ml and Huh-7 Lunet cells under 600µg/ml. 
• Retroviral particles were produced by Fugene transfection (Roche, Switzerland) 
of phoenix cells.  
• Briefly, phoenix cells were seeded at 7x105 cells per well into a 6 well culture dish 
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coated with poly-L-lysine hydro bromide (Sigma, Ca, USA) in DMEM (10% FBS) 
24hrs prior to transfection. 1hr prior to transfection media refreshed with P/S free 
DMEM (3%FBS), 1.5ml per well. 
• Fugene/plasmid complex was made up as follows;  
o 1µg DNA added to 6µl Fugene dissolved in 100µl Optimem (Gibco). 
o This was incubated at room temperature for 20min to allow formation of 
complex. 
• Cells were transfected in 6 well tissue culture plates overnight, after which the 
culture media was changed to DMEM (3% FBS + P/S).  
• Culture media containing retroviral particles was harvested at 48 and 72hrs post 
transfection and passed through a 0.2µM filter to remove any contaminating 
phoenix cells. Transduction of target cells was performed immediately.  
• Target cells were seeded at 1.5x105cells/well in a 6 well tissue culture  
plate 24hrs prior to transduction. To transduce, cells were incubated overnight 
with harvested retrovirus culture media diluted 1:1 in DMEM (3% FBS + P/S). 
After which the media was changed to DMEM (10% FBS + P/S). 
• 72hrs post transduction cells were put under selection, control non-transduced 
cells were used to gauge how effective the transduction was and to verify 
selection efficacy.   
2.1.6: Transient transfection of Huh-7.5 cells. 
 
Plasmid transfection  
Moesin-GFP, N-Moesin-GFP and LifeAct-Ruby DNA plasmids were all transefected 
into Huh-7.5 cells using Lipofectamine transfection.  
• Transfections were carried out using the Lipofectamine (Invitrogen, CA, USA) kits 
according to the manufacturer’s guidelines.  
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• Briefly, Huh-7.5 cells were seeded at 6x105 cells per well in a 6 well culture dish 
in P/S free media 24hrs prior to transfection. 
• Plasmid/lipofectamine complex made up as follows; 
o 4µg DNA added to 200µl of Optimem (Gibco) and mixed gently. 
o 8µl lipofectamine reagent added to 200µl of Optimen and mixed gently. 
o Diluted DNA and diluted lipofectamine reagent combined and incubated at 
room temperature for 15min to allow formation of complex. 
• Complex added to well containing 1000µl of P/S free DMEM. 
• Transfections were carried out at 37°C for 8hrs. 
• After which the transfection mixture was replaced with DMEM (3% FBS + P/S).  
• Expression efficiency was typically monitored 48 hrs post transfection.  
siRNA transfection 
Claudin-1 and CD81 siRNA (Invitrogen) were transfected into Huh-7.5 cells using 
Lipofectamine transfection.  
• Transfections were carried out using the Lipofectamine RNAiMAX (Invitrogen, 
CA, USA) kits according to the manufacturer’s guidelines.  
• Briefly, Huh-7.5 cells were seeded at 6x105 cells per well into a 6 well tissue 
culture dish in P/S free media 24hrs prior to transfection.  
• siRNA-RNAiMax complex was made up as follows;  
o 100pmol siRNA added to 200µl of Optimem (Gibco) and mixed gently. 
o 4µl RNAiMAX added to 200µl of Optimen and mixed gently. 
o Diluted siRNA and diluted RNAiMAX combined and incubated at room 
temperature for 15min to allow formation of complex. 
• Complex added to well containing 1000µl of P/S free DMEM. 
• Transfections were carried out at 37°C for 8hrs. 
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• After which the transfection mixture was replaced with DMEM (3% FBS + P/S).  
• Expression efficiency was typically monitored 48hrs post transfection.  
2.1.7: Cytotoxicity testing 
The cytotoxicity of compounds used in this study was tested using the Cell Titer One 
Solution Cell Proliferation (MTS) Assay (Promega) according to the manufacturer’s 
guidelines. 
• Briefly, cells were seeded at 1.5x104 cells per well of a 48 well tissue culture 
plate. 
• Cells then treated with compound at a defined concentration and cultured for a 
defined period of time, (24 or 48hrs) as stated in figure legends. 
• Cells then washed with PBS followed by incubation with 200µl MTS (tetrazolium 
compound) at working concentrations and incubated for 2hrs at 37°C  
• 100µl of supernatant transferred to a 96 well plate and absorbance read at 
490nm. Final absorbance was determined by deleting absorbance recorded for 
an empty control well. 
2.1.8: Cholesterol quantification. 
 
The Amplex Red Cholesterol Assay Kit (Invitrogen, CA, USA) was used to quantify 
total cellular cholesterol according to the manufacturer’s guidelines.  
• Briefly cells were enumerated using a haemocytometer and 25x104 cells were 
pelleted by centrifugation (12,000rpm for 5min) and lysed in 250µls of 1x 
Reaction buffer. 
• 50µl of cholesterol samples diluted in reaction buffer plus cholesterol 
reference controls were added to separate wells of a 96 well plate. 
• 50µl of Amplex Red Reagent was then added to samples.  
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• Wells then incubated at 37°C for 30min. 
• Fluorescence was read in a Multi detector microplate reader (Biotech Synergy 
HT), excitation 530 and emission detection at 590.  
• A no cholesterol control was used as a background. Final fluorescence 
reading deduced by subtracting the background. 
• In each assay a standard curve was produced using the cholesterol reference 
standard (Fig.2.1) allowing cholesterol levels to be expressed as µM 
cholesterol per 1x104 cells. 
 
 
 
Figure 2.1: Cholesterol standard curve  
2.1.9: Flow cytometry 
HCV infection level 
Throughout this study HCV infection level was determined using a primary antibody 
directed at the non-structural region 5A (NS5A) of HCV (9E10).  
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• Cells were removed from tissue culture plastic with trypsin.   
• 25x104 cells were seeded per well into a 96 well round bottom plate and fixed with 
1% PFA for 5min at 4°C.  
• Fixed cells were incubated at room temperature in PBS plus 1% BSA (blocking) 
and 0.1% saponin (permeabilisation) for 20min.  
Cells were now removed from containment level 3 
• Cells centrifuged at 1200rpm and the pellet re-suspended in primary antibody 
9E10 (diluted in PBS + 1% BSA, 0.1% saponin) for 30min followed by 2x PBS 
washes.  
• This was followed by incubation with secondary antibody Alexa-fluor 488 or RPE 
conjugated anti-mouse IgG 2a (Invitrogen) (diluted in PBS + 1% BSA, 0.1% 
saponin) for 30min at room temperature and 2x PBS washes.  
• Percentage NS5A positive cells were determined by running the cells through a 
FACScalibur flow cytometer (BD Biosciences) and analysis on FLowJo software 
(Tree Star, San Carlos, CA).  
Cell surface protein expression 
• Cell surface expression was determined on live cells. Trypsin or cell dissociation 
buffer (as stated in figure legend) was used to remove the cells from tissue 
culture plastic.  
• Cells were blocked with FACS buffer (PBS + 2% BSA, 0.01% Azide) for 20min at 
room temperature.  
• 25x104 cells were then seeded per well into a 96 well round bottom plate and 
centrifuged at 12,000rpm to pellet the cells.  
• Cells were then re-suspended in 100µl of primary antibody diluted in FACS buffer, 
(concentrations in Table 2.4), and incubated for 30min at room temperature.  
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• This was followed by 2x PBS washes and then incubation with 100µl of 
appropriate secondary antibody (concentrations in Table 2.2) for 30min at room 
temperature. 
• Cells were then washed again (2xPBS) and fixed with 1% Para formaldehyde 
(PFA) for 5min at 4°C. 
• Protein surface expression was determined by running cells through a 
FACScalibur flow cytometer (BD Biosciences) and analysis using FlowJo 
software (Tree Star, San Carlos, CA). 
2.1.10: Immuno-fluorescence  
HCV infection level 
Throughout this study to visualize HCV infectivity we stained the cells using a primary 
antibody directed at HCV non-structural region NS5A (9E10).  
• Cells were fixed with ice-cold methanol for 5min.  
• Fixed cells were then incubated with PBS plus 1% BSA (blocking) and 0.1% 
saponin (permeabilisation) for 20min.  
• Primary antibody (9E10) was added to the cells at 1:200 dilution in PBS + 1%BSA 
+ 0.1% saponin and incubated at room temperature for 30min followed by 2x PBS 
washes.  
• Alexa fluor 488 or 594 conjugated anti-mouse IgG2a secondary antibody was 
then added at 1:1000 dilution in PBS + 1%BSA + 0.1% saponin for a further 
30min at room temperature, followed by 2x PBS washes 
• NS5A positive cells visualized on Nikon TE2000 fluorescence microscope on a 
Zeiss META head confocal microscope.  
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Figure 2.2: NS5A stain of HCVcc J6/JFH infected cells. 
Huh-7.5 cells 72hrs post EP with J6/JFH RNA. NS5A stained with 9E10 primary 
antibody and Alexa-flour 488 conjugated secondary antibody (Green), cell nuclei 
counterstained with DAPI (Blue), visualized on Nikon TE2000 fluorescence 
microscope. 
 
Cellular protein expression  
To visualize cellular protein expression by confocal microscopy cells were seeded 
onto 24 well plates containing 13µm glass cover slips. For fluorescent microscopy 
analysis only, glass cover slips were not used. 
• Cells were fixed with appropriate fixative (See Table 2.4) or stained live (SR-BI 
expression only).  
• Fixed cells were then incubated with PBS/1% BSA (blocking) and 0.1% saponin 
(permeabilisation) or Triton-X-100 (permeabilisation) (P-ERM only) for 20min. 
This step not included for SR-BI expression.  
• Primary antibody was added to the cells at appropriate dilution in PBS + 1%BSA 
+ 0.1% saponin, PBS/1%BSA (P-ERM only) or serum free DMEM (SR-BI only) 
and incubated at room temperature for 30min followed by 2x PBS washes. See 
table 2.4 for antibody concentrations. 
• Appropriate Alexa-fluor 488 or 594 conjugated secondary antibody was then 
added at 1:1000 dilution in PBS/1%BSA/0.1%saponin, PBS/1%BSA (P-ERM 
only) or serum free DMEM (SR-BI only) for a further 30min at room temperature, 
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followed by 2x PBS washes. Cells stained for SR-BI expression then fixed with 
3% EM grade formaldehyde. 
• Cells counter stained with DAPI (sigma) diluted in PBS. 
• Stained cells visualized and imaged on Nikon TE2000 fluorescence microscope 
or cover slips mounted onto glass slides using ProLong Antifade mounting agent 
(Invitrogen, CA, USA) and imaged on a Zeiss META head confocal microscope 
with a 63x water immersion objective. Background fluorescence of samples was 
corrected based on control samples stained with species-matched IgG and 
secondary antibody only. 
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Table 2.4: List of antibody concentrations. 
IF: Immuno-fluorescence, FC: Flow cytometry, ELISA: Enzyme linked 
immunosorbent assay, WB: Western blot 
Antibody Application Dilution Fixative for IF
9E10 (Anti-HCV NS5A) IF 1/200 Methanol
2.s131 (Anti-CD81) IF/FC 1ug/ml 3% EM grade formaldehyde
PF72 (Anti-SR-BI) IF/FC 1ug/ml
Live cell stain followed by 3% EM 
grade formaldehyde fixation
Anti-Claudin IF 1ug/ml Methanol
Anti-Occludin IF 1ug/ml Methanol
Anti-P-ERM IF 1/200 3% EM grade Formaldehyde
Anti-P-ERM WB 1/1000
Anti-Beta1 FC 1ug/ml
Anti-Beta2 FC 1ug/ml
Anti-Beta3 FC 1ug/ml
Anti-Beta4 FC 1ug/ml
Anti-alpha1 FC 1ug/ml
Anti-alpha2 FC 1ug/ml
Anti-alpha4 FC 1ug/ml
Anti-alpha5 FC 1ug/ml
Anti-alpha6 FC 1ug/ml
Anti-alphaVBeta3 FC 1ug/ml
Anti-alphaVBeta5 FC 1ug/ml
Anti-alphaVBeta6 FC 1ug/ml
Anti-Fibronectin ELISA 10ng/ml
Anti-Collagen I ELISA 10ng/ml
Anti-collagen IV ELISA 10ng/ml
Anti-Beta-actin (AC-15) WB 1/2500
Anti-Mouse Alexa fluor-488 IF/FC 1/1000
Anti-Mouse Alexa fluor-RPE FC 1/1000
Anti-Mouse Alexa fluor-594 IF/FC 1/1000
Anti-Rabbit Alexa fluor-488 IF 1/1000
Anti-human Alexa fluor-488 IF/FC 1/1000
Anti-mouse-HRP ELISA 1/5000
Anti-human-HRP ELISA 1/400
Anti-Mouse-HRP WB 1/2500
Anti-Rabbit-HRP WB 1/2500
Primary antibodies
Secondary antibodies
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2.2: Specific assays  
 
Chapter 3 
2.2.1: Antibody engagement cell spread assay 
 
For all cell spread assays cells were serum starved overnight prior to assay. Specific 
treatments were carried out on the morning of the assay as specified in table 2.5. For 
the cholesterol modulation assays the cells were removed from tissue culture plastic 
with trypsin and treated at 37°C in solution in universals (2x106 cells in 1ml of 
DMEM). For the remaining spread assays adherent cells were treated in a T25 flask 
or well of a 6 well tissue culture dish. 
• 96 well ELISA plates (Thermo electron corporation) were prepared by coating 
with specified antibody at 5µg/ml diluted in 100µl of PBS and incubated at 4°C 
overnight.  
• Antibody coated plates were then blocked with PBS/1%BSA for 30min and 
washed 2x with PBS.  
• With the exception of the cholesterol modulation assay where cells are already in 
solution, the cells were removed from tissue culture plastic using trypsin. 3x104 
cells were then seeded per well in 100µl of serum free DMEM.  
• Phase images were taken of cells at specified time points post seeding. For 
assays carried out in category three containment level, cells were fixed by adding 
EM grade formaldehyde directly to the wells (final concentration 3.4%) prior to 
removing cells for imaging.  
• A Nikon TE2000 fluorescence microscope was used to image the cells. The total 
number of spreading and non-spread cells were enumerated in a field of view and 
percentage cell spread determined (See Fig.3.2 for assay set up). 
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TIRF microscopic analysis of cell spread assay 
For TIRF microscopy spread assays we used Huh-7.5 cells expressing TRIP 
CD81.GFP (See section 2.1.5) and Lifeact-Ruby (See section 2.1.6). Cells were used 
24hrs post transfection with Lifeact-Ruby.  
• 35mm glass bottom dishes (World Precision Instruments Inc., FL, USA) were 
coated with specified antibody at 5µg/ml diluted in PBS and incubated at 4°C 
overnight.  
• Antibody coated plates were then blocked with PBS/1%BSA for 30min and 
washed 2x with PBS.  
• Cells were removed from tissue culture plastic using trypsin and 3.5x105 cells 
were then re-suspended in 2500µl DMEM (No phenol red) (Gibco) + 20mM 
Hepes + 10% FBS and seeded into the coated 35mm dishes. 
• 3 Fields of view per well were randomly selected and imaged by TIRF microscopy 
every 10 min up to 80 min using a Nikon A1R microscope.  
 
Table 2.5: Treatment summary for spread assays. 
Treatment Source Concentration Pre-treatment
C3 transferase (Rho inhibitor) Cytoskeleton 5ug/ml 4hr at 37degC
Rac-1 inhibitor (Rac inhibitor) Calbiochem 100uM 1hr at 37degC
Y27632 (ROCK inhibitor) Sigma 2.5uM 4hr at 37degC
Dynasore Sigma 80uM 30min at 37degC
Bisindolymaleimide (PKC inhibitor) Calbiochem 100nm 1hr at 37degC
U0126 (MAPK inhibitor) Calbiochem 100uM 1hr at 37degC
PD98059 (MAPK inhibitor) Calbiochem 100uM 1hr at 37degC
SB203580 (MAPK inhibitor) Calbiochem 100uM 1hr at 37degC
Cytocholasin D Sigma 5uM 1hr at 37degC
Latrunculin B Sigma 0.1uM 1hr at 37degC
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2.2.2: Recombinant sE2 engagement cell spread assay 
 
Plate preparation 
• 96 well ELISA plates (Thermo electron corporation) were prepared by coating 
with 10/76b capture antibody at 1µg/ml diluted in 100µl of PBS and incubated at 
4°C overnight.  
• Well then blocked with PBS/1%BSA for 1hr. 
• Recombinant soluble E2 (JFH-10/76b) was then added to the wells at 1 in 3 
dilution in PBS and incubated at 37°C for 2hrs. 
• sE2 coated plates were then blocked with PBS/1%BSA for 30min and washed 2x 
with PBS. 
• Control wells contained 10/76b only or empty wells blocked with PBS/1%BSA. 
Spread assay  
• Huh-7.5 cells were serum starved overnight and then removed from tissue culture 
plastic using trypsin. 3x104 cells were then seeded per well in 100µl of serum free 
DMEM.  
• Phase images were taken of cells at 1hr post seeding using a Nikon TE2000 
fluorescence microscope. 
ELISA for detection of bound sE2. 
• A cocktail of human anti-E2 antibodies (CBH2 and CBH4B) at 4ug/ml were added 
to each well and incubated at room temperature for 45min followed by 3x washes 
with PBS. 
• Wells then incubated with appropriate HRP conjugated secondary antibody 
(Jackson ImmunoResearch laboratories) for 45min.  
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• Bound antibodies were visualized using TMB substrate (BioFX laboratories) and 
reaction was terminated after 5min incubation with stop reagent (BioFX 
laboratories).  
• Absorbance was read on plate reader at 490nm (Multiskin ascent, Thermo 
Electron Corporation).  
 
2.2.3: P-ERM western blot for anti-CD81 engagement time course assay. 
 
Lysate preparation 
 
• lysates were prepared by seeding 1x106 Huh-7.5 cells per well into wells of a 6 
well tissue culture dish. Cells were then serum starved overnight.  
• Cells stimulated with anti-CD81 mAb (1.s262) diluted at 5µg/ml in serum free 
DMEM for 0,1,5,10,15 and 30min. 
• Tissue culture media was removed and the cell monolayer rinsed with PBS at 
room temperature. All subsequent steps were carried out on ice using fresh, ice-
cold buffers to prevent protein degradation.  
• 2ml of ice cold PBS were added per well and adherent cells removed using a cell 
scraper. The cell suspension was transferred to universal and pelleted by 
centrifugation at 1200 rpm for 5 min at 4°C.   
The cell pellet was re-suspended in 500µl of NP40 lysis buffer (10mM Tris-HCL; 
pH 7.5, 2mM CaCl2, 2mM MgCl2, 1%NP40 plus1x Complete Mini Protease 
Inhibitor Cocktail Tablet + 1x Complete PhosStop Phosphatase Inhibitor Cocktail 
Tablet (Roche)) and incubated on ice for 30 min. 
• The lysate was centrifuged at 15 000 rpm in a Biofuge primo R centrifuge  
(Heraeus) for 15 min at 4°C to separate nuclei and unsolubilized cell membranes 
from protein, after which the supernatant was collected and  
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frozen at -20°C.  
• Protein was quantified using the BCA Protein Assay kit (Thermo Scientific, IL, 
USA) according to the manufacturer’s instructions. 
o Briefly, 100µl of each sample or BSA standard were mixed with 200 µl of 
BCA Working Reagent in a 96-well microtiter plate in triplicates and 
incubated at 37°C for 30 min.  
o The plate was allowed to cool to RT and the absorbance at 490 nm 
measured using ELISA plate reader (Multiskin ascent, Thermo Electron 
Corporation). 
o To determine the protein concentration of each sample, a standard curve 
was prepared by plotting the average Blank-corrected 490 nm 
measurement for each BSA standard versus its concentration in µg/ml.  
 
Figure 2.3: BCA protein assay standard curve.   
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SDS Polyacrylmide Gel Electrophoresis (SDS-PAGE).  
Proteins were separated on 12% SDS gel.  
• To prepare samples, defined amounts of protein were mixed with 3x Laemmli 
loading dye (H2O + 30% v/v Glycerol + 6% w/v SDS + 0.02% v/v Bromophenol 
Blue + 0.2M Tris-HCl; pH 6.8 plus 10% 2-mercaptoethanol) (Reducing conditions) 
and the total volume adjusted to 25µl with H2O. Samples were heat-denatured at 
95°C for 5min and allowed to cool to room temperature prior to loading.  
• Proteins were separated by electrophoresis using the Mini Protean 3 System 
(Bio-Rad Laboratories, CA, USA) according to the manufacturer’s instructions.  
o Briefly, 20µl of protein sample were loaded per lane and gels run at 200 
volts for 30-45 min.  
o Proteins were transferred onto PVDF membranes (Millipore, MA, USA) 
using a Mini Trans-Blot Electrophoretic Transfer Cell System (Bio-Rad) 
according to the manufacturer’s recommendations. 
o Briefly, PVDF membranes were cut to the appropriate size and pre-treated 
with methanol for 1-2 min, rinsed with ultra pure water, and incubated in 
transfer buffer  (25mM Trizma base + 0.2M Glycine + 200 ml MeOH + 0.5 
ml 10% SDS) at room temperature for 5-20 min. Gels were equilibrated in 
transfer buffer for 5min to prevent shrinking and incomplete transfer. 
o Transfer was carried out at 350 A for 60min at room temperature.  
Immunoprobing and chemiluminescent detection of proteins.   
• All subsequent steps were carried out in 50 ml Falcon tubes with gentle agitation 
on a tube roller (Barloworld Scientific, UK) at RT.  
• To block unspecific binding of antibodies, membranes were incubated in 2.5 ml of 
TBST (10mMTrizma base + 0.1M Sodium Chloride + 10% v/v Tween 20) + 5% 
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dry milk for 1hr.  
• After which the blocking buffer was removed and the membranes were incubated 
with primary antibody, Anti-P-ERM, diluted in TBST + 5% BSA overnight followed 
by 5 x 5min washes, then Anti-β-actin diluted in TBST + 5% dry milk for 1hr 
followed by 5 x 5min washes with excess TBST.  
• Membrane then Incubated with appropriate HRP conjugated secondary antibody  
(Amersham, Biosciences, PA) diluted in 2ml TBST + 5% dry milk followed by 5 x 
5min washes with excess TBST.  
• Chemiluminescent detection of HRP-conjugated antibodies was performed using 
the ECL Western Blotting Detection System (Amersham, UK) according to the 
manufacturer’s instructions. Briefly, membranes were immersed in ECL detection 
reagent for 1 min, wrapped in cling film, and exposed to CL- XPosure Blue X-Ray 
Film (Thermo Scientific) for 1-5 min.   
Antibody concentrations detailed in Table 2.4 
Chapter 4 
2.2.4: ECM adhesion assay. 
 
Plate preparation  
• 96 well plates (Falcon, Becton Dickinson) were coated with human extra-cellular 
matrix (ECM) proteins; Fibronectin (Sigma), Collagen type I (Sigma), Collagen 
type VI (BD Biosciences), and laminin (Sigma) at 10µg/ml (50µl/well) and 
incubated at room temperature for 1hr.  
• Wells were then blocked with PBS/1% BSA for 30min followed by 3x PBS 
washes.  
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Adhesion assay 
• Hepatoma cells were serum starved overnight and then removed from tissue 
culture plastic with trypsin.  
• Cells were counted using a haemocytometer and 4x104 cells were seeded per 
well in 50µl serum free DMEM. For crystal violet calibration curve 0.5, 1, 2, 3, 4 
and 5x104 cells were seeded per well. 
•  Cells were incubated at 37°C for a defined period of time.  
• Non-adhered cells were removed with PBS wash.  
• Adhered cells were then fixed with ice-cold methanol for 5min. 
• Adhered cells were then stained with crystal violet to determine adhesion or 
stained for HCV non-structural protein NS5A to determine percentage infectivity 
of adhered cells. 
 
Crystal violet stain 
• Fixed cells were incubated with 0.1% crystal violet for 1hr 
• Cells were then washed 3x with PBS and crystal violet solubalised in 36% acetic 
acid.   
• Absorbance was read at 600nm on plate reader (Multiskin ascent, Thermo 
Electron Corporation).  
• Control wells with no cells were used to determine background. Specific adhesion 
was determined by subtracting the absorbance read on PBS/1% BSA only coated 
plates from ECM coated plates that had been blocked with PBS/1% BSA.  
Quantification of HCV infected cells 
• Fixed cells were stained for HCV non-structural protein NS5A as described in 
section 2.1.10 and then cell nuclei counterstained with DAPI (Sigma).  
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• To determine the proportion of infected cells, three fields of view were imaged 
using the Nikon TE2000 fluorescence microscope. The number of NS5A positive 
cells and total nuclei per field of view were enumerated allowing calculation of 
percentage-infected cells.  
2.2.5: ECM ELISA 
 
Plate preparations 
• For control assays 96 well plates were coated with gelatin for 1hr followed by 
specific concentrations of human fibronectin, collagen I and collagen IV for a 
further 1hr incubation (100µl/well).  
• To determine ECM production of Huh-7.5 cells, 0.5x104 cells in 200µl DMEM (3 or 
10% FBS) were seeded per well into gelatin coated 96 well plates. The cells were 
then incubated at 37°C for a specified time. 
• Cells lysed with cell lysis buffer (20mM NH4OH, 0.5% Triton X-100). The lysis 
step allowed the removal of plates from the level three containment laboratory. 
•  A titration of human fibronectin was carried out alongside Huh-7.5 fibronectin 
production assays enabling the concentration of fibronectin produced in µg/ml to 
be determined  (See Fig.2.4) 
• Plates were analyzed immediately by ELISA or stored at 4°C prior to analysis. 
ELISA 
• Wells were blocked with 1% gelofusine in 0.5% Tween20/PBS for 1hr, followed by 
3x washes with wash buffer (0.5%Tween20/PBS). 
• Wells were incubated with ECM specific primary antibodies at a concentration of 
10ng/ml for 45min followed by 3x washes with wash buffer. 
• Wells then incubated with appropriate HRP conjugated secondary antibody 
(Jackson ImmunoResearch laboratories) for 45min.  
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• Bound antibodies were visualized using TMB substrate (BioFX laboratories) and 
reaction was terminated after 5min incubation with stop reagent (BioFX 
laboratories).  
• Absorbance was read on plate reader at 450nm (Multiskin ascent, Thermo 
Electron Corporation).  
 
 
Figure 2.4:Fibronectin standard curve 
 
2.2.6: Anti-CD81 engagement filopodia induction assay 
 
• Huh-7.5 cells were seeded into wells of 24 well plates containing 13µm glass 
cover slips (5x104 cells per well) and cultured in serum free DMEM overnight 
at 37°C. 
• Cells incubated with specific antibody for 0, 10 or 240min before fixation with 
3.6% EM grade formaldehyde.  
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• For cells fixed at zero hours (prior to addition of anti-CD81 mAb), Anti-CD81 
mAb diluted in 0.5%BSA/PBS was added to the wells for 1hr at 37°C 
• All cells were then incubated with Alexa fluor 488 conjugated secondary 
antibody diluted in 0.5%BSA/PBS for 30min at room temperature followed by 
2xPBS washes. 
• Phalloidin-594 (Sigma) diluted 1 in 200 in 0.5%BSA/PBS was then added and 
incubated at room temperature for 30min followed by 2xPBS washes. 
• Cells then counterstained with DAPI (Sigma) for 1min at room temperature. 
•  Stained cells visualized mounted onto glass slides using ProLong Antifade 
mounting agent (Invitrogen, CA, USA) and imaged on a Zeiss META head 
confocal microscope with a 63x water immersion objective. Background 
fluorescence of samples was corrected based on control samples stained with 
species-matched IgG and secondary antibody only. 
2.2.7: Wound healing assay 
 
Huh-7.5 cells (7x105 cells per well) were seeded into wells of a 6 well dish 24hrs prior 
to the start of the assay and serum starved overnight. For assays using CD81 knock 
down cells (See section 2.1.6), the cells were seeded 24hrs prior to transfection and 
48hrs prior to the start of the assay. In this scenario cells were serum starved for 3hrs 
on the morning of the assay.  
• A P200 tip was used to form a wound in the cell monolayer. 
• Media was then refreshed with serum free DMEM containing 15µg/ml mitomycin 
C (SIGMA-ALDRICH, MO USA) and images of wound taken immediately (0hrs)  
• Wells then incubated at 37°C for 24hrs and then further images of the wound 
were then taken. A black marker pen was used to mark the area of the wound 
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being imaged; this ensured the same area was imaged at each time point (See 
Fig.2.5).  
• Images taken by phase on a Nikon TE2000 fluorescence microscope and area of 
wound determined using IPLab 4.0 (BD Biosciences) software. 
 
Figure 2.5: Schematic of wound healing assay. 
2.2.8: Invasion assay 
 
Mock vs. HCV infected cell invasion assays 
Huh-7.5 cells were electroporated with in vitro transcribed full length HCV RNA or 
mock RNA (see section 2.1.4). Cells were cultured in DMEM (3% FBS) and then 
serum starved overnight prior to assay. Invasion assays were set up 96hr post 
electroporation. 
• Cells were labeled with CMFDA (Invitrogen, CA USA) by incubating the cells at 
37°C with 5µM CMFDA (DMEM + 3% FBS) for 30min.  
• Labeled cells were then washed with PBS and removed from tissue culture plastic 
with trypsin.  
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• Cells were pelleted by centrifugation at 12,000rpm for 5min and the pellet re-
suspended in serum free DMEM.   
• A viable cell count was performed using trypan blue (Invitogen, CA USA) and a 
heamocytometer. 4x104 cells (200µl) were seeded into the top well of a collagen 
coated (calf collagen, Sigma) 8µm pore transwell (BD Falcon, CA USA) in a 24 
well tissue culture plate. Cells were also seeded onto a 24 well plate as a control. 
• The bottom chamber was filled with 400µl serum free DMEM. Cells were cultured 
for 24hr at 37°C. 
•  Non-migratory cells were mechanically removed with a cotton bud and confirmed 
under light microscope.  
• Migratory and control cells were fixed with ice cold methanol for 5min and then 
stained for HCV non-structural protein NS5A (See sectin 2.1.4) using 9E10 
primary antibody and Alexa-fluor 594 conjugated secondary antibody.  
• Three fields of view per well were captured on a Nikon TE2000 fluorescence 
microscope. The number of invaded cells was enumerated per field of view. The 
proportion of infected invaded cells and those in the control wells were also 
determined.  
All other invasion assays 
For the majority of assays hepatoma cells were serum starved overnight prior to 
assay set up and any specified pretreatment steps were carried out in serum free 
conditions (See Table 2.6). For assays using CD81 knock down cells, the cells were 
used 24hr post transfection and serum starved for 3hr prior to the assay.  
Cells were removed from tissue culture plastic with trypsin. Cells were pelleted by 
centrifugation at 12,000rpm for 5min. The pellet was then re-suspended in serum 
free DMEM.  
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•  A viable cell count was performed using trypan blue and a heamocytometer. 
4x104 cells (200µl) were seeded into the top well of a collagen coated (calf 
collagen, Sigma) transwell (Falcon 8µM pore, 24 well plate).  
• The bottom chamber was filled with 400µl serum free DMEM. Where compounds 
were used cells were seeded in the presence of the compound and the 
compound was also present in the bottom chamber of the transwell. 
• Cells were cultured for 24hr at 37°C 5% 02. Where specified cells were cultured in 
a hypoxic incubator (New Brunswick Galaxy 48R, Eppendorf) at 1% 02.  
• Non-migratory cells were mechanically removed with a cotton bud and confirmed 
under light microscope. 
• Migrated cells were fixed with ice-cold methanol for 5min and then stained with 
0.1% crystal violet for 1hr followed by 3x PBS washes.  
• Three fields of view per well were captured on a Nikon TE2000 fluorescence 
microscope. The numbers of invaded cells were enumerated for each field of 
view.  
 
Table 2.6: Treatment summary for invasion assays. 
 
Antibody concentrations detailed in Table 2.4 
 
Name Source Concentration Pre-treatment
HIF NSC-134754 
Dr. M. Ashcroft, University College London, 
London 
1uM 3hrs at 37degC
Anti-VEGF (VG67e)
Prof.R.Bicknell, University of Birmingham, 
Birmingham
400ng/ml
VEGF-165 Peprotech 10ng/ml
Anti-CD81 (1.s262) In house, K.Hu and M.Goodall 0.1,1,10ug/ml
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Chapter 5 
2.2.9: Infectious co-culture assay 
 
Standard assay for flow cytometry analysis 
• Huh-7.5 cells were electroporated with in vitro transcribed full length HCV RNA 
(See section 2.1.4) 72hrs prior to use in assay.  
• Naïve unlabelled target cells were seeded into collagen coated (calf collagen, 
Sigma) 12 well plates at a seeding density of 12.5x104 cells per well. To 
determine the role of receptors in co-culture transmission target cells were 
seeded in the presence of control or receptor antagonists (Antibody and 
concentration specified in the figure legend) and allowed to rest for 1hr at 37°C 
prior to addition of producer cells. 
• Infected producer cells were labeled with CMFDA (Invitrogen, CA USA) by 
incubating the cells at 37°C with 5µM CMFDA (DMEM + 3% FBS) for 30min. 
• Labeled producer cells were then washed with PBS and removed from the tissue 
culture plastic with trypsin. 12.5x104 producer cells were then seeded into co-
culture with the naïve target cells. To enable distinction between nAb resistant 
and nAb sensitive transmission producer cells were seeded in the presence or 
absence of control or anti-glycoprotein antibody (Antibody and concentration 
specified in the figure legend). Final co-culture contained a 1:1 ratio of producer: 
target cells, each well totaling 25x104 cells in 1ml of DMEM (3% FBS).  
• 48hr post co-culture supernatants were collected and used in a standard 
infectious assay to allow quantification of cell-free virus and to determine efficacy 
of anti-glycoprotein antibody (See section 2.1.4). Trypsin was used to harvest the 
cells from each well.  
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• Harvested cells were seeded into a 96 well round bottom dish where they were 
centrifuged at 12,000rpm and fixed with 1%PFA for 5min at 4°C.  
• Cells were then stained for HCV non-structural protein NS5A and analyzed by 
flow cytometry as described in section 2.1.9. This allowed determination of de 
novo transmission events (See Fig.5.2).  
Co-culture assays to determine requirement for cell contact 
All assays were performed in collagen coated 6 well dishes and in the presence or 
absence of control or anti-glycoprotein antibody.  
• For standard seeding density: A total of 50x104 cells were seeded per well at a 
1:1 ratio of producer: target cells and at a final volume of 2ml per well.  
• For 0.25x seeding density: A total of 12.5x104 cells were seeded per well, again at 
a ratio of 1:1 producer: target cells and at a final volume of 2ml per well. 
• For indirect co-culture: 25x104 target cells were seeded into a collagen coated 6 
well dish and 25x104 infected producer cells were seeded onto the underside of 
an inverted 0.1µM transwell insert (BD Falcon, CA USA) and incubated at 37°C 
for 30min. The transwell inserts were then carefully added to the 6 well dishes 
containing the target cells.  
• 48hrs post co-culture supernatants were collected. For in-direct co-culture 
supernatant was collected from the top and bottom chambers. Supernatants were 
then used in a standard infectious assay (See section 2.1.4). 
• For standard and 0.25x seeding density cells were harvested, fixed, stained and 
analyzed as previously described for standard assay. For in-direct co-culture 
producer and target cells were analyzed independently.  
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Optimized co-culture assay for confocal microscopy analysis 
To enable optimum visualization of foci of infection a number of preliminary 
experiments were carried whereby different producer: target ratios and cell seeding 
densities were explored. The optimized assay was as follows: 
• The co-culture was performed on collagen coated 13µm glass cover slips in 24 
well plates.  
• Producer and target cells were seeded at a 1:20 ratio at 0.75x standard seeding 
density (9.4x104 cells per well) in a total volume of 500µl.  
• 48hr post co-culture the cells were fixed with ice-cold methanol and stained for 
non-structural protein NS5A (See section 2.1.10) using 9E10 primary antibody 
and anti-mouse IgG2a Alexa-fluor 594 secondary antibody.  
• Cells nuclei were counterstained with (DAPI) (Sigma) and mounted onto glass 
slides using ProLong Antifade mounting agent (Invitrogen, CA, USA).  
• Stained cells were imaged on a Zeiss META head confocal microscope with a 
40x water immersion objective. Background fluorescence of samples was 
corrected based on control samples stained with species-matched IgG and 
secondary antibody only. 
 
 
 
 
 
 
 
 
 
 
76 
3. Results: The role of CD81 in hepatoma cell spread. 
 
3.0 Introduction  
 
Tetraspanins are widely expressed small membrane proteins that share common 
structural features: four transmembrane domains, a small intracellular loop, two short 
intracytoplasmic termini, and two extra-cellular loops (EC1 and EC2). They associate 
with each other and non-tetraspanin partner proteins, CD81 is reported to interact 
with tetraspanin CD9, immunoglobulin like proteins EWI-2 and EWI-F as well as 
integrins α3β1, α4β1 and αvβ5, and signaling proteins including protein kinase C 
(PKC) (42, 74, 411, 427, 458, 481, 528, 556). Posttranslational palmitoylation of 
juxta-membrane cysteine residues are essential to stabilize protein-protein 
interactions and to permit a link to cholesterol and gangliosides, allowing the 
formation of higher ordered networks at the cell surface termed tetraspanin enriched 
microdomains (TEMS) (43, 76, 77, 536). However, the role of palmitoylation may 
vary depending on the tetraspanin in question (77). TEMS are distinct from lipid rafts 
since they do not contain glycosylphosphatidylinositol-anchored proteins or caveolin 
(196, 270).  
 
Tetraspanins are described to function as ‘molecular organizers’ by regulating 
associated signaling proteins via lateral protein-protein interactions. At the present 
time there is no data to support the existence of tetraspanin-specific agonist ligands 
(299, 561). Their role(s) can vary depending on both the cell type and tetraspanin in 
question and include cell adhesion, proliferation, motility, activation and signal 
transduction, processes often associated with cancer progression (561). 
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All anti-tetraspanin antibodies published to date bind EC2 that is implicated in 
tetraspanin-tetraspanin and tetraspanin-partner protein interactions (459). Anti-
tetraspanin antibodies are thought to function by blocking tetraspanin – partner 
protein interactions (177, 352, 427) or by activating tetraspanin intracellular signaling 
through cross-linking and aggregation of cell surface proteins (449). Tetraspanin 
CD81 was originally identified as the target protein for an antibody that inhibited the 
proliferation of a number of lymphoid cell lines (356). Since then studies with anti-
CD81 antibodies have suggested a role for CD81 in: Human T cell leukemia virus 
type I (HTLV) (218) and Human immunodeficiency virus (HIV) (164) induced 
syncytium formation; rat astrocyte morphology (158), T-cell maturation (51), and 
hepatic stellate cell migration. These studies have highlighted the diversity of role(s) 
for CD81 in different cell types and yet the mechanisms underlying these cellular 
processes are poorly defined.  
 
Several studies have reported that recombinant forms of HCV E2 glycoprotein and 
anti-CD81 engagement of immune cells promote actin cytoskeletal rearrangement 
and altered cellular functions (104, 105, 253, 486, 498) including: T cell stimulation 
via the activation of Lck a Src family protein kinase (104, 498); inhibition of NK 
cytolytic activity (105, 486) and B-cell activation and proliferation (93, 403). These 
findings suggest that HCV engagement of CD81 on immune cells may promote liver 
inflammation and implicate a role for HCV in B-lymphocyte disorders including 
cryoglobulinemia and B cell non-Hodgkin lymphoma (93, 104, 403). However a 
recent study by Yoon and colleagues demonstrated that HCVcc had no effect on NK 
cell activity, suggesting that earlier reports may be an artefact of using recombinant 
HCV E2 (549).  
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Coffey et al., reported ezrin phosphorylation following CD81 engagement of B 
lymphocytes and hypothesized that ezrin and F-actin rearrangement(s) following 
CD81 engagement may be an underlying mechanism of CD81 function in other cell 
types (95). Anti-CD81 induced phosphorylation of Ezrin Radoxin Moesin (ERM) 
proteins on NK cells promotes their migration (253). Ligation of CD81 expressed on 
hepatoma cells (Huh-7) has been reported to activate MAPK-ERK and Rho-family 
GTPase signaling pathways, promoting cellular proliferation, and facilitating HCV 
entry (54, 66, 558).  
The aim of this chapter is to ascertain the effect(s) of CD81 engagement using a 
panel of antibodies recognizing novel epitopes for their effect(s) on hepatoma 
morphology and to ascertain whether HCV infection perturbs CD81-dependent 
cellular processes.  
 
 
 
79 
3.1 CD81 engagement promotes actin polymerisation dependent hepatoma cell 
spread.  
 
To ascertain the distribution of CD81 and actin in the hepatoma cell line Huh-7.5  
(47) the cells were fixed and stained with anti-CD81 mAb 2.s131 and phaloidin (F-
actin stain) and imaged by confocal microscopy. CD81 localized at the cell 
membrane and in intracellular punctate regions, and co-localized with F-actin 
specifically at areas of cell contacts (Pearson’s co-localization co-efficient Rr = 
0.4210 (+/- 0.1121)) (Fig.3.1A). To determine whether anti-CD81 engagement of 
hepatoma cells promotes actin polymerization and subsequent changes in cellular 
morphology the cells were engineered to express GFP tagged CD81 and Ruby 
tagged Lifeact. The latter is a fluorophore tagged 17aa peptide that binds to 
filamentous actin (F-actin) without inhibiting its function allowing live cell imaging of 
the actin cytoskeleton (399).  AcGFP.CD81 and Lifeact-Ruby expressing Huh-7.5 
cells were seeded onto glass bottom 35mm dishes that had been coated with anti-
CD81mAb 1.s262, anti-Beta-1 Integrin or irrelevant IgG control and blocked with 1% 
BSA to prevent non-specific binding. The cells were imaged by total internal 
reflection microscopy (TIRF). TIRF microscopy is an imaging technique that utilizes 
an evanescent wave to excite only the first 100nm of sample enabling highly 
sensitive images to be taken of the cell membrane (310).  Images were collected 
every 10 mins over the course of 80 mins. Both anti-CD81 and anti-Beta-1 integrin 
promoted hepatoma cell spread, whereas the cells failed to attach and spread on 
control irrelevant IgG coated plates and could not be imaged (Fig.3.2B&C). Specific 
areas of actin - CD81 co-localization were observed in both anti-CD81 and anti-Beta-
1 treated cells, indicating that their co-localization is not dependent on anti-CD81 
engagement.  
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Figure 3.1: CD81 and F-actin expression in Huh-7.5 hepatoma cells. 
(A) Huh-7.5 cells were cultured on glass cover slips for 24hrs prior to formaldehyde 
fixation and saponin permeabilisation. CD81 was visualized using 2.s131 mAb and 
alexa-fluor 488 secondary antibody (green), F-actin visualized using phalloidin-594 
(Red). Cell nuclei were counter stained with DAPI (Blue) and the cells imaged with a 
Zeiss META head confocal microscope with a 60x water immersion objective. White 
scale bar equal to 10µm. CD81 and F-actin co-localization was quantified ((Pearsons 
co-localization coefficient (Rr) = 0.42 (+/-0.1)) for 10 representative images using 
ImageJ co-localization software. Huh-7.5 cells were engineered to express GFP 
tagged CD81 (Green) and Ruby tagged Lifeact (Red) to visualize F-actin. Cells were 
seeded onto glass bottom 35mm dishes coated with (B) anti-CD81 (1.s262) or (C) 
anti-Beta-1 and images collected by TIRF microscopy (Nikon A1R) every 10min for a 
total of 80min. The data set is representative of two independent experiments.  
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To study the processes involved in anti-CD81 induced cell spread we developed an 
assay to quantify antibody-induced changes in cell morphology. Hepatoma cells were 
seeded onto antibody coated 96 well plates for defined periods of time before 
imaging by phase microscopy. This method allowed us to enumerate the percentage 
of spreading cells (Fig.3.2A). To confirm that anti-CD81 induced cell spread was 
dependent on CD81 expression we compared parental HepG2 cells that lack CD81 
to those transduced to express CD81. HepG2.CD81 cells spread on both anti-CD81 
and anti-Beta-1 coated wells in contrast to HepG2 parental cells that only spread on 
anti-Beta-1 coated wells (Fig.3.2B). Furthermore anti-CD81 IgG and not FAb 
fragments induced HepG2.CD81 cell spread, demonstrating that anti-CD81 induced 
cell spread is dependent on antibody bivalency (Fig.3.2C). To ascertain whether anti-
CD81 induced changes in hepatoma shape were dependent on actin polymerization 
the cells were treated with Latrunculin B and Cytocholasin D, and assayed for their 
response to anti-CD81 and anti-Beta-1 integrin ligation. Latrunculin B and 
Cytocholasin D treated HepG2.CD81 cells showed no detectable spread in response 
to anti-CD81 and anti-Beta-1, demonstrating an actin polymerization dependent 
process (Fig.3.2D). Similar results were observed with Huh-7.5 cells and both 
hepatoma cell lines demonstrated a dose-dependent cell spread in response to anti-
CD81 mAb 1.s262 (Fig.3.2E). Huh-7.5 and HepG2.CD81 cells showed different 
spread kinetics with maximum spread noted after 1hr and 6hrs, respectively (data not 
shown).  
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Figure 3.2: CD81 engagement promotes actin-polymerization dependent 
hepatoma cell spread. 
(A) Cartoon of antibody induced cell spread assay. mAbs are immobilized  onto 
ELISA plates (5µg/ml, 4°C overnight incubation). Wells blocked with PBS/1%BSA for 
30min at room temperature. Cells were seeded at 3x104 cells/well and incubated at 
37°C for a defined period of time and imaged by phase microscopy. (B) Phase 
images of HepG2 and HepG2.CD81 spread on anti-CD81 1.s262, anti-Beta-1 
integrin and irrelevant IgG control coated plates at 6hrs post seeding. (C) Phase 
images of HepG2.CD81 spread on anti-CD81 2.s66 IgG and 2.s66 Fab and irrelevant 
IgG control coated plates at 6hrs post seeding (D) Phase images of HepG2.CD81 
spread on anti-CD81 1.s262 and anti-Beta-1 integrin coated plates after pre-treating 
cells with Cytocholasin D, Latrunculin B or DMSO control. (E) Dose dependent 
spread of HepG2.CD81 (6hrs post seeding) and Huh-7.5 cells (1hr post seeding) in 
response to CD81 ligation with mAb1.s262 at 0.1, 0.3, 1, 3 and 10µg/ml. Results are 
representative of three independent experiments.  
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Our laboratory developed a panel of anti-CD81 mAbs that have been mapped to a 
number of EC2 epitopes. The antibodies were screened for their reactivity with 
mutant CD81 EC2 proteins described by Drummer et al., 2002 & 2005 (Screen 
carried out by Ke Hu), enabling the mAbs to be classified into 6 epitope groups 
(Table 3.1). To evaluate the epitope specificity of antibody induced cell spread a 
selection of antibodies were screened for their ability induce HepG2.CD81 cell 
spread (Fig.3.3). All antibodies induced between 30% and 55% of HepG2.CD81 cells 
to spread. The high frequency of cell spread induced by anti-CD81 mAbs from 
different epitope groups suggest that specific EC2 epitope binding is not required to 
induce cell spread. 
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Table 3.1: CD81 antibody epitope grouping. 
HCV E2 WT V123A T149A L162P T167I P176S I182F N184Y F186S K124T V146E F150S C157S T166I C190R
Antibody - A helix B helix 3-10 
helix
C helix CD loop D helix D helix D helix A helix B helix B helix BC loop C helix E helix
2.s20
2.s131
2.s63
I 2.s66
2.s48
2.s139
1.s201
1.s290
III 1.s337
IV 1.s262
1.s135
1.s73
1.s141
VI 2.s155
2.s169
Dimer Monomer
II
V
Table 3.1: CD81 antibody epitope grouping 
Arrows depict reduction in binding of antibody to mutant CD81 EC2 protein compared to WT EC2 protein 
↓ - 25 – 75% reduction in binding, ↓↓ - 75 – 90% reduction, ↓↓↓ >90% reduction in binding 
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Figure 3.3: Diverse panel of anti-CD81 mAbs induce HepG2.CD81 cell spread.  
A panel of anti-CD81 mAbs plus anti-Beta-1 integrin and irrelevant control IgG were 
immobilized onto ELISA plates (5µg/ml, 4°C overnight incubation). Wells were then 
blocked with PBS/1%BSA for 30 min at room temperature prior to seeding 
HepG2.CD81 (3x104 cells/well) cells. Cells were incubated at 37°C for 6hrs and 
imaged by phase microscopy. The frequencies of spreading cells were enumerated 
and the results are representative of three separate experiments.  
85 
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To explore whether antibody affinity for CD81 associates with cell spread the 
percentage of cell spread was compared to binding affinity (Kd) (Fig.3.4A). Kd was 
determined for a selected number of mAbs using a technique called surface plasmon 
resonance. Briefly soluble CD81 EC2 was immobilized onto the surface of a 
biosensor chip and anti-CD81 binding was determined by flowing over increasing 
concentrations of antibody (Christopher Davis performed the surface plasmon 
resonance assays and determined the Kd value for each antibody). No association 
was observed between the Kd and the frequency of cell spread. Since the Kd values 
were determined using a recombinant protein that may not be representative of 
cellular expressed forms of CD81 we also compared cell spread to cell surface 
bound antibody. Cell surface bound antibody was determined by flow cytometry 
analysis at antibody saturating concentrations and expressed as median 
fluorescence intensity (MFI) (Fig.3.4B) (flow cytometry analysis performed by Ke Hu). 
Again no association was observed suggesting that antibody binding affinity is not 
indicative of anti-CD81 induced cell spread.  
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Figure 3.4: Antibody binding affinity is not indicative of anti-CD81 induced 
hepatoma cell spread.  
Cell spread displayed in Fig.3.3 plotted against (A) antibody affinity (Kd) or (B) cell 
surface bound antibody expressed as median fluorescent intensity (MFI). No 
discernable association was observed (Spearman, n.s.). 
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3.2 The CD81 C terminus links to the actin cytoskeleton through association 
with actin-associated proteins Ezrin Radoxin Moesin. 
 
Recent reports have identified the C terminus of CD81 as an essential regulator of 
CD81 induced effects (95, 411). To investigate whether anti-CD81 induced hepatoma 
cell spread is dependent on either the N or C termini, two independent cell lines that 
express low or negligible endogenous CD81 (HepG2 cells and Huh-7 Lunet cells) 
were transduced to express wild type (WT) or mutant CD81 proteins lacking the N-
terminal (CD81ΔN) or C-terminal (CD81ΔC) regions. Cell surface CD81 expression was 
determined by flow cytometry and the Median fluorescence intensity (MFI) recorded 
(Fig.3.5A). HepG2 and Huh-7 Lunet cells expressing CD81ΔC demonstrated a 
significantly reduced level of anti-CD81 induced cell spread compared to cells 
expressing wild type CD81, whilst no difference was observed in anti-Beta-1 induced 
cell spread. In contrast deletion of the N terminus had no detectable effect on anti-
CD81 or ant-Beta-1 induced cell spread compared to wild type control in either cell 
line (Fig.3.5B).  
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Figure 3.5: A role for CD81 C terminus in actin polymerization dependent 
hepatoma cell spread. 
HepG2 and Huh-7 Lunet cells were transduced to express wild type CD81 (WT), 
CD81ΔN and CD81ΔC proteins. (A) Cell surface expression of CD81 was analyzed by 
flow cytometry (anti-CD81 2.s131mAb used). CD81 expression (Black line) IgG 
control (Solid grey). Median fluorescent intensity (MFI) was determined and is stated 
in the top right corner of each graph. (B) Parental and transduced cells were seeded 
onto anti-CD81 1.s262, anti-Beta-1 integrin, and irrelevant control IgG coated wells 
(All coated at 5µg/ml). Phase images were taken and the frequency of spreading 
cells determined. Results are representative of three independent experiments. Error 
bars indicate standard deviation from the mean. A significant difference between 
percentage cell spread determined for CD81ΔC compared to WT expressing cells in 
response to anti-CD81 mAb ligation was observed in both a HepG2 and Huh-7 Lunet 
cell background (p= 0.0020 and <0.0001 respectively, Two tailed unpaired T-test).  
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Ezrin Radoxin Moesin (ERM) proteins bind actin and recent studies have highlighted 
a role for CD81-ERM association in a number of different cell types including Retinal 
pigment epithelium (RPE), Human umbilical vein endothelial cells (HUVEC), HeLa 
cells and lymphocytes (74, 365). Intramolecular associations between the N and C 
termini of ERM proteins hold the proteins in an inactive (closed) conformation. 
Phosphorylation of threonine residues in the actin binding domain(s) (ezrin Thr567, 
radixin Thr564, moesin Thr558) promote an active (open) conformation that allows 
the C terminus to interact with actin and the N terminal (FERM) domain to bind 
membrane proteins (140, 308, 448). Recent reports have demonstrated an essential 
role for the CD81 C terminus to associate with ERM in a number of cell lines (95, 
411).  
 
Given our earlier observation showing a role for the CD81 C terminus in hepatoma 
cell spread we were interested to investigate the role of ERM proteins in CD81 
dependent hepatoma spread. To determine whether CD81 engagement promotes 
ERM phosphorylation, Huh-7.5 hepatoma cells were incubated with anti-CD81 mAb 
1.s262 for defined periods of time before lysis and western blot analysis with 
antibodies specific for phosphorylated ERM (P-ERM) and actin. P-ERM was detected 
in the untreated cell lysates and showed no detectable increase following antibody 
treatment (Fig.3.6A). Additional experiments confirmed P-ERM expression in Huh-7.5 
cells that co-localized with CD81 at the cell surface (Pearson’s co-localization 
coefficient, Rr = 0.662 +/- 0.047) (Fig.3.6B). Finally, to determine whether ERM 
proteins are functionally relevant in anti-CD81 induced cell spread Huh-7.5 cells were 
transduced to express a GFP tagged dominant negative Moesin, N-Moesin-GFP, and 
control, Moesin-GFP (13) (Fig.3.6C). N-moesin-GFP was previously reported to alter 
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cell morphology by interfering with ERM dependent processes (13). Huh-7.5 cells 
expressing the dominant negative N-Moesin-GFP showed significantly reduced anti-
CD81 induced spread compared to control Moesin-GFP expressing cells, 
demonstrating a role for ERM proteins in anti-CD81 induced cell spread (Fig.3.6D). 
Deletion of CD81 C terminus or use of a dominant negative ERM protein significantly 
reduced but did not eradicate anti-CD81 induced cell spread, suggesting that CD81 
may be linked to the actin cytoskeleton through a number of indirect interactions 
consistent with CD81 being part of a TEM.  
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Figure 3.6: Actin associated proteins Ezrin Radoxin Moesin (ERM) facilitate 
ant-CD81 induced hepatoma spread.  
(A) Huh-7.5 cells were exposed to anti-CD81 mAb 1.s262 for defined time periods 
prior to cell lysis and western blot analysis. Blots were probed for P-ERM and β-actin 
(loading control). (B) Huh-7.5 cells were cultured on glass cover slips for 24hrs prior 
to formaldehyde fixation and Triton-X 100 permeabilisation. CD81 was visualized 
using mAb 2.s131 and alexa-fluor 594 secondary antibody (Red), P-ERM visualized 
using anti-P-ERM (Cell signaling) and alexa-fluor 488 secondary antibody (Green). 
Cell nuclei were counter stained with DAPI (Blue) and the cells imaged with a Zeiss 
META head confocal microscope with a 60x water immersion objective. White scale 
bars represents 10µm. Pearsons co-localization coefficient Rr = 0.66 (+/-0.04) 
(ImageJ co-localization software). Mean and standard deviation of Rr determined 
from 10 images. (C) Cartoon of the structure of Moesin, Moesin-GFP, and N-Moesin-
GFP proteins based on work by Amieva et al., 1999. (D) Huh-7.5 cells were 
transfected to express Moesin-GFP and dominant negative N-Moesin-GFP (13) 
24hrs prior to seeding onto anti-CD81 1.s262, anti-Beta-1 integrin, and irrelevant 
control IgG coated wells (All coated at 5µg/ml). Frequency of GFP+ve cell spread 
was determined. Results expressed as percentage cell spread and are 
representative of three independent experiments. Error bars indicate standard 
deviation from the mean. A significant difference between percentage cell spread 
determined for Moesin-GFP compared to N-Moesin-GFP positive cells in response to 
anti-CD81 mAb ligation was observed (p<0.0001, Two tailed unpaired T-test).  
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3.3 Investigation into the role of different signaling pathways involved in anti-
CD81 induced cell spread.  
 
Signaling proteins including Rho-family GTPases, and several Ser/Thr kinases 
including ROCK (Rho associated kinase) have been shown to be stimulated following 
CD81 engagement (54) or to associate with CD81 (PKC) (556). Furthermore, all of 
these pathways have been implicated with either the activation of ERM proteins (308, 
448, 547) or the regulation of the actin cytoskeleton in different cell types (88, 253, 
272, 277, 366). To determine whether any of these signaling proteins play a role in 
anti-CD81 induced hepatoma cell spread, Huh-7.5 cells were pretreated with specific 
inhibitors against Rho (C3 transferase, 5µg/ml), Rac (Rac 1 inhibitor, 100µM), ROCK 
(Y276232, 2.5µM) and PKC (Bisindymaleimide, 100nM) prior to seeding the cells 
onto anti-CD81 coated wells. All inhibitors were present throughout the entire assay 
(Fig.3.7). All inhibitors had minimal effects on anti-CD81 induced cell spread.  
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Figure 3.7: Effect of inhibitors to Rho family GTPases (Rho and Rac) and 
Ser/Thr kinases (ROCK and PKC) on anti-CD81 induced hepatoma cell spread.  
Huh-7.5 cells were treated with inhibitors to Rho (C3 transferase, 5µg/ml), Rac (Rac 
1 inhibitor, 100µM), ROCK (Y276232, 2.5µM) and PKC (Bisindymaleimide, 100nM) 
as well as untreated or DMSO control. Concentrations used had no cytotoxic effects 
determined using an MTS assay (data not shown). Treated cells were seeded onto 
anti-CD81 1.s262 and irrelevant IgG control coated wells in the continued presence 
of the inhibitors for 1hr. Cells were imaged by phase microscopy. Images 
representative of three independent experiments.  
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Ab engagement of CD81 has been reported to activate mitogen activated protein 
kinase (MAPK) in a number of cell types resulting in different cellular responses, 
including the activation of T cells (104) and increased proliferation of hepatoma cell 
lines (54, 66, 498). MAPK signaling has been associated with the modulation of cell 
spread, including the regulation of macrophage, fibroblast and endothelial cell spread 
(115, 451, 491). AP-1 (Activator protein-1) is a transcription factor regulated by 
MAPK (489, 514). Our laboratory has previously used an AP-1-luciferase reporter 
assay to monitor MAPK signaling in Huh-7.5 cells. Huh-7.5 cells have a high basal 
MAPK activity that is reduced following treatment with MAPK inhibitors U0126, 
PD98059, and SB203580 (All AP-1 reporter work was carried out by Michelle 
Farqhuar). To ascertain whether MAPK signaling is involved in anti-CD81 induced 
hepatoma spread, Huh-7.5 cells were treated with the inhibitors and seeded onto 
anti-CD81 and monitored for spread after 1hr. None of the inhibitors modulated anti-
CD81 induced cell spread implying that this process is MAPK independent (Fig.3.8). 
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Figure 3-8: MAP Kinase independent cell spread 
Huh-7.5 cells were treated with MAPK inhibitors (SB203580, PD98059, and U0126) 
at 100µM and DMSO control. Treated cells were then seeded onto anti-CD81 1.s262 
and irrelevant IgG control coated wells in the continued presence of the inhibitors for 
1hr. Concentrations used had no cytotoxic effects determined using an MTS assay 
(data not shown). Cells were imaged by phase microscopy and representative 
images presented.  
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Dynamin is a large GTPase and primary research focused predominantly on its role 
in clathrin mediated endocytosis. Interestingly dynamin has been found to localize 
with actin filaments and recent evidence suggests that dynamin coordinates actin 
cytoskeleton dynamics associated with cell spread (24, 176, 318, 420, 422, 524). To 
investigate a role for dynamin in anti-CD81 induced hepatoma cell spread, cells were 
incubated with the dynamin specific inhibitor dynasore prior to and during the cell 
spread assay (298).  Dynasore significantly reduced anti-CD81 induced hepatoma 
spread and yet had no detectable effect on anti-Beta-1 induced cell spread (Fig.3.9) 
demonstrating a role for dynamin in anti-CD81 induced hepatoma cell spread.  
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Figure 3.9: Anti-CD81 induced hepatoma cell spread is dependent on large 
GTPase Dynamin.  
Huh-7.5 cells were pretreated with dynamin inhibitor dynasore (40µM) and DMSO 
control. Pretreated cells were then seeded onto anti-CD81 1.s262, anti-Beta-1 
integrin and irrelevant IgG control coated wells for 1hr in the continued presence of 
inhibitor. (A) Cells were imaged by phase microscopy. (B) The frequency of 
spreading cells was determined. Error bars indicate standard deviation from the 
mean. A significant difference between percentage cell spread for control compared 
to dynasore treated cells in response to anti-CD81 mAb ligation was observed, (p< 
0.0001, Two tailed unpaired T-test used). Results are representative of three 
separate experiments.  
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 3.4 HCV E2 glycoprotein does not induce hepatoma cell spread 
 
HCV E2 glycoproteins have been reported to bind to CD81 (384) and we were 
interested to know whether sE2 would induce hepatoma spread. Given our earlier 
observation that bivalent anti-CD81 was required to promote cell spread, we 
captured sE2 (JFH-1) at 1 in 3 dilution onto 96 well plates via an antibody specific for 
an epitope tag expressed at the C-terminus of E2. sE2 was bound by the specific 
antibody and yet failed to promote hepatoma spread (Fig.3.10). Previous research 
has reported modulation of intracellular signaling upon sE2-CD81 binding and HCV 
infection (54, 66) making it important to determine the effects of HCV infection on 
anti-CD81 induced cell spread.  
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Figure 3.10 HCV E2 glycoprotein engagement of CD81 did not induce 
hepatoma cell spread.  
(A) sE2 was immobilized onto ELISA plates by 10/76b capture; bound glycoprotein 
was detected with 4µg/ml cocktail of human anti-E2 mAb (CBH2/CBH4G). 
Absorbance displayed for BSA only, 10/7b (capture) only, sE2 only and 10/76b plus 
sE2 coated wells. sE2 used at 1 in 3 dilution. (B) Huh-7.5 cells were seeded onto 
captured sE2-coated plates (1 in 3 dilution) or control BSA or 10/76b (capture) only 
coated wells for 1hr. Cells were imaged by phase microscopy. Images are 
representative of two separate experiments.  
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3.5 HCV infection perturbs anti-CD81 induced cell spread.  
 
Huh-7.5 cells were electroporated with genomic HCV RNA of different JFH-1 
chimeric strains (J6/JFH genotype 1b and SA13/JFH genotype 5a) and 96hr post 
electroporation mock and HCV infected cells were assessed for their ability to spread 
in response to anti-CD81 ligation. The frequency of cells expressing NS5A was 
determined by flow cytometry. HCV infected cells showed a reduced spread in 
response to anti-CD81 stimulation (Fig.3.11A). It is important to note that the 
frequency of infected cells varied between electroporations and this in turn reflected 
the defect in anti-CD81 induced hepatoma cell spread observed, despite this HCV 
infection repeatedly perturbed anti-CD81 induced cell spread.  
 
To determine whether this phenomenon was common for other anti-tetraspanin and 
associated proteins, Huh-7.5 cells supporting full-length HCVcc (J6/JFH) or control 
mock infected Huh-7.5 cells were seeded onto plates coated with antibodies specific 
for tetraspanins and tetraspanin associated proteins. Furthermore to ascertain 
whether this perturbation was due to HCV replication the assay was performed with 
Huh-7.5 cells supporting JFH-1 sub genomic replicon (SGR). J6/JFH infected cells 
showed reduced spread compared to mock cells in response to anti-CD81 and anti-
CD9 induced spread.  In contrast J6/JFH infected cells spread in a comparable 
manner to mock cells in response to other anti-tetraspanin and associated protein 
specific antibodies. Hepatoma cells supporting SGR RNA spread in a comparable 
manner to mock infected cells in response to all antibodies tested (Fig.3.11B), 
suggesting that virus particle genesis or the viral structural proteins perturb anti-
CD81 induced changes in hepatoma morphology.  
 
 
102 
Many viruses down regulate their receptors to prevent super infection (55, 348, 511). 
To investigate whether virus infection modulated CD81 expression, uninfected and 
infected cells were stained for CD81 and Beta-1 integrin expression (Fig.11C). No 
differences were noted in cell surface CD81 or Beta-1 integrin expression, 
demonstrating that reduced cell surface CD81 expression does not account for the 
observed changes in anti-CD81 induced cell spread.  
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Figure 3.11: HCV infection reduces anti-CD81 induced hepatoma spread.  
(A) HCV strain J6/JFH and SA13/JFH RNA were delivered into Huh-7.5 cells by 
electroporation (ep) and 96hr later seeded onto anti-CD81mAb 1.s262 coated wells 
for 1hr. Cells were imaged by phase microscopy and the frequency of spreading cells 
determined. A significant difference between percentage cell spread determined for 
J6/JFH and SA13/JFH infected cells compared to mock cells in response to anti-
CD81 mAb ligation was observed, (p = 0.0195 and 0.0053 respectively, Two tailed 
unpaired T-test). HCV NS5A expression was determined for each cell population by 
flow cytometry. (B) J6/JFH full length and JFH-1 sub-genomic (SGR) RNA were 
delivered into Huh-7.5 cells by ep and 96hrs later seeded onto anti-CD81 1.s262, 
anti-CD9, anti-CD51, anti-EWI-2, anti-Beta-1 integrin and irrelevant IgG control 
coated plates. Phase images were taken at 1hr post seeding and the frequency of 
spread cells determined. HCV NS5A protein expression was determined for each cell 
population by flow cytometry. A significant difference between percentage cell spread 
determined for J6/JFH compared to mock cells in response to anti-CD81 and anti-
CD9 mAb ligation was observed, (p=0.0005 and 0.0046 respectively, Two tailed 
unpaired T-test). (C) Cell surface CD81 and Beta-1 integrin expression were 
determined for J6/JFH, SGR and mock infected Huh-7.5 cells using flow cytometry. 
Error bars indicate standard deviation from the mean. Results are representative of 
three indepent experiments.  
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To investigate whether HCV particles or virus binding to CD81 are required to perturb 
anti-CD81 induced cell spread two mutant viruses were employed: J6/JFH del B 
contained a mutation in domain III of NS5A that prevents a phosphorylation event 
that is critical for particle assembly whilst permitting genome replication and protein 
translation (473); JFH1W529A contains a mutation that prevents E2-CD81 binding 
(515). Both viruses had no significant effect on anti-CD81 induced cell spread 
suggesting that HCV particle genesis and/or CD81 engagement is essential to 
modulate anti-CD81 induced cell spread (Fig.3.12A). The frequencies of NS5A 
positive cells were determined by flow cytometry (Fig.3.12B). For the mutant viruses, 
J6/JFH del B and JFH1W529A, the frequency of NS5A positive cells were low, 42 and 
48 % respectively, compared to full length J6/JFH, 85%, suggesting a possible 
alternative explanation for theminimal effect(s) on anti-CD81 induced hepatoma 
spread.  
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Figure 3.12: Anti-CD81 induced spread of J6/JFH del B virus and JFH-1 CD81 
mutant virus expressing hepatoma cells. 
J6/JFH, J6/JFH del B (473) and JFH1W529A mutant (515) RNA were delivered into 
Huh-7.5 cells by electroporation (ep) and 96hrs later seeded onto anti-CD81mAb 
1.s262 coated plates for 1hr. Cells were imaged by phase microscopy and the 
frequency of cell spread determined. HCV NS5A protein expression was determined 
for each cell population by flow cytometry. Error bars indicate standard deviation from 
the mean. Experiments were performed in triplicate and results are representative of 
three independent experiments. A significant difference between percentage cell 
spread determined for J6/JFH compared to mock infected cells in response to anti-
CD81 mAb ligation was observed, (p=0.0062, Two tailed unpaired T-test). No 
significant difference between cell spread determined for J6/JFH del B and 
JFH1W529A expressing cells compared to mock infected cells in response to anti-
CD81 mAb ligation was observed (p=0.1266 and 0.2546 respectively, Two tailed 
unpaired T-test).  
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Cholesterol metabolism is important for many aspects of the HCV lifecycle (235, 540) 
and has been reported to play a role in tetraspanin membrane organization  (78, 402, 
439, 521). To investigate whether changes in cholesterol modulate anti-CD81 
induced spread Huh-7.5 hepatoma cells were treated with methyl-beta-cyclodextrin 
(MβCD) to selectively remove cholesterol or with MβCD-cholesterol complexes to 
promote cholesterol uptake in naïve cells or cells treated with MβCD (87). All 
treatments had their expected effect(s) on total cholesterol levels (Fig.3.13A). 
Reducing total cellular cholesterol decreased hepatoma cell spread in response to 
anti-CD81 or anti-Beta-1 integrin ligation (Fig.3.13B). In contrast, increasing total 
cholesterol perturbed anti-CD81 induced cell spread and had no significant effect on 
anti-Beta-1 integrin induced effects (Fig.3.13B). Importantly, we noted that HCV 
infection promotes total cellular cholesterol levels (Fig.3.13C), providing an 
explanation for the observed perturbation of anti-CD81 induced spread in HCV 
infected cells. 
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Figure 3.13: CD81 dependent cell spread is sensitive to changes in cholesterol. 
Huh-7.5 cells were treated in suspension with MβCD (5mM), Cholesterol (+MβCD) or 
MβCD followed by cholesterol(+MβCD) or left untreated (Cholesterol used at 5mM). 
(A) Cells were counted and lysed for total cell cholesterol quantification (Amplex Red 
Cholesterol Assay Kit, Invitrogen) or (B) seeded onto anti-CD81 mAb 1.s262, anti-
Beta-1 integrin or irrelevant IgG control coated wells for 1hr. Cells were imaged by 
phase microscopy and the frequency of spreading cells determined. A significant 
difference between percentage cell spread determined for MβCD treated compared 
to untreated cells in response to anti-CD81 and anti-Beta-1 ligation was observed 
(p=0.0004 and P=0.004 respectively, Two tailed unpaired T-test). A significant 
difference was observed between cholesterol(+MβCD) treatment of naïve or MβCD 
treated cells compared to untreated cells in response to anti-CD81 mAb ligation but 
not anti-Beta-1 integrin ligation, p=0.0179, 0.0467, 0.1968 and 0.1134 respectively. 
(C) J6/JFH RNA was delivered into Huh-7.5 cells by electroporation (ep) 96hrs later 
cells were counted and lysed for total cell cholesterol quantification. A significant 
difference between total cell cholesterol in J6/JFH infected cells compared to mock 
infected cells was observed, (p<0.0001, Two tailed unpaired T-test). Error bars 
indicate standard deviation from the mean. Experiments were performed in triplicate 
and results are representative of three separate experiments.  
A 
B 
C 
??
??
??
?
??
??
??
???
??
??
??
?
??
??
???
??
???
???
??
??
??
??
??
??
?
??
??
??
???
??
??
??
?
??
??
???
??
???
???
??
??
??
?
??
??
?? ????????? ???????????
???
? ?
?????
????
??
??
???
??
107 
 
 
108 
3.6 Discussion  
 
The function of tetraspanin CD81 in hepatoma cell biology is largely unknown. In this 
study we used a diverse panel of novel CD81 EC2 binding antibodies to investigate 
the effect(s) of ligation on hepatoma cell morphology. Antibodies can be useful tools 
for investigating tetraspanin function(s), they are reported to disrupt partner protein 
interactions or promote intracellular signaling through protein aggregation at the cell 
surface (177, 352, 427, 449). Importantly anti-CD81 mAbs may also mimic ligation of 
CD81 by HCV glycoproteins. Ligation of CD81 on immune cells by anti-CD81 mAb or 
HCV sE2 glycoprotein activates numerous signaling cascades and induces actin 
dependent morphological changes (95, 104, 253, 342, 486, 498). We observed 
hepatoma spread upon engagement of a diverse panel of immobilized anti-CD81 
mAbs but not recombinant protein sE2. Importantly HCV infection was found to 
perturb this response. Our observations point to an indirect mechanism of inhibition 
through perturbation of intracellular events possibly the result of increased total 
cellular cholesterol levels. Tetraspanins are often associated with cancer progression 
and hence these observations may have important consequences in HCV associated 
liver disease.  
 
To investigate the effect(s) of CD81 ligation on hepatoma cells, the cells were 
seeded onto anti-CD81 mAb immobilized onto ELISA plates and cultured for defined 
periods of time before imaging by phase microscopy (Fig.3.2A). Huh-7.5 and 
HepG2.CD81 cells were observed to spread in a dose dependent manner in 
response to IgG whilst they did not spread after binding corresponding Fab 
fragments, indicating this process is dependent on antibody bivalency and cross-
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linking CD81 is most likely required (Fig.3.2C). Furthermore actin polymerization 
inhibitors Latrunculin B (Lat B) and Cytochalasin D (Cyt D) successfully blocked cell 
spread revealing the process to be dependent on actin polymerization (Fig.3.2.D). 
The actin polymerization inhibitors have different modes of action; Lat B binds actin 
monomers preventing polymerization (100, 336) whilst Cyt D binds F-actin high 
affinity binding sites inhibiting filament elongation (141).  
 
CD81 and F-Actin were observed to co-localize at hepatoma cell contacts and further 
analysis using TIRF microscopy demonstrated that during anti-CD81 and anti-Beta-1 
integrin induced hepatoma cell spread, actin and CD81 co-localized in specific 
regions on the lower surface of the cell (Fig.3.1). These observations demonstrate 
that CD81-F-actin co-localization is not dependent on CD81 engagement as 
previously observed on B cells (95). An explanation for this could be due to 
differences in cell type, resting lymphocytes used in the previous studies are cultured 
in suspension as opposed to hepatoma cells that adhere to cell culture plastic and 
grow in monolayers. They are also quiescent, held in the G0 stage of the cellular 
lifecycle, differing again from hepatoma cells that are continually dividing (151). 
 
The regions of high CD81 expression observed on the cell surface of Huh-7.5 cells 
by TIRF microscopy may represent tetraspanin-enriched microdomains (TEMS). 
Tetraspanins are reported to continually interchange between confined (TEM) and 
randomly diffused states (132), whether tetraspanins interact with partner proteins 
and function outside of TEMS is relatively unknown and currently under debate (530). 
Interestingly CD81 is reported to function independently of TEMS for HCV entry 
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(402). New live cell imaging techniques, for example single particle tracking are only 
now becoming available to properly address these questions (132, 530).  
 
A high frequency of cell spread in response to CD81 ligation by antibodies targeting 
different epitopes of CD81 (Fig.3.3), suggesting that antibody-induced cell spread is 
independent of EC2 epitope. Cell spread did not correlate with antibody affinity (Kd) 
determined using recombinant CD81 EC2 (Fig.3.4A). Since recombinant EC2 may 
not be truly representative of in vitro CD81, cell spread was also compared to cell 
surface bound antibody (MFI), again no correlation was observed (Fig.3.4B). These 
results suggest that cell spread is independent of antibody binding affinity. To 
determine whether ligation of other cell surface proteins could induce hepatoma cell 
spread we compared cell spread to antibodies specific for different cell surface 
proteins (data not shown). All tetraspanin and integrin antibodies tested induced cell 
spread to varying degrees, whereas antibodies to HCV co-receptor claudin-1 induced 
cell spread to a much lower degree than anti-CD81. Antibodies targeting a further 
HCV co-receptor, SR-BI, did not induce cell spread. As well as differences in the 
frequency of cell spread observed, the morphology of the spreading cells varied 
depending on the cell surface protein engaged. 
 
CD81 induced hepatoma cell spread was repeatedly perturbed by HCV infection. It is 
not uncommon for viruses to down regulate cell surface receptors to prevent super-
infection (55, 348, 511), we therefore compared CD81 expression of naïve and 
infected Huh-7.5 cells (Fig.3.11C). No change in CD81 expression was observed 
eliminating this as a possible mechanism.  Infection only perturbed anti-CD9 induced 
cell spread and had no effect on antibodies to other other tetraspanin (CD63, CD82) 
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or associated proteins (EWI-2, Beta-1 integrin) (Fig.3.11B). CD81 and CD9 have 
been reported to work in conjunction with one another, in vitro studies have shown a 
strong phenotype only upon silencing both CD81 and CD9 (72, 262, 466) and single 
tetraspanin knock out mice are reported to have a mild phenotype compared to 
double knock outs (466, 467). The observed inhibition of both CD81 and CD9 
induced spread suggests these tetraspanins may be working together in this process. 
sE2 ligation of CD81 did not induce hepatoma cell spread (Fig.310), this differs from 
previous observations where antibody and sE2 engagement of CD81 have induced 
similar effects (54, 95, 104, 105, 253). Yoon et al., 2009 reported that HCV infection 
had no effect on NK cell function suggesting that earlier results with sE2 may be 
incorrect, demonstrating that recombinant E2 is not always representative of E2 on 
viral particles most likely due to configuration and concentration differences.  
 
To ascertain whether HCV infection inhibits anti-CD81 induced spread directly 
through HCV envelope binding to CD81 or indirectly through HCV replication and/or 
protein expression, experiments were performed using Huh-7.5 cells expressing 
mutant viruses and a JFH-1 sub genomic replicon (Fig.3.11&12). Mutant virus 
J6/JFH del B has a mutation in domain III of NS5A that prevents assembly of viral 
particles (473) and JFH1W529A mutant virus was previously demonstrated to be 
deficient in CD81 binding (515). No reduction in anti-CD81 induced spread of cells 
expressing these mutant viruses or JFH-1 sub-genomic replicon was observed 
compared to controls. These results suggest firstly that HCV genome replication is 
not enough to drive this perturbation and secondly that engagement of CD81 by HCV 
is essential in this process.  In all assays cells were cultured for 96hrs post delivery of 
viral RNA to ensure a high level of infection, unfortunately due to variations in 
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electroporation efficiency and the fact that sub-genomic RNA and mutant viruses are 
unable to transmit infection (See chapter 5) we were unable to achieve a comparable 
level of infection compared to the full length viruses. Less than 50% of J6/JFH del B, 
JFH1W529A and sub-genomic replicon expressing cells were NS5A positive compared 
to greater than 60% of the full-length virus infected cells. Therefore the lower NS5A 
expression levels may be an alternative explanation for these results, thus it is still 
un-resolved as to whether CD81 engagement is needed for this phenotype.  
 
The C terminus of CD81 has previously been reported to be important for eliciting 
anti-CD81 induced affects on immune cells (95, 411). Hepatoma cells expressing a 
CD81 protein lacking its C terminus (CD81ΔC) had a significantly reduced spread 
compared to cells expressing CD81 WT and CD81ΔN protein upon CD81 ligation, 
implying that the C terminus is also important for CD81 function in hepatoma cells 
(Fig.3.5). A PDZ domain located on the C terminus of CD81 is reported to bind actin-
associated proteins Ezrin, Radoxin, Moesin (ERM) (411). Threonine phosphorylation 
of all ERM proteins (ezrin Thr567, radixin Thr564, and moesin Thr558) induces a 
conformational change leading to activation (140, 308, 448). We failed to observe 
any change in P-ERM levels following antibody ligation of CD81 on hepatoma cells 
(Fig.3.6A) as previously reported for NK and B cells respectively (95, 253). A high 
basal level of P-ERM was observed in our hepatoma cells that may have masked 
any small changes in P-ERM levels. Despite this CD81 co-localized with P-ERM at 
the surface of hepatoma cells, and cells expressing a dominant negative N-moesin 
protein had significantly reduced anti-CD81 induced cell spread (Fig.3.6). These 
observations suggest that ERM proteins do indeed play a role in anti-CD81 induced 
hepatoma cell spread and we hypothesize this is through interactions with the C 
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terminus of CD81. The CD81ΔC and N-moesin-GFP expressing cells only exhibited 
partial inhibition of anti-CD81 induced cell spread suggesting that this is not the only 
means by which CD81 can link to the actin cytoskeleton consistent with CD81 
functioning as part of a TEM in this process.  
 
Of note HCV infection was not inhibited in cells expressing the dominant negative N-
moesin-GFP protein compared to control (data not shown) suggesting firstly that 
HCV infection is independent of ERM proteins and secondly that the mechanism 
underlying anti-CD81 induced spread is independent of the mechanism involved in 
HCV entry. Coffey et al., 2009 observed a Syk dependent Tyrosine phosphorylation 
of Ezrin upon CD81 ligation in B cells. Syk is a non-receptor protein kinase and was 
originally thought to only be present in heamatopoetic cells but has since been 
identified in a number of non-haematopoietic cell lineages including endothelium, 
epithelium and importantly hepatocytes (487, 527). Interestingly HCV NS5A N- 
terminus interacts directly with Syk and NS5A expression has been reported to inhibit 
Syk kinase activity (220), this could be a possible explanation for HCV perturbation of 
anti-CD81 induced cell spread.  Further work is necessary to determine whether Syk 
dependent tyrosine phosphorylation of Ezrin upon CD81 ligation occurs in 
hepatocytes. 
 
CD81 ligation has been associated with regulating a number of signaling cascades. 
MAPK signaling for example was previously demonstrated to increase upon CD81 
ligation on hepatoma cells (54, 66, 558). Work in our laboratory using an AP-1 
reporter system demonstrated that MAPK inhibitors (U0126, PD98059, and 
SB203580) inhibit MAPK signaling in Huh-7.5 cells (Michelle Farhquar, unpublished 
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data). However none of these inhibitors were found to have any observable effect on 
hepatoma cell spread (Fig.3.8) suggesting CD81 induced hepatoma cell spread is 
MAPK independent. A further kinase Protein Kinase C (PKC) is also associated with 
CD81 (556), and inhibion of PKC again had no effect on anti-CD81 induced 
hepatoma cell spread.  Rho GTPases are primarily involved in modulation of actin 
dynamics and have also been associated with CD81 function (54, 272, 366, 398). We 
investigated the effect(s) of a number of Rho GTPase family inhibitors; again none of 
the inhibitors had any observable effect(s) on cell spread (Fig.3.7). The inhibitors 
used all have limitations in specificity that may explain their inability to inhibit spread. 
(438, 494) (154, 438).  Another Rho family GTPase member that is not tested in this 
study is cdc42 again this GTPase has been implicated in modulating cell spread 
(389). The involvement of Rho GTPases in cancer progression is fueling ongoing 
research to identify more specific inhibitors (295), these may be useful for the future 
work needed to dismiss the involvement of Rho GTPase family members in anti-
CD81 induced hepatoma cell spread.  
 
Dynasore, an inhibitor of the large GTPase dynamin, specifically perturbed anti-CD81 
induced cell spread and not anti-Beta-1 integrin induced cell spread (Fig.3.9). These 
results suggest that dynamin is either directly or indirectly involved in CD81 function. 
Further experiments are necessary to determine whether dynamin specifically inhibits 
CD81 function or whether this perturbation is common to other tetraspanins. To date 
no literature exists on a link between tetraspanins and dynamin although dynamin is 
reported to associate with actin (176, 318, 419, 420). Dynamin has also been 
reported to regulate the localization of Rac a member of the Rho family GTPases 
(422).  Although our data does not implicate Rac GTPase involvement in anti-CD81 
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induced hepatoma cell spread our analysis is not conclusive and reports have 
previously implicated Rho GTPases in anti-CD81 induced effects (54). It is therefore 
plausible that inhibition of dynamin may indirectly inhibit anti-CD81 induced cell 
spread through inhibition of Rac. Furthermore, a direct association between HCV co-
receptor tight junction protein Occludin and dynamin has recently been reported 
(287) and research carried out by our laboratory has demonstrated that Occludin can 
be found associated with Claudin-1 and CD81 on the surface of hepatoma cells (188) 
linking CD81 indirectly with dynamin.  
 
Cholesterol is important for correct tetraspanin localization and function (78, 402, 
439, 521). In fact levels of membrane cholesterol can alter the function of numerous 
cell surface proteins effecting, cell signaling, adhesion and migration (390). 
Modulation of cholesterol levels have previously been shown to reduce CD81-
Claudin-1 and CD81-CD81 association in hepatoma cells (188). Further to this a 
number of studies have demonstrated that cholesterol depletion inhibits HCV entry 
(188, 235, 402). To determine whether cholesterol levels modulate anti-CD81 
induced hepatoma cell spread, Huh-7.5 cells were pre-treated with MβCD to deplete 
cholesterol or with MβCD-cholesterol complexes to increase cholesterol uptake. Anti-
CD81 and anti-Beta-1 integrin induced hepatoma cell spread were reduced upon 
depletion of cellular cholesterol. Furthermore a significant decrease in anti-CD81 but 
not anti-Beta-1 integrin induced cell spread upon addition of cholesterol was 
observed (Fig.3.13). These findings suggest that cholesterol levels are important for 
CD81 function in hepatoma cells.  
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Numerous viruses rely on and modulate cholesterol metabolism for effective viral 
production and replication and HCV is no exception (111). Hepatocytes acquire 
cholesterol through two major processes, firstly through the mevalonate pathway that 
synthesizes cholesterol and other lipids from acetyl-CoA (163) and secondly by 
acquisition of cholesterol from low and high-density lipoproteins (LDL and HDL) in the 
plasma through LDL receptor and Scavenger receptor BI  (SR-BI) respectively (254, 
406). A number of studies have reported that inhibitors of steps in the mevalonate 
pathway can inhibit HCV replication demonstrating HCV reliance on lipid and 
cholesterol metabolism (86, 217, 236). HCV infection in vivo is often associated with 
reduced serum cholesterol levels (201, 344, 426). A number of mechanisms are 
thought to be responsible for this for example HCV infection induces oxidative stress 
through mitochondrial dysfunction resulting in increased levels of reactive oxygen 
species (ROS) that in turn reduce fatty acid oxidation and export (470). Peroxisome 
proliferator activated receptor alpha (PPRPα) expression is reduced (114), PPRPα is 
responsible for up-regulating genes involved in transport and β-oxidation of fatty 
acids (453). Microsomal triglyceride transfer protein (MTP) activity is also reported to 
be reduced upon HCV infection (376), MTP is involved in the assembly and secretion 
of VLDL (213). Furthermore HCV infection up regulates numerous genes associated 
with cholesterol and fatty acid metabolism by activating ER associated transcription 
factors SREBPs (sterol regulatory element binding protein) (504). The increase in 
production together with reduced release ultimately results in higher cholesterol/lipid 
levels inside the cell thought to provide an ideal environment for HCV replication and 
production (463). In support of the literature we observed a significant increase in 
cellular cholesterol levels of J6/JFH infected Huh-7.5 cells compared to mock 
infected cells (Fig.3.13C). The observed increase in cellular cholesterol levels 
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provides an explanation for the perturbation of anti-CD81 induced hepatoma cell 
spread by HCV infection.  
 
The main function of the liver is to control cholesterol homeostasis and therefore 
HCV induced alteration(s) in cholesterol metabolism may have many pathological 
consequences. An example of which is Liver steatosis, caused by accumulation of 
lipid droplets, it occurs in approximately 73% of patients infected with genotype 3a 
and 50% of patients infected with other genotypes (343, 344). Until now changes in 
cholesterol levels induced by HCV infection have not been studied with respect to 
effect(s) on cell surface protein function(s), this is an area of research that will need 
further attention in the future.  
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4. Results: The role of CD81 in hepatoma migration and 
effects of HCV infection.  
4.0 Introduction 
The major causes of liver disease are viral hepatitis B and C, alcoholic liver disease 
and non alcoholic steatohepatitis (NASH). Fibrosis, a wound healing response to 
damage is a characteristic feature of liver disease and is associated with increased 
extra-cellular matrix (ECM) production (32). ECM comprises approximately 3% of the 
relative mass of a normal liver and has an important role in structure and cell 
proliferation, gene expression, migration and differentiation (36). In normal liver ECM 
is found in the portal tracts, sinusoidal walls and central veins (281) and comprises 
predominantly of collagens I, III, IV and V. Collagens I, III, and V are found in the 
portal tract and central vein whereas collagen IV is found with laminin in a low density 
basement-like membrane along the sinusoids.  The other major ECM components of 
the liver include fibronectin, tenascin and nidogen. Increased ECM restricts intra-
hepatic blood flow and promotes fibrotic scars that can promote the development of 
regenerating hepatocyte nodules, defined as liver cirrhosis (150). Intra-hepatic blood 
flow is restricted and hepatocyte function diminishes. Cirrhosis is a major clinical risk 
factor in the development of hepatocellular carcinoma (HCC) (273). 
 
Unlike HBV, HCV does not integrate into the host genome and the role of HCV in 
HCC pathogenesis is unclear. The observation that HCC develops in HCV infected 
patients predominantly after liver cirrhosis  (68, 200, 246, 273) supports an indirect 
mechanism for HCV induced pathology. In rare cases HCC has been reported to 
develop prior to cirrhosis and recent research has reported a link between HCV 
protein expression and oncogenic cellular pathways, including core (17, 33, 340), 
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NS3 (294) and NS5A (89, 330). In patients suffering from HCC, recurrence of a 
tumour following treatment is high leading to a poor long-term survival prognosis 
(537). In a study by Yang et al. 64% of patients (n=348) developed intrahepatic 
recurrences and 14% had extrahepatic metastasis after tumor resection. Recurrence 
after treatment is thought to occur because of multicentric HCC or local intrahepatic 
metastasis (537).  
 
Metastasis is the process by which a tumor cell moves from the primary tumor to a 
secondary site, this process is complex and involves a number of steps including; 
detachment from the primary tumor, migration/invasion through surrounding tissue, 
and transport through blood or lymph vessels and growth at the secondary site (546). 
These steps involve transition from a non-motile, polarized epithelial cell to a non-
polarized, motile, mesenchymal cell state, a reversible process termed epithelial 
mesenchymal transition (EMT) (546). EMT is not only associated with cancer 
progression but is a fundamental process during development and tissue 
regeneration (83, 233). Numerous factors are involved in the induction of EMT 
associated with cancer progression, including transforming growth factor beta (TGFβ) 
(551), hepatocyte growth factor (HGF) (417) and insulin like growth factor (IGF-1) 
(168). Furthermore, the ECM composition has been demonstrated to induce EMT 
(435). Interestingly, the stabilization of hypoxic inducible factor (HIF-1α) has also 
been implicated in the induction of EMT (198, 532, 534, 535) and recent research 
demonstrating that HCV infection stabilizes HIF-1α under normoxic conditions, 
highlights a novel mechanism for HCV associated HCC pathogenesis (191, 341, 
400). 
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Changes in cell-cell and cell-ECM adhesion are mediated by an altered expression of 
adhesion proteins such as E-Cadherin (370), N-Cadherin (211) and specific integrins 
(187). Integrins are a large family of heterodimeric cell membrane proteins containing 
an alpha and beta subunit that interact with different ECM ligands and coordinate 
inside out and outside in signaling (212). Not surprisingly they have been implicated 
in regulating hepatocellular adhesion and migration (345, 346, 531, 538). The 
transcription factors Snail, Slug and TWIST are all implicated in controlling E-
cadherin expression during EMT (64, 183, 532) and they can all be regulated by HIF-
1α (534, 535). The modulation of actin cytoskeleton dynamics is mediated through 
the induction of complex signaling cascades. For example, TGFβ induced EMT 
engages the cytoskeletol modeling Rho GTPases (408) and different kinases 
including mitogen activated protein kinase MAPK (22) and phosphoinositol-3 kinase 
PI3K (23). It Is important to note that not all metastatic cancers possess the 
molecular signatures of EMT (471, 508), however current evidence demonstrates 
that hepatocellular carcinoma involves EMT of hepatocytes (33, 160, 169, 552). 
 
As previously mentioned tetraspanins have been implicated in tumor progression 
(561). Tetraspanins are commonly expressed on filopodia and lamellipodia, a prime 
location to co-ordinate cell adhesion and invasion (372). A number of tetraspanins 
are directly or indirectly linked to integrins and have been demonstrated to modulate 
integrin signaling and localization (41, 42, 195, 427). For example, CD151 
redistributes integrins α3β1 and α6β4 to the leading edge of a migrating cell (513). In 
addition, tetraspanins can recruit signaling proteins such as protein kinase C (PKC) 
and phosphatidylinositol 4-kinase (PI4K) to be in close proximity with integrins (539, 
556).  
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Expression levels of certain tetraspanins have been reported to associate with 
patient outcome, for example high CD151 expression levels in lung, colon and 
prostate cancer predict poor patient outcome (15, 190, 482). In contrast, high CD82 
expression levels are associated with good prognosis (484). CD9 expression has 
been associated with both tumor suppression and progression, depending on the cell 
type (203, 416, 501). Tetraspanin expression levels are hypothesized to modulate 
cell migration and adhesion by regulating the function or enzymatic activity of 
associated partner proteins (530). For example tetraspanin CD151 activates 
proMMP-7, a matrix metalloproteinase involved in ECM degradation, and increased 
CD151 expression promotes MMP-7 function and thus results in increased 
metastatic potential of the cell in question (436). A further example is the association 
of tetraspanin CD82 with integrin α6 and epidermal growth factor receptor (EGFR), 
where CD82 induces the internalization of these surface proteins and concomitant 
changes in cell-ECM adhesion and invasive potential (192, 353). In addition to 
investigating the effect(s) of tetraspanin expression on cellular processes in vitro 
studies have used anti-tetraspanin antibodies to elucidate the role of tetraspanin 
function as discussed in the previous chapter. 
 
CD81 has been reported to interact with a number of integrins namely α3β1, α4β1 
and αvβ5 (42, 75, 427, 481, 528) and in some instances these associations have 
been implicated in altering cell-ECM adhesion (481, 528). The role of CD81 as a 
coordinator of metastasis is not straightforward, with some studies reporting CD81 as 
a tumor suppressor (42, 481) and others suggesting a tumor promoter role (262, 312, 
528). Mazzocca and colleagues reported that activation of CD81 with anti-CD81 
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mAbs in liver tumor cells increased their proliferation and CD81 expression 
decreased cell motility (66, 313).  
In the previous chapter we established that engagement of CD81 on hepatoma cells 
induced an actin polymerization dependent cell spread that was perturbed by HCV 
infection. In this chapter we aim to expand on these findings by investigating a 
possible role for CD81 in hepatoma migration and whether HCV infection perturbs 
these cellular processes.  
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4.1 Role of tetraspanin CD81 in hepatoma-ECM adhesion 
 
To investigate whether CD81 is involved in hepatoma cell-ECM adhesion we 
established an assay to quantify cell adhesion. Cells were seeded in 96 well tissue 
culture plate and incubated for 1hr at 37°C. Non-adhered cells were removed by 
washing and the remaining cells fixed with methanol and stained with crystal violet. 
Adhered cells were quantified by measuring absorbance at 600nm. A linear 
relationship between the number of cells seeded and absorbance was observed 
(Fig.4.1A). A maximal number of hepatoma cells successfully adhered to the plate 
following 15min incubation (Fig.4.1B). To investigate the relative adhesion of Huh-7.5 
cells to different ECM proteins, their association to laminin, fibronectin, collagen I and 
collagen IV coated wells was determined. ECM coated wells were incubated for 
30min with 1% BSA to block non-specific binding prior to seeding the cells. Results 
are presented as specific adhesion to ECM by subtracting the optical density 
obtained for BSA only coated wells (Fig.4.1C). 
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Figure 4.1: Development of hepatoma-ECM adhesion assay. 
Huh-7.5 cells were seeded in triplicate (A) at known concentrations into a 96 well 
tissue culture plastic plates and incubated at 37°C for 1hr or (B) at a concentration of 
4x104 cells per well and incubated for 15, 30, 45 or 60min at 37°C. Non-adhered cells 
were washed off with PBS and adhered cells fixed with ice-cold methanol. Attached 
cells were stained with 0.1% crystal violet and quantified by absorbance read at 
600nm. (C) Huh-7.5 cells were seeded in triplicate at a concentration of 4x104 cells 
per well into ECM coated wells (laminin, fibronecin, collagen I, collagen IV (10µg/ml) 
and uncoated control). All wells were blocked with 1% BSA/PBS prior to seeding the 
cells. Cells were then incubated for 15min at 37°C. Non-adhered cells were washed 
off with PBS and adhered cells fixed with ice-cold methanol. Attached cells were 
stained with 0.1% crystal violet and quantified by absorbance read at 600nm. 
Specific adhesion was determined by subtracting the absorbance reading of the BSA 
uncoated control. All results are representative of three independent experiments. 
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Initial experiments investigated whether CD81 engagement would alter Huh-7.5 
adhesion to fibronectin. Huh-7.5 cell monolayers were removed from tissue culture 
plastic using trypsin and cell suspensions treated with a panel of anti-CD81mAbs 
(Described in section 3.1) prior to seeding onto fibronectin-coated wells. All mAbs 
were used at 1µg/ml, a concentration previously demonstrated to saturate the cell 
surface by flow cytometry (Flow cytometry analysis carried out by Ke Hu, data not 
shown). As a positive control we used an antibody against integrin β1 subunit, 
previously shown to inhibit cell-ECM adhesion (46). All of the anti-CD81 mAbs had a 
minimal effect on Huh-7.5 cell adhesion to fibronectin whilst the anti-Beta-1 (integrin) 
antibody significantly reduced cell adhesion (Fig.4.2A).  
 
CD81 expression levels were previously reported to reduce epithelial cell adhesion to 
fibronectin (481). We therefore investigated the role of CD81 expression on 
hepatoma-ECM adhesion. To do this we engineered two hepatoma cell lines (CD81 
negative), HepG2 and Huh-7 CD81null cells to express CD81 and compared their 
adhesion to different ECM proteins, laminin, collagen I, collagen IV and fibronectin. 
CD81 cell surface expression was confirmed by flow cytometry. No differences were 
noted in hepatoma-ECM adhesion between parental and CD81 expressing cells 
(Fig.4.2B&C).  
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Figure 4.2: CD81 is not involved in hepatoma - ECM adhesion. 
(A) 96 well tissue culture plates were coated with fibronectin (10µg/ml) or left 
uncoated (control), wells then blocked with 1% BSA/PBS. Huh-7.5 cells were 
incubated for 30min at 37°C in the presence of CD81mAbs (1µg/ml) in suspension 
prior to seeding onto coated plates (4x104 cells per well). Cells were allowed to 
adhere for 15min at 37°C. Non-adhered cells were washed off with PBS and adhered 
cells fixed with ice-cold methanol. Attached cells were stained with 0.1% crystal violet 
and quantified by absorbance read at 600nm. Specific adhesion was determined by 
subtracting absorbance reading from the BSA control. 96 well plates were coated 
with laminin, fibronecin, collagen I, collagen IV (10µg/ml) or left uncoated (control), 
wells then blocked with 1% BSA/PBS. HepG2 (B) and Huh-7null (C) and 
corresponding cells engineered to express CD81 were seeded at a concentration of 
4x104 cells per well. Attached cells were quantified as in previous experiments. CD81 
cell surface expression was detected using 2.s131 (anti-CD81mAb) primary antibody 
and Alexa-fluor 488 secondary antibody and analyzed by flow cytometry. Grey filled 
lines represent IgG control, Red lines represent parental cells and Blue lines 
represent cells engineered to express CD81. In all assays cells were serum starved 
overnight prior to the assay and the assay was performed in serum free DMEM. Error 
bars indicate standard deviation from the mean. Results are representative of three 
independent experiments. 
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Several viruses have been reported to modulate cell surface expression of adhesion 
molecules including integrins resulting in altered cell-ECM adhesion. Examples 
include: Ebola virus infection down-regulates β1 integrin expression and reduces the 
adhesion of infected cells to ECM (446); Rotavirus infection increases integrin 
expression of intestinal cells (184) and Epstein-Barr virus up-regulates α5 integrins in 
transformed B lymphocytes and promotes their invasion (210). To investigate 
whether HCV infection alters hepatoma-ECM adhesion, mock and HCV strain J6/JFH 
infected Huh-7.5 cells (3 days post infection) were seeded onto different ECM protein 
coated wells. Adhered cells were fixed with methanol, and stained with crystal violet 
to determine adhesion or with anti-NS5A antibody to determine the frequency of 
ECM-bound infected cells. No significant differences were noted between the 
adhesion of mock or J6/JFH infected cells to fibronectin (Fig.4.3A-B), demonstrating 
that HCV infection does not modulate hepatoma-ECM adhesion. In support of this 
conclusion HCV infection did not alter integrin expression (Fig.4.3C).  
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Figure 4.3 HCV infection does not alter cell-ECM adhesion 
96 well plates were coated with fibronectin, laminin, collagen I, collagen IV (10µg/ml ) 
or left uncoated, wells then blocked with 1% BSA/PBS. (A) Huh-7.5 cells were 
infected with J6/JFH HCVcc. At day 3 post infection J6/JFH infected and naïve Huh-
7.5 cells were seeded at 4x104 cells per well into the different ECM coated wells or 
(B) at days 3, 4 and 5 post infection cells were seeded onto fibronectin coated wells. 
Cells were allowed to adhere for 15min at 37°C and attached cells were then either 
stained with crystal violet to determine specific adhesion as in previous assays or 
anti-NS5A and DAPI to determine HCV infection level of adhered cells. For (B) a 
proportion of cells were PFA fixed each day, stained for NS5A and analyzed by flow 
cytometry to quantify infection level of cells prior to seeding (Approximately 65, 84 
and 93% NS5A +ve at days 3,4 and 5 respectively). (C) Integrin cell surface 
expression of J6/JFH HCVcc infected or naïve Huh-7.5 cells was determined by flow 
cytometry using specific anti-integrin antibodies as detailed in Table 2.4. Cell surface 
expression expressed as median fluorescence intensity (MFI). Error bars indicate 
standard deviation from the mean. Experiments were performed in triplicate and 
results are representative of three independent experiments. 
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As previously mentioned ECM plays an essential role in liver structure and function 
(36) and increased ECM production is frequently associated with liver disease (32). 
Hepatic stelate cells are thought to be the most important cells in coordinating liver 
fibrosis and express collagens and basement membrane (149). Hepatocytes are the 
dominant source of plasma fibronectin in the body and although the role of plasma 
fibronectin in fibrosis is not known, mRNA for cellular fibronectin has also been 
reported in hepatocytes. Thus, the role of hepatocyte ECM expression in fibrosis is 
still under debate (161, 307, 334, 507). Recent reports demonstrating hepatocyte 
EMT argue for a more dominant role of hepatocytes in fibrosis than originally thought 
(33, 160, 552).  
To ascertain whether HCV infection alters hepatoma ECM production we developed 
a quantitative ELISA to measure collagen I, collagen IV and fibronectin ECM proteins 
(Fig.4.4A). Huh-7.5 cells were seeded onto gelatin-coated plates and infected with 
mock or J6/JFH HCVcc and 96hr post infection cells were lysed and ECM expression 
quantified. A replicate plate was methanol fixed and stained for NS5A to determine 
the level of infected cells (Fig. 4.4B). Naïve and J6/JFH infected Huh-7.5 cells 
expressed comparable levels of fibronectin and collagen I, no detectable collagen IV.  
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Figure 4.4: HCV infection does not alter hepatoma ECM expression. 
(A) 96 well plates were coated with gelatin followed by ECM proteins. Plates were 
then developed using ECM ELISA described in section 2.2.5. (B) Huh-7.5 cells were 
seeded onto gelatin coated plates. Cells were infected with J6/JFH HCVcc or mock 
infected one day post seeding. On day 5 post seeding one plate was fixed with ice 
cold methanol and stained with anti-NS5A and cell nuclei counter stained with DAPI 
to determine HCV infection level of adhered cells. Cells were lysed from the replicate 
plate and ECM expression determined using the ECM ELISA. Error bars indicate 
standard deviation from the mean. Experiments were performed in triplicate and 
results are representative of three independent experiments. 
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To investigate this further the production of fibronectin was determined over 5 days, 
and no significant differences were observed (Fig.4.5A). Finally we compared 
fibronectin expression during the first 12hrs post seeding. Mock and J6/JFH infected 
cells were seeded onto gelatin-coated plates and cells lysed 4, 8 and 12hrs later 
(Fig.4.5B). Both mock and J6/JFH infected cells expressed comparable levels of 
fibronectin over the first 12hrs post seeding.  
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Figure 4.5: HCV infection does not alter hepatoma ECM expression.  
(A) Huh-7.5 cells were seeded onto gelatin coated 96 well plates. Cells were infected 
with J6/JFH HCVcc or mock infected one day post seeding. Cells were then lysed at 
days 3, 4 and 5 post infection and stored at 4°C. All plates were then developed 
using the ECM ELISA described in section 2.2.5 and expression displayed as µg/ml 
of fibronectin produced. On a replicate plate cells were fixed with ice-cold methanol 
and stained with anti-NS5A and cell nuclei counter stained with DAPI to determine 
HCV infection level. (B) J6/JFH (5 days post infection, approximately 80% NS5A 
positive determined by flow cytometry) or mock infected cells were seeded onto 
gelatin coated plates. Cells were then lysed at 4, 8 and 12hrs post seeding. The plate 
was developed using the ECM ELISA and expression displayed as µg/ml of 
fibronectin produced. Error bars indicate standard deviation from the mean. 
Experiments were performed in triplicate and results are representative of three 
independent experiments.  
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4.2 Role of CD81 in hepatoma invasion  
 
The ability of a cell to migrate or invade though ECM is an important phenotypic 
feature that defines a cells metastatic potential. Invading cells induce membrane 
ruffles at their leading edge in a process involving the reduction of rigid actin stress 
fibers leaving only fine cortical actin (25, 256). This leads to the formation of flat or 
sheet like projections containing a branched actin network termed lamellipodia. 
Filopodia emerge from lamellipodia as rod like protrusions with tight bundled actin. 
Invadopodia is the term for a further cellular membrane protrusion, these are actin 
rich protrusions containing high expression levels of integrins and cell MT1-MMPs 
and enable remodeling and cell penetration into ECM  (18, 546).  
 
Tetraspanin-integrin complexes localize to microvilli like protrusions, including CD81-
α3β1 complexes on mammary carcinoma cells. Interestingly anti-CD81 mAbs have 
been reported to induce cellular protrusions and matrix metalloproteinase MMP-2 
production and increased cell invasion (460). We previously observed that anti-CD81 
ligation promoted hepatoma cell spread. To determine whether antibody engagement 
induced microvilli or filopodia like protrusions, Huh-7.5 cells were seeded onto glass 
cover slips and exposed to anti-CD81 mAbs or IgG control (2µg/ml). Wells were fixed 
with EM grade formaldehyde at 0, 10 and 240min post exposure to antibody. CD81 
was visualized using a 488 conjugated secondary antibody and F-actin visualized 
with phalloidin-594, cells were imaged by confocal microscopy. Huh-7.5 cells had 
numerous microvilli or filopodia protruding from their cell body with CD81 expressed 
at the cell surface, however we failed to observe any increase in filopodia following 
anti-CD81 stimulation (Fig.4.6).    
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Figure 4.6: Anti-CD81 mAbs do not induce hepatoma filopodia 
Huh-7.5 cells were cultured on glass cover slips and serum starved overnight. Cells 
were incubated at 37°C with anti-CD81 mAbs (2.s131 and 2.s48) or IgG control 
diluted in serum free DMEM for 0,10 or 240 mins. Cells were then fixed with EM 
grade formaldehyde and CD81 visualized using an Alexa-fluor-488 secondary 
antibody, actin was visualized with phalloidin-594 and cell nuclei counter stained with 
DAPI. Images were taken using a Zeiss META head confocal microscope with a 60x 
water immersion objective. Images are representative of three separate experiments.  
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To investigate whether CD81 engagement has a role in hepatoma migration a 
confluent monolayer of Huh-7.5 cells were wounded using a p200 tip and wound 
closure measured over 24hrs in the presence of anti-CD81 mAb (1.s262) or 
irrelevant control IgG (Fig.4.7A). No differences were observed in wound closure in 
antibody treated or untreated cells.  
 
As previously described the processes involved in cell migration and cell invasion 
differ and we therefore investigated the effect(s) of CD81 ligation on hepatoma 
invasion through a collagen coated 8µm pore-size transwell insert (Fig.4.7B). Cells 
were incubated for 24hrs at 37°C followed by mechanical removal of non-invaded 
cells and methanol fixation of invaded cells. The invaded cells were stained with 
crystal violet and counted. Anti-CD81 mAb had no effect on hepatoma invasion.  
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Figure 4.7: Anti-CD81 mAb has no effect on hepatoma migration or invasion.  
(A) Huh-7.5 cells (1x106) were seeded into 6 well dishes and serum starved 
overnight. A wound was performed using a P200 tip and media replaced with serum 
free DMEM ( plus mitomycin C at 15µg/ml) containing anti-CD81 mAb (1.s262) or 
IgG at 10µg/ml. Cells were incubated at 37°C and phase images taken at 0 and 
24hrs. Percentage wound closure determined using IPLab 4.0 (BD Biosciences). (B) 
Huh-7.5 cells were serum starved overnight. Trypsin was used to remove the cells 
from the tissue culture plastic prior to re-suspension in serum free DMEM containing 
anti-CD81 mAb (1.s262) at 0.1,1, and 10µg/ml or irrelevant control IgG at 10µg/ml. 
Cells were seeded (4x104 cells/200ul/cell) into the top chamber of an 8µm pore 
collagen coated transwell insert. The lower chamber contained 300µl of DMEM 
containing the corresponding treatment. Cells were incubated at 37°C for 24hrs. Non-
invaded cells were mechanically removed and invaded cells methanol fixed and 
stained with 0.1% crystal violet. 3x fields of view were imaged per transwell at 40x 
magnifcation on a fluorescent microscope (NikonTE2000, Japan). The number of 
invaded cells was determined and invasion expressed relative to control. Two tailed 
unpaired T-test’s were performed to determine whether there was a significant 
difference in wound closure or invasion between untreated and anti-CD81 treated 
cells. No significant differences were observed P>0.05.  Error bars indicate standard 
deviation from the mean. Assays were performed in duplicate and the results are 
representative of three separate experiments. 
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To determine whether CD81 expression modulates hepatoma cell migration, CD81 
expression was silenced using CD81 siRNA treatment and wound closure compared 
to irrelevant control siRNA treated cells (Fig.4.8A). The assay was performed in the 
presence of mitomycin C, mitomycin C prevents cell proliferation and thus enables 
discrimination between cell proliferation and cell migration. Cells were fixed and 
stained for CD81 at the end of the assay to confirm reduction in CD81 expression. 
We observed a small but significant reduction in cell migration of siRNA CD81 
treated cells compared to control.  
 
Two approaches were taken to investigate the effects of CD81 expression on 
hepatoma cell invasion through a collagen coated transwell insert. Firstly invasion of 
HepG2 parental cells and those engineered to express CD81 (HepG2.CD81) were 
compared. Secondly CD81 expression was silenced in Huh-7.5 cells using CD81 
siRNA treatment and invasion compared to irrelevant control siRNA treated cells. A 
control well was stained for CD81 to confirm CD81 silencing. We observed increased 
invasion of HepG2 cells expressing CD81 compared to parental cells demonstrating 
that CD81 expression increases hepatoma invasion potential (Fig.4.8B). Confirming 
this phenomenon we observed a decrease in the invasion of the CD81 silenced Huh-
7.5 cells compared to control (Fig.4.8C). These results demonsrate in two 
independent hepatoma cell lines that CD81 expression increases hepatoma cell 
invasion and implicates CD81 as a tumour promoter.  
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Figure 4.8: CD81 expression increases hepatoma cell invasion.  
(A) Huh-7.5 cells were seeded into 6 well dishes and transfected with si CD81 RNA 
(CD81 KD) or irrelevant control siRNA. 24hrs post transfection a wound was 
performed using a P200 tip and media replaced with serum free DMEM, cells were 
incubated at 37°C and images taken at 0 and 24hrs post wound. Images display 
expression of CD81 KD cells and control cells taken 24hrs post wound on. CD81 
expression visualized using anit-CD81 (2.s131) primary antibody and alexa-fluor 488 
secondary antibody (green). A two tailed unpaired T-test was performed to determine 
whether there was a significant difference in wound closure between control and 
CD81 KD cells. A significant difference was observed P=0.0387. (B) HepG2 and 
HepG2 cells engineered to express CD81 (HepG2.CD81) or (C) Huh-7.5 control and 
Huh-7.5 CD81 KD cells were cultured in a tissue culture flask in serum free 
conditions overnight, cells were trypsinised and re-suspended in serum free DMEM. 
Cells then seeded (4x104 cells/200µl/well) in the top chamber of an 8µm pore 
collagen coated transwell insert. The lower chamber contained 300µl of serum free 
DMEM. Cells were incubated at 37°C for 24hrs. Non-invaded cells were mechanically 
removed and invaded cells methanol fixed and stained with 0.1% crystal violet. 3x 
fields of view were imaged per transwell at 40x magnification on a on a fluorescent 
microscope (NikonTE2000, Japan). The number of invaded cells was determined 
and invasion expressed relative to control. Images display CD81 expression of CD81 
KD cells and control cells taken at the end of the assay in replicate wells. CD81 
expression was visualized using anti-CD81 specific antibody (2.s131) and alexa-fluor 
488 secondary antibody. Two tailed unpaired T-tests were performed to determine 
whether there was a significant difference in invasion between HepG2 and 
HepG2.CD81 cells and control and CD81 KD cells. A significant difference was 
observed, P=< 0.0001 and 0.004 respectively. Error bars indicate standard deviation 
from the mean. Assays were performed in duplicate and the results are 
representative of three separate experiments. 
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4.3 HCV infection modulates hepatoma cell invasion 
 
We previously demonstrated that HCV infection modulates CD81 dependent 
hepatoma cell spread (Chapter 3) and were interested to assess the effect(s) of HCV 
infection on hepatoma invasion and migration. Unfortunately due to category three 
restrictions of imaging we were unable to study the effects of infection on hepatoma 
migration in a scratch wound assay.  
 
Huh-7.5 cells were electroporated with J6/JFH 96hrs prior to the assay. The invasion 
assay was carried out as previously described with the following exceptions; (i) cells 
were labeled with CMFDA (cell tracker green) prior to the assay instead of a crystal 
violet stain post invasion, (ii) cells were seeded in replicate (control) 24 well plates 
not containing transwell inserts, the control and invaded cells were then stained for 
NS5A at the end of the assay to determine the frequency of infected invaded cells 
compared to non-invaded cells. A greater number of cells in the J6/JFH infected 
culture invaded compared to the uninfected cells (Fig.4.9A). However, no difference 
was observed in the frequency of NS5A expressing cells in the control and invaded 
cell population (Fig.4.9B) and thus we hypothesize that a soluble factor may be 
responsible for the increased invasive phenotype of the infected cell population.  
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Figure 4.9: Effect of HCV infection on invasion. 
(A) HCV J6/JFH RNA was delivered into Huh-7.5 cells by electroporation (ep). 72hrs 
post ep cells were cultured in serum free conditions overnight. Cells labeled with 
CMFDA, removed from tissue culture plastic with trypsin and re-suspension in serum 
free DMEM. Cells seeded (4x104 cells/200µl/well) into the top chamber of an 8µm 
pore collagen coated transwell insert or control 24 well plates not containing a 
transwell insert. The lower chamber contained 300µl of serum free DMEM. Cells 
were incubated at 37°C for 24hrs. Non-invaded cells were mechanically removed and 
the invaded and control cells methanol fixed. 3x fields of view were imaged per 
transwell at 40x magnification on a fluorescent microscope (NikonTE2000, Japan). 
The number of invaded cells was determined and invasion expressed relative to 
control. A Two tailed unpaired T-test was performed to determine whether there was 
a significant difference in the invasion of naive and J6/JFH infected cells. A 
significant difference was observed P=0.0010. (B) Fixed cells were stained for NS5A 
and infection level determined for control and invaded cells. Error bars indicate 
standard deviation from the mean. Assays were performed in duplicate and the 
results are representative of three separate experiments. 
 
 
B A 
%
 H
C
V
 i
n
fe
c
te
d
 c
e
ll
s
 
140 
 
 
141 
Previous research reported that HCV infection promotes Vascular endothelial growth 
factor (VEGF) expression (191, 341, 400). Chris Mee has since confirmed this in our 
laboratory (Fig.4.10A). VEGF promotes angiogenesis and elevated VEGF levels in 
patients with HCC are considered to be one of the most important indicators of 
increased tumor angiogenesis (214). Angiogenesis is the process by which new 
blood vessels are formed and is vital in tumor development. Without a blood supply 
tumors cannot grow above a certain size due to hypoxia and lack of essential 
nutrients. Blood supply is also essential for tumor cells to metastasize to other areas 
of the liver or to other organs, a common complication of HCC (537). Apart from its 
important role in angiogenesis VEGF has been demonstrated to reduce HepG2 
hepatoma cell polarity (319, 423). VEGF has also been reported to increase the 
migration of HepG2 cells (531). We therefore investigated whether exogenous VEGF 
stimulation (Fig.4.10B) or neutralization of endogenous VEGF with an anti-VEGF 
mAb (VG67e) (Fig.4.10C) would modulate Huh-7.5 cell invasion. We observed no 
effect of exogenous VEGF or VG67e on Huh-7.5 cell invasion suggesting that VEGF 
does not promote Huh-7.5 cell invasion.  
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Figure 4.10: Huh-7.5 hepatoma cell invasion is independent of VEGF 
(A) Levels of VEGF secretion from naïve and J6/JFH infected Huh-7.5 cells was 
quantified by ELISA (Peprotech), data provided by Chris Mee. A Two tailed unpaired 
T-test was performed to determine whether there was a significant difference in 
VEGF production between naive and J6/JFH infected cells. A significant difference 
was observed P<0.0001. Huh-7.5 cells were cultured in serum free DMEM overnight. 
Cells were removed from tissue culture plastic with trypsin and re-suspension in 
serum free DMEM containing (B) exogenous VEGF (10ng/ml) or untreated control 
and (C) anti-VEGF (VG67e) (400ng/ml) or untreated control. Cells were seeded 
(4x104 cells/200µl/well) into the top chamber of an 8µm pore collagen coated 
transwell insert. The lower chamber contained 300µl of serum free DMEM and 
relevant treatment. Cells were incubated at 37°C for 24hrs. Non-invaded cells were 
mechanically removed and invaded cells methanol fixed and stained with 0.1% 
crystal violet. 3x fields of view were imaged per transwell at 40x magnification on a 
fluorescent microscope (NikonTE2000, Japan). The number of invaded cells was 
determined and invasion expressed relative to control. Two tailed unpaired T-test’s 
were performed to determine whether there was a significant difference in invasion 
between untreated and exogenous VEGF treated or anti-VEGF (VG67e) treated 
cells. No significant differences were observed P>0.05.  Error bars indicate standard 
deviation from the mean. Assays were performed in duplicate and the results are 
representative of three separate experiments. 
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VEGF production is increased in hepatoma cells following HCV infection through 
stabilization of hypoxia inducible facor -1alpha (HIF-1α) (191, 341, 400). HIF-1α is a 
regulatory sub unit of the HIF transcription complex. Under normal cellular oxygen 
levels HIF-1α is continually expressed and degraded by the following oxygen 
dependent process; HIF-1α is hydroxylated by HIF prolylhydroxylases enabling it to 
be recognized by von Hippel-Lindau tumor suppressor protein (pVHL). pVHL is a 
recognition component of the E3 ubiquitin ligase complex and targets HIF-1α for 
proteasomal degradation (238). If HIF-1α becomes stably expressed it is 
translocated to the nucleus where it binds to ubiquitously expressed HIf-1β and 
recruits other transcriptional co-factors making up the HIF transcription complex 
(238). As well as VEGF the HIF transcription complex is responsible for the up-
regulation of numerous genes responsible for proliferation, cell survival, metastasis 
and glycolysis (238). HIF-1α can be stabilized through a number of mechanisms 
including growth factor induction, genetic mutations of oxygen sensing genes, loss of 
tumor suppressor function, mitochondrial dysfunction as well as hypoxia (388). To 
determine whether hepatoma cell invasion increases upon stabilization of HIF-1α we 
compared invasion of Huh-7.5 cells under hypoxic (1%O2) or normoxic (22% O2) 
conditions. We observed a significant increase in cell invasion under hypoxic 
conditions compared to the normoxic control (Fig.4.12A&B). To establish whether the 
increased invasive potential is dependent on HIF-1α, hepatoma cells were treated 
with the HIF-1 translation inhibitor, NSC-134754 (1µM) (79, 388). We observed a 
significant decrease in cell invasion under hypoxic conditions in the presence of 
inhibitor whilst only a moderate inhibition was observed under normoxic conditions. 
We propose that the increased invasion of HCV infected hepatoma cells may be 
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mediated through a VEGF independent pathway induced by the stablization of HIF-
1α. 
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Figure 4-11: Hypoxia promotes Huh-7.5 cell invasion. 
(A) Huh-7.5 cells were cultured in serum free DMEM overnight. Cells were removed 
from tissue culture plastic with trypsin and re-suspended in serum free DMEM or (B) 
DMEM containing NSC-134754 (1µM) or DMSO control. Cells seeded (4x104 
cells/200µl/well) into the top chamber of an 8µm pore collagen coated transwell 
insert. The lower chamber contained 300µl of serum free DMEM +/- relevant 
treatment. Cells were incubated at 37°C for 24hrs in normoxic (22%02) or hypoxic 
(1%02) conditions. Non-invaded cells were mechanically removed and invaded cells 
methanol fixed and stained with 0.1% crystal violet. 3x fields of view were imaged per 
transwell at 40x magnification on a fluorescent microscope (NikonTE2000, Japan). A 
Two tailed unpaired T-test was performed to determine whether there was a 
significant difference in invasion between Huh-7.5 cells under normoxic and hypoxic 
conditions.  A significant difference was observed P<0.0001. Further Two tailed 
unpaired T-tests were performed to determine whether there was a significant 
difference in invasion of Huh-7.5 cells under normoxic or hypoxic conditions in the 
presence and absence of HIF inhibitor. T tests were performed on raw data. 
Significant differences were observed P=0.027 and 0.0039 respectively.  Images in 
(A) are representative of invaded cells in normoxic and hypoxic conditions. The 
number of invaded cells was determined and invasion expressed relative to control. 
Error bars indicate standard deviation from the mean. Assays were performed in 
duplicate and the results are representative of three independent experiments. 
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To determine whether a HIF inducible factor is responsible for the increased invasive 
potential of HCV infected cells we quantified the invasion of uninfected and HCV 
infected Huh-7.5 cells in the presence of HIF inhibitor, NSC-134754 (79, Poon, 2009 
#570). We observed a significant decrease in invasion of infected cells in the 
presence of NSC-134754 (1µM) (Fig.4.11A). Interestingly we also observed a 
significant decrease in the percentage of NS5A positive invaded cells in the presence 
of NSC-134754 (Fig.4.11B). The HIF inhibitor may specifically inhibit the invasion of 
HCV infected cells or may differentially regulate the proliferation of uninfected and 
HCV infected cells or block HCV replication. 
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Figure 4.12: HCV induced cell invasion is sensitive to HIF-1α  inhibitor.  
HCV J6/JFH RNA or control no RNA was delivered into Huh-7.5 cells by 
electroporation (ep). 72hrs post ep cells cultured in serum free conditions overnight. 
HCV infected and control cells were labeled with CMFDA, removed from tissue 
culture plastic with trypsin and re-suspended in serum free DMEM containing NSC-
134754 (1µM) or DMSO control. Cells were seeded (4x104 cells/200µl/well) into the 
top chamber of an 8µm pore collagen coated transwell insert. The lower chamber 
contained 300µl of serum free DMEM plus relevant treatment. Cells were then 
incubated at 37°C for 24hrs. Non-invaded cells were mechanically removed and 
invaded cells methanol fixed. (A) 3x fields of view were imaged per transwell at 40x 
magnification on a fluorescent microscope (NikonTE2000, Japan). The number of 
invaded cells was determined and invasion expressed relative to control. No 
significant difference in invasion of naïve cells in the presence and absence of HIF 
inhibitor was observed (P=0.1726, two tailed unpaired T-test). A significant difference 
was observed in invasion of J6/JFH infected Huh-7.5 cells in the presence and 
absence of HIF inhibitor (P=0.0270, two tailed unpaired T-test). (B) Fixed cells were 
stained for NS5A and infection level determined for control and NSC-134754 treated 
cells. A significant difference was observed in infection level of invaded cells in the 
presence and absence of HIF inhibitor (P=0.0013, two tailed unpaired T-test). Error 
bars indicate standard deviation from the mean. Assays were performed in duplicate 
and the results are representative of three separate experiments. 
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To investigate this further we assessed the effects of the HIF inhibitor on HCV 
replication and hepatoma proliferation. At 1µM the HIF inhibitor successfully inhibited 
HCV infection (Fig.4.12A). To determine whether the HIF inhibitor affects HCV 
transmission J6/JFH infected cells were treated with NSC-134754 and viral spread 
quantified over a 48hr period by monitoring NS5A expression by flow cytometry 
(Fig.4.12B). A decrease in the percentage of infected cells in the presence of NSC-
134754 compared to control was observed, demonstrating that NSC-134754 inhibits 
new rounds of infection. To determine whether the HIF inhibitor has a cytotoxic or 
anti-proliferative effect on Huh-7.5 cells we performed an MTS assay (colorimetric 
test that measures metabolic function). We observed a small decrease in MTS signal 
after a 24hr treatment with NSC-134754 compared to control (Fig.4.12C), this can be 
more clearly seen in the corresponding phase images (Fig.4.12D). Results suggest 
that HCV infection may be dependent on HIF-1α stabilization.  
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Figure 4.13: HIF-1α  dependent modulation of proliferation and infection.  
(A) Huh-7.5 cells were treated with NSC-134754 and control at 5,1,and 0.1 µM plus 
DMSO control. 24hrs post treatment an MTS assay was performed to determine 
metabolic function results presented as absorbance at 490nm (minus background). 
(B) Representative phase images of treated cells prior to MTS assay. (C) Huh-7.5 
cells were seeded into 96 well tissue culture plate (0.75x104 cells/well), the following 
day cells were pre-treated for 1hr with DMSO control or NSC-134754 (1µM) 
containing DMEM (3% FBS). Cells were infected with J6/JFH HCVcc in the presence 
or absence of inhibitor. 48hrs post infection cells were fixed with ice-cold methanol 
and stained for NS5A. Infected cells enumerated and infection level represented as 
Infectious units (IU) per ml. (D) HCV J6/JFH RNA was delivered into Huh-7.5 cells by 
electroporation (ep). 48hrs post ep cells seeded into 12 well dishes (25x104cells/well) 
in the presence of DMSO control or NSC-134754 (1µM) containing DMEM (3% FBS). 
0, 24 and 48hrs post treatment cells were harvested, fixed, stained for NS5A and 
quantified using flow cytometry. Results presented as frequency of NS5A positive 
cells. Error bars indicate standard deviation from the mean. Assays were performed 
in duplicate and the results are representative of three independent experiments.  
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4.4 Discussion 
 
HCV infection is one of the leading causes of hepatocellular carcinoma and recent 
research suggests HCV protein expression may be directly responsible (17, 33, 89, 
294, 330, 340). Liver cancer is very difficult to treat and is associated with a high 
frequency of relapse and metastasis (537). As such a greater understanding of the 
processes involved is desperately needed for the development of future anti-cancer 
drugs. In this chapter we demonstrate a role for HCV receptor tetraspanin CD81 in 
hepatoma invasion and furthermore report that HCVcc infection increases the 
invasive potential of hepatoma cells.   
 
Tetraspanins are relatively small membrane proteins and are not believed to directly 
interact with extra-cellular matrix (ECM) proteins (530), however a number of 
tetraspanins namely CD151, CD82, CD9 and importantly CD81 are associated with 
integrins and may therefore be able to indirectly alter cell-ECM interactions (427, 42, 
43, 195) . Major integrin-ligand binding combinations for the ECM proteins we used 
are as follows; Fibronectin binds αIIβ3, αVβ3, αVβ6, αVβ1, α5β1, α8β1, collagen 
binds αI0β1, α2β1, α1β1, α11β1, and finally laminin binds α10β1, α2β1, α1β1, same 
as collagen, and additionally α7β1, α6β4, α6β1 and α3β1 (212). A number of integrin 
subunits were detected on the cell surface of Huh-7.5 hepatoma cells (Fig.4.3.B). 
This included high expression levels of the most predominant beta subunit, β1, as 
well as detection of a number of alpha subunits that form dimers with the β1 subunit 
to bind fibronectin (α5), collagen,  (α1, α2) and laminin (α1, α2, α6). We observed no 
effect of CD81 expression on hepatoma cell (Huh-7 and HepG2 cells) adhesion to 
different ECM proteins (Fig.4.2B&C). In addition to studying the effect(s) of 
tetraspanin expression on cell adhesion, tetraspanin targeting antibodies have also 
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been reported to alter cell-ECM adhesion by regulating tetraspanin – partner protein 
interactions (177, 352, 427). Adhesion of hepatoma cells to ECM protein, fibronectin, 
was not affected by ligation of cell surface CD81 with a diverse panel of anti-CD81 
mAbs (previously described in chapter 3) (Fig.4.2A). In conclusion our findings 
demonstrate that CD81 is not involved in hepatoma cell-ECM adhesion.  
 
Previous research reported the induction of microtubule like projections from 
mammary carcinoma cells embedded in matrigel after exposure to CD81 mAbs, 
thought to be coordinated through an association of CD81 with laminin binding 
integrin α3β1 (460). We were unable to detect α3 integrin cell surface expression on 
our hepatoma cells using flow cytometry analysis. Numerous filopodia like 
protrusions were observed extending from the cell body of Huh-7.5 cells and CD81 
was highly expressed along the cell membrane of these protrusions, ideally located 
to function in the modulation of filopodia and cell migration. However, CD81 
engagement did not promote filopodia/microtubule like protrusions (Fig.4.6). 
Furthermore ligation of CD81 had no effect on hepatoma cell migration and invasion  
(Fig.4.7A&B).  
 
However, CD81 expression was observed to increase hepatoma migration in two 
independent cell lines and in both the scratch wound and collagen invasion transwell 
assays (Fig.4.8). This is in contrast to an earlier publication by Mazzoca et al., 2008 
(313) who reported decreased invasion of CD81 expressing HepG2 cells in response 
to Insulin-like growth factor (IGF-1) stimulation. CD81 was reported to coordinate this 
process through its association with type II phosphoinositide 4-kinase (PI4KII) 
leading to the re-localization of actinin-4 into CD81 enriched intracellular vesicles 
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preventing actin cytoskeleton remodeling. These findings were supported with an in 
vivo mouse model experiment whereby Huh-7 cells with un-detectable levels of 
CD81 were observed to metastasize more than those expressing CD81, of note the 
differences between the two cell types were small and the error bars large. The 
discrepancies between the two data sets are difficult to explain. IGF-1 is an inducer 
of epithelial mesenchymal transition (EMT) (168), a complex process often involved 
in tumor progression, it is therefore important to study cell invasion/migration in the 
absence of exogenous factors. In the absence of IGF-1 Mazzoca et al., (2008) (313) 
observed no differences in the invasion of HepG2 and HepG2 cells expressing 
CD81. Interestingly CD81 was observed to be highly expressed in intracellular 
vesicles in the HepG2 cells featured in Mazzoca et al., 2008 (313) this differs from 
our cells where CD81 is predominantly expressed at the plasma membrane. In vivo 
studies of hepatocytes in liver tissue also report that CD81 is expressed 
predominantly around the plasma membrane (396). This comparison suggests that 
CD81 may not be localized correctly in the HepG2 cells in Mazzoca’s paper, and may 
explain the discrepancy between our results. In support of Mazzoca’s findings a 
previous publication reported that a loss of CD81 expression was associated with 
differentiation and metastasis in HCC patients, however this report is limited having 
only a small sample number (219). Observations in our laboratory would suggest that 
CD81 expression is not altered in the diseased liver (396). It is clear that further in 
vivo research is needed to clarify whether CD81 expression is associated with liver 
cancer progression. 
 
In support of our findings that CD81 promotes hepatoma invasion and migration 
CD81 expression in other cell types has been reported to increase their invasive 
 
 
153 
potential (72, 262, 312, 528). Recent reports are beginning to unravel the highly 
dynamic and complex relationship between CD81 and its partner proteins (72, 247, 
262). CD81 is reported to associate with MT1-MMP (247, 262) along with other 
tetraspanins including CD151, CD9 and TSPN12 (262, 529). MT1-MMP is a 
membrane bound matrix metalloproteinase that enables cell penetration into ECM, 
high expression levels of MT1-MMP have so far been reported to associate with poor 
prognosis in breast cancer patients, no research to date has looked at its role in HCC 
(205, 224). Lafleur et al., 2009 (262) reported that CD81 expression increases MT1-
MMP function by preventing lysosomal degradation, this may explain the increased 
migration observed in our hepatoma cells. Interestingly in the study by Lafeur et al., 
2009 a double knock out of CD81 and CD9 was needed to observe this phenotype, 
in future studies it may be of interest to investigate whether a stronger phenotype is 
observed following knock down of both CD81 and CD9 in hepatoma cells. Other 
CD81 associated membrane proteins have also been reported to modulate the 
migratory phenotype of cells, including immunoglobulin-like proteins EWI-2 and EWI-
F (72, 247, 411). Chambrion et al., 2010 (72) reported that CD9 and CD81 
expression in HEK-293 cells negatively regulated EWI-F(CD9-P1) induced effects on 
cell migration. A further publication this time investigating EWI-2 function reported 
that expression of EWI-2 to glioblastoma cell lines reduced CD9 and CD81 
association with MMP-2 and MT1-MMP leading to a decrease in invasion potential 
(247). These observations suggest that EWI-2 and EWI-F expression levels may 
regulate CD81 localization and function or vice versa and are worth considering in 
future experiments. Previous research into tetraspanin partner-protein interactions 
and function has predominantly centered on biochemical-immunoprecipitation 
studies. Current research utilizing new live cell imaging techniques in particular total 
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internal reflection microscopy (TIRF) and single particle tracking technologies 
suggest that tetraspanins are more dynamic than originally thought and diffuse 
between tetraspanin enriched microdomains as a single or a group of molecule(s) 
(132). Our laboratory has now started to use these techniques for in vitro study of 
CD81 dynamics in hepatoma cells (Helen Harris, unpublished data). 
 
In the previous chapter we reported that HCV infection reduced CD81 induced cell 
spread, we therefore wanted to investigate the effect(s) of infection on CD81 function 
in hepatoma-ECM adhesion and invasion through collagen. We observed no effect(s) 
of infection on hepatoma integrin expression (Fig.4.3C), hepatoma–ECM adhesion 
(Fig 4.3A&B), or hepatoma ECM expression (Fig. 4.4 & 4.5). However infection 
promoted hepatoma invasion through collagen (Fig. 4.9).  
 
Since antibody engagement of CD81 had no effect on hepatoma cell-ECM adhesion, 
migration or invasion we hypothesized that it would be unlikely for HCV particle 
association with cell surface expressed CD81 to account for the increased invasion 
of infected cells. Given our results that siRNA silencing of CD81 expression reduced 
hepatoma invasion, we hypothesize that CD81 expression levels may predict the 
invasive capacity of hepatocytes. Earlier results showing that HCV infection does not 
alter CD81 expression levels (Fig.3.11C) eliminate this as a possible explanation for 
their increased invasive capacity.  
 
The complex nature of cellular migration and invasion means that HCV infection 
could increase hepatoma invasion through numerous mechanisms independent of 
CD81. If HCV infected cells have an increased invasive potential perse one might 
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expect the frequency of infected invaded cells to be greater than the control 
population. This was not the case and thus we postulated that a soluble factor 
secreted from the infected cells might have a paracrine effect on the entire infected 
cell population (Fig.4.9). Previous research reported that HCV infection causes 
mitochondrial deregulation resulting in stabilization of HIF-1α (191, 341, 380, 400). 
Nasimuzzaman et al., 2007 (341) identified that HIF-1α stabilization in hepatoma 
cells induced by HCV protein expression resulted in an up-regulation of VEGF 
expression. Increased expression of VEGF upon HCV infection was confirmed by 
work performed in our laboratory (Fig.4.10). We hypothesized that VEGF may 
regulate hepatoma migration as previously described (531). However, exogenous 
VEGF or neutralization of endogenous VEGF had no effect on Huh-7.5 cell invasion 
(Fig.4.10).  These results suggest HCV infection induced increase in invasion 
potential is VEGF independent.  
 
To investigate whether a HIF-1α inducible factor may be responsible for the 
increased invasion observed for HCV infected cells, uninfected Huh-7.5 cells were 
subjected to hypoxic conditions and their invasion compared to cells in replicate wells 
in normoxic conditions. A dramatic increase in hepatoma cell invasion was observed 
under hypoxic conditions compared to control, this increased invasion was inhibited 
by HIF-1α inhibitor NSC-134754 (Fig.4.12), demonstrating that HIF-1α stabilization 
promotes hepatoma invasion. The HIF-1α inhibitor inhibited the invasion of infected 
cells, and interestingly the frequency of infected invaded cells was reduced 
compared to control (Fig.4.13). There are several interpretations of this data; HIF-1α 
inhibitor (i) specifically reduced the invasion of HCV infected cells or (ii) differentially 
regulated the proliferation of uninfected and HCV infected cells or (iii) blocked HCV 
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replication. To ascertain whether the HIF-1α is essential for HCV replication we 
investigated cell free infection and transmission of HCV infection in the presence and 
absence of the HIF-1α inhibitor. The HIF-1α inhibitor completely blocked HCV 
infection and furthermore transmission of HCV infection during cell culture was 
perturbed (Fig.4.14). These results suggest that HCV infection is dependent on HIF-
1α and explain why there was a reduced frequency of infected invaded cells in the 
presence of inhibitor. A modest reduction in Huh-7.5 cell proliferation was observed 
in the presence of the HIF-1α inhibitor at 1µM concentration, this was most clearly 
observed by phase microscopy (Fig.4.14). It is reported that Huh-7.5 cells under 
normal conditions do not stably express HIF-1α (341, 400), suggesting NSC-134754 
exerts a degree of non-specific inhibition of hepatoma cell proliferation.  
 
We can conclude that HCV infection increases hepatoma cell invasion through a 
VEGF independent pathway and postulate that this could be through an alternative 
protein induced by HIF-1α stabilization. We can also speculate that induction of HIF-
1α may be an advantage to HCV infection whilst having a possible pathological 
consequence for the host.  
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5. Results: Neutralizing antibody resistant HCV transmission  
 
5.0 Introduction 
 
It is accepted that HCV persists in vivo predominantly through rapid sequence 
evolution. HCV replicates using an RNA dependent polymerase (RdRp) that has no 
proof reading ability, thus resulting in a highly varied viral population in an individual 
patient termed a quasispecies (closely related species of virus subjected to genetic 
mutations, competition and selection) (37, 117). In general the humoral immune 
response is one of the first lines of defense against microbial infections. Neutralizing 
antibodies (nAbs) are readily detected in chronically infected patients (29, 290). 
Although these antibodies have been shown to effectively neutralize infection in 
standard in vitro assays they are un-able to clear the virus in vivo (454). Studies in 
both humans and chimpanzees have shown that HCV evolves to escape from nAbs 
(290, 497). In particular sequence evolution in a highly variable region of E2 (HVR-1) 
is reported to occur in response to nAbs (434, 450, 497). HCV has also been shown 
to escape nAbs targeting functional domains of E2 for example the CD81 binding 
domain (7, 152, 180, 226, 240, 359). Escaping from these antibodies though comes 
at a great price to viral particle infectivity (239).  It is therefore likely that HCV utilizes 
other mechanisms to escape the humoral immune response.  
 
Many viruses have developed mechanisms to transmit directly from cell-to-cell within 
an infected host. These routes of transmission are less reliant on particle diffusion 
and are generally considered to be more efficient. In some cases cell-to-cell 
transmission can protect virions from nabs and are therefore often defined as 
neutralizing antibody resistant (337, 415).  
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The HCV retroviral pseudo-particle system (HCVpp) has been used to determine the 
efficacy of patient nAbs against native E1 and E2 glycoprotein’s (30, 179, 208, 391). 
HCVpp has been invaluable to understand the humoral immune response to HCV 
although as previously explained this system has its limitations. HCVpp can only be 
used to measure viral cell entry and not secondary infection events and therefore 
cannot be used to understand cell-to-cell transmission of the virus. With the recent 
development of the cell culture system allowing efficient propagation of full length 
HCV virus genomes in vitro (HCVcc) it is now possible to investigate cell-to-cell 
transmission of HCV (283, 499, 560).  
 
A recent study from our laboratory reported that HCVcc infection can spread in the 
presence of an agarose overlay, traditionally used to minimize cell free viral 
dissemination, and in the presence of nAbs, suggesting that HCV can transmit via 
cell free and cell-to-cell routes (480). A new technique using two-photon microscopy 
detected clusters of virus antigen expressing hepatocytes within infected liver tissue, 
again indicative of HCV cell-to-cell transmission (278).  
 
In this study we aimed to establish an in vitro co-culture assay to investigate nAb 
resistant cell-to-cell HCV transmission.  
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5.1 Establishment of an in vitro co-culture system to study neutralizing 
antibody resistant transmission. 
 
To quantify viral transmission in vitro it is essential to distinguish naïve uninfected 
target cells from infected producer cells. Timpe et al., 2008 previously published a 
co-culture assay in which target cells were labeled with a fluorescent dye, CMFDA 
,and co-cultured with unlabelled producer cells. Following a 48hr incubation the cells 
were harvested, stained for viral antigen NS5A and analysed by flow cytometry. 
NS5A+ / CMFDA+ cells were identified as infected target cells.  It has since become 
apparent that this method yields false positives, by the aggregation of unlabeled 
infected producer cells and labeled target cells. In contrast labeling infected producer 
cells instead of target cells and quantification of CMFDA-/NS5A+ cells eliminates 
false positives as demonstrated in Figure 5.1.  
 
The revised co-culture assay used throughout this study is depicted in Figure 5.2. 
Briefly Huh-7.5 cells were electroporated with full length HCV RNA and incubated at 
37°C for 72hrs. These infected producer cells were labeled with CMFDA and co-
cultured at a 1:1 ratio with naïve unlabelled “target cells” in the presence of control or 
nAb for a defined period of time. Upon culmination of the assay both the supernatant 
and cells were harvested. The levels of infectious extra-cellular virus were measured 
by inoculating Huh-7.5 cells as listed in the materials and methods. Harvested cells 
were fixed, stained for NS5A, and analyzed by flow cytometry to determine the 
frequency of newly infected target cells. Non-structural protein NS5A is only 
expressed once replication has occurred making it a good marker for infectivity (383). 
Despite the elimination of all cell free virus, 14.6% of target cells still became infected 
(Fig.5.2), demonstrating the presence of nAb resistant HCV transmission. 
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Figure 5.1: Comparison of labeling method to enumerate HCV transmission.  
Transmission from HCV infected Huh-7.5 producers to Huh-7.5 or to the relatively 
non-permissive Huh-7 Lunet cells was monitored by flow cytometry. (A) The lower 
two FACS plots represent transmission observed where target cells were labeled 
with CMFDA. The upper two FACS plots represent transmission observed in a 
parallel experiment where producer cells were labeled with CMFDA. The apparent 
infection of Huh-7.5 cells was higher when the target cells were labeled (lower 
left/Blue compared to upper left./Red). Approximately 25% of CMFDA positive Huh-7 
Lunet cells were recorded as NS5A positive (lower right/Blue) in contrast to very few 
Huh-7 Lunet cells detected in the NS5A positive quadrant when the target cells were 
unlabeled (upper right/Blue). (B) Further analysis of forward vs. side scatter plots of 
the infected target cell population revealed that double CMFDA/NS5A positive cells 
(Red) were composed mainly of aggregates (high forward scatter), in contrast to the 
NS5A positive cells (Red) where the majority of cells appeared as a single cell 
population (low forward scatter) 
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Figure 5.2: The infectious co-culture assay.  
(A) HCV strain H77/JFH RNA was delivered into producer cells by electroporation 
(ep). 72h post ep producer cells were labeled with CMFDA and co-cultured with 
unlabeled naïve target cells at a 1:1 ratio in the presence of 10µg/ml irrelevant control 
IgG or anti-E2 nAb 9/27. (B) i) Supernatant was collected upon termination of the 
assay and used to infect naïve Huh-7.5 cells in a standard infectious assay, infectivity 
was readily detectable in the presence of control IgG, none was observed in culture 
media containing nAb, data represented as foci forming units per ml (FFU/ml). ii) 
Cells were harvested, fixed, stained for NS5A and quantified by flow cytometry. The 
cartoon is typical of the data obtained; events appearing within the top left hand 
quadrant represent (CMFDA - / NS5A +) infected target cells, representative dot plots 
are shown where the frequency of infected target cells is depicted.  
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We next wanted to establish whether antibodies to different epitopes of E2 also fail to 
neutralize cell culture transmission. Three epitope specific antibodies were used 
9/27, 3/11 and 11/20 (208). These antibodies target specific regions of H77 E2 
glycoprotein. 9/27 targets the HVR-1 region (396-407) and 11/20 and 3/11 target 
different regions of the CD81 binding domain (412-423 and 436-447 respectively). 
Pooled patient IgG isolated from 6 HCV chronically infected patients was also used. 
All antibodies were evaluated for their effects on HCV strain H77/JFH chimera, 
transmission (Fig.5.3).  
Patient IgG and mAbs 9/27 and 11/20 neutralized all detectable cell-free virus  at the 
following concentrations; 3µg/ml for 9/27, 10µg/ml for 11/20 and 300µg/ml for patient 
sera.  In the absence of detectable extra-cellular virus HCV transmission still 
occurred, interestingly the percentage of newly infected target cells varied depending 
on the antibody under study. Both 9/27 and 11/20 were the most effective Abs at 
reducing transmission and continued to neutralize infection once all cell-free virus 
had been eliminated, however they were unable to completely ablate transmission at 
a maximum concentration of 30µgml.   
 
From these assays we were able to define optimal conditions to measure cell-to-cell 
transmission. For H77/JFH chimera we used mAb 9/27 at 4µg/ml. This was the most 
effective neutralizing antibody and at this concentration we could be confident that all 
cell free virus was neuralized. Where other JFH-1 chimeric viruses were used, cell 
free infectivity was neutralized using pooled patient IgG at 300µg/ml. 
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Figure 5.3: Effect of anti-glycoprotein antibodies on H77/JFH cell free 
infectivity and co-culture transmission.  
(A) Anti-E2 monoclonal antibodies 9/27, 3/11, and 11/20 and (B) Pooled IgG isolated 
from 6 HCV infected individuals were titrated for their effect(s) on H77/JFH 
transmission. Co-culture transmission (white bars), expressed as the percentage of 
infected target cells, plotted against the left Y-axis. Cell-free infectivity (black bars) 
expressed as foci forming units per ml (FFU/ml), plotted against the right Y-axis. The 
treatments were performed in duplicate and the error bars indicate standard deviation 
from the mean. The data set is representative of three independent experiments. 
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 5.2 Transmission of diverse HCV genotypes in co-culture. 
 
HCV can be grouped into 7 major genotypes and numerous sub-types (166, 444). To 
investigate whether all genotypes can transmit in co-culture in the presence of nAbs 
Huh-7.5 cells were electroporated with RNA from 11 chimeric JFH viruses, 
representative of all major genotypes and subtypes  (166). Co-culture transmission 
was determined in the presence of pooled patient IgG at 300µg/ml and control IgG. 
 
The levels of infectious cell free virus varied between the different genotypes and 
generally predicted efficiency of co-culture transmission (Fig.5.4A), for example 
genotype 5a virus (SA13/JFH) produced the highest level of cell-free virus and 
transmitted the most efficiently (Fig.5.4C). Cell-free virus of genotypes 1a, 1b, 3, 4, 5 
and 6 were completely neutralized by pooled patient IgG (Fig.5.4B). We determined 
the proportion of nAb resistant (co-culture transmission in the presence of nAb) and 
nAb sensitive transmission (Total co-culture transmission minus nAb resistant 
transmission) for all viruses (Fig.5.4C). nAb resistant transmission constituted greater 
than 50% of the transmission events with the exception of genotype 6a virus 
(HK61/JFH) indicating that this is a preferred route of transmission in co-culture 
under the conditions used in this assay.  
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Figure 5.4: Genotype transmission in co-culture. 
A panel of chimeric JFH-1 RNA was delivered into Huh-7.5 cells by ep. 72hrs 
post ep cells were labeled with CMFDA and co-cultured with unlabelled target 
cells in the presence of pooled patient IgG or control IgG (300µg/ml) for 
48hrs. Supernatants were harvested at the end of the assay and evaluated for 
their levels of infectious virus, (A) cell free infectivity displayed as foci forming 
units per ml (FFU/ml) and (B) neutralization of cell-free infectivity presented 
as percentage neutralization. (C) Cells were harvested, stained for NS5A and 
analysed by flow cytometry to determine the frequency of newly infected 
target cells. Results displayed as a stacked histogram, the white bars 
represent nAb resistant (Percentage infected target cells in the presence of 
nAb) and black bars represent nAb sensitive (Total transmission – nAb 
resistant transmission) transmission. The treatments were performed in 
duplicate and the error bars indicate standard deviation from the mean. The 
data set is representative of two independent experiments. 
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5.3 nAb resistant transmission is dependent on cell contact and particle 
assembly. 
 
To determine the importance of cell contact for nAb resistant virus 
transmission two systems were employed, firstly the seeding density was 
reduced to 0.25x of the standard density to lower the frequency of cell 
contacts. Secondly the producer and target cells were completely separated 
using a transwell system, thereby eliminating all cell contacts. Producer cells 
were seeded on the underside of a transwell insert and target cells into the 
bottom well, allowing the two cell populations to reside in the same chamber 
and to reduce limitations of viral diffusion.  
 
The proportion of nAb resistant transmission was greatly reduced at 0.25x 
standard cell density compared to control (Fig.5.4A&B), suggesting that cell 
contacts are important for efficient nAb resistant transmission. Upon 
separation of target and producer cells in the transwell system nAb resistant 
transmission was ablated confirming that nAb resistant transmission is 
dependent on cell contacts (Fig.5.4C), indicating that HCV may transmit via a 
direct cell-to-cell transfer of infection.   
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Figure 5.5: nAb resistant transmission requires cell contact. 
H77/JFH RNA was delivered into Huh-7.5 cells by ep and used in the 
following assays set up in parallel (A) Standard assay. (B) 0.25x standard 
density. (C) Transwell assay; Producer cells were seeded on the underside of 
a transwell insert and target cells seeded into the bottom chamber. For each 
assay an irrelevant control IgG or nAb 9/27 was used at 4µg/ml. For (A) and 
(B) cells were harvest as normal and for (C) the target cells were harvested 
separately. All cells were stained for NS5A and analysed by flow cytometry. 
Results are represented as stacked histograms displaying nAb resistant 
(white bars) and nAb sensitive (black bars) transmission. For all assays cell 
free infection was determined in a standard infectious assay and >95% of cell 
free infection was neutralized in the presence of nAb 9/27. The treatments 
were performed in duplicate and the error bars indicate standard deviation 
from the mean. The data set is representative of three independent 
experiments. 
Standard 0.25x Density Transwell 
nAb Sensitive nAb Resistant 
%
 I
n
fe
c
te
d
 t
a
rg
e
ts
 
 Producers       Targets 
A C B 
167 
 
 
168 
 It is possible that HCV infection can transmit in a nAb resistant manner via 
direct transfer of RNA or incomplete viral particles through a cell fusion event 
similar to that reported for herpes viruses (483).  Further to this it has been 
suggested that HCV RNA can be incorporated into exosomes and may 
transfer HCV infectivity (306, 424).  
 
To investigate whether viral particles are required for nAb resistant 
transmission a mutant virus J6/JFH del B was employed that contains a 
mutation in the third domain of NS5A preventing a phosphorylation event that 
is critical for particle assembly whilst permitting wild type levels of replication 
and protein translation (473). To ensure that control (J6/JFH) and mutant 
(J6/JFH del B) producer cells supported comparable levels of replicating RNA 
at the start of the assay NS5A expression of the cells was monitored by flow 
cytometry prior to co-culture T=0hr (Fig.5.6). No nAbs were used in this 
assay. The mutant virus showed minimal evidence of transmission indicating 
that particle assembly is essential for viral transmission in co-culture.  
 
 
169 
Figure 5.6: Particle assembly is essential for co-culture transmission. 
J6/JFH and J6/JFH del B RNA were delivered into Huh-7.5 cells by 
electroporation ep. 72hrs post ep a standard co-culture assay was performed. 
NS5A expression was determined at 72hrs post ep (0h) and after co-culture 
transmission (48hr). No nAb was used in this assay. Representative dot plots 
are shown displaying (A) the percentage of infected producer cells at 0hrs 
and (B) the percentage of infected target cells at the end of the assay +/- 
standard deviation. The assay was performed in duplicate. The data set is 
representative of two independent experiments. 
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5.4 Receptor dependency of nAb resistant transmission of HCVcc 
 
Results so far demonstrate that HCV can transmit efficiently in co-culture in a 
nAb resistant manner, that is dependent on cell contact and particle 
assembly. These results suggest that HCV transmits via a direct cell-to-cell 
manner as well as through release of cell free viral particles. We next wished 
to determine whether direct cell-to-cell transmission is dependent on all four 
entry factors, CD81, SR-BI, Claudin-1 and Occludin, previously demonstrated 
to be essential for cell-free viral entry (39, 133, 288, 384, 385, 418).  
5.4.1 Role of tetraspanin CD81 in nAb resistant transmission.  
 
HCV glycoprotein E2 binds to a defined domain on the large extra cellular 
loop of tetraspanin CD81, an essential co-receptor reported to be involved in 
the early steps of HCV entry (119, 384, 468). To date there has been 
contradicting evidence for the dependency of CD81 in cell-to-cell 
transmission. Timpe et al., 2008 and Witteveldt et al., 2009 have shown that 
HCV can transmit in co-culture in a CD81 independent manner, however both 
of these studies labelled the target cells, and we believe this may have 
resulted in false positives (Fig.5.1). A further study reported that CD81 was 
essential for HCV transmission (407). To confirm whether CD81 is indeed 
essential for nAb resistant co-culture transmission the effects of a panel of 
anti-CD81 monoclonal antibodies on HCV transmission were investigated. All 
of the anti-receptor antibodies were incubated with the target cells for 1hr at a 
concentration of 5µg/ml prior to culturing with H77/JFH infected producer cells 
and nAb 9/27. All anti-CD81 antibodies inhibited greater than 95% of nAb 
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resistant and nAb sensitive transmission, demonstrating that both routes of 
transmission are CD81 dependent (Fig.5.7A). To investigate this further a 
titration of one of the anti-CD81 monoclonal antibodies, 2.s131 was performed 
(Fig.5.7B). The antibody inhibited nAb resistant and nAb sensitive 
transmission to comparable levels.  
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Figure 5-7: Effect of anti-CD81 monoclonal antibodies on HCV 
transmission. 
H77/JFH RNA was delivered into Huh-7.5 cells by electroporation. (A) 72hrs 
post ep a standard H77/JFH co-culture assay was performed. Target cells 
were incubated with a panel of anti-CD81 monoclonal antibodies or control 
IgG at 5µg/ml for 1hr prior to co-culture. Results are displayed as a stacked 
histogram, nAb resistant transmission (white bars) and nAb sensitive 
transmission (black bars). (B) Anti-CD81 mAb 2.s131 was titrated in a 
standard H77/JFH co-culture assay. The percentage inhibition of nAb 
sensitive () and nAb resistant () transmission plotted. For all assays cell 
free infection was determined in a standard infectious assay and >95% of cell 
free infection was neutralized in the presence of nAb 9/27 at 4µg/ml. The 
treatments were performed in duplicate and the error bars indicate standard 
deviation from the mean. The data set is representative of three independent 
experiments.     
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To confirm whether CD81 is essential for co-culture transmission we used a 
Huh-7 derived cell line (Lunet) that was reported to express low to 
undetectable levels of CD81 (251). CD81 cell surface expression was 
determined by flow cytometry and a small frequency of Lunet parental cells 
expressed low levels of CD81. Lunet parental cells transduced to stably 
express CD81 expressed similar levels to Huh-7.5 cells (Fig.5.8A). H77/JFH 
and SA13/JFH transmission to parental Lunet cells and those transduced to 
express CD81 was monitored (Fig.5.8B). No nAb was used during co-culture. 
A small amount of SA13/JFH NS5A expression could be detected in the Lunet 
parental cells after co-culture, suggesting a potential CD81 independent 
transmission route. Alternatively, this transmission could be attributed to the 
small population of cells expressing CD81. To investigate this anti-CD81 
(2.s131) was added to the co-culture, the low level of transmission previously 
observed was eliminated, suggesting this was not the result of CD81 
independent transmission (Fig.5.8B). These findings were confirmed in a 
further assay that was analysed instead by confocal microscopy (Fig.5.8C).  
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Figure 5.8: Transmission to a hepatoma cell line with low CD81 
expression levels.  
(A) Histograms display cell surface expression of CD81 on Huh-7.5 cells, 
Huh-7 Lunet cells and Huh-7 Lunet cells transduced to express CD81. (B) 
H77/JFH and SA13/JFH RNA was delivered into Huh-7.5 cells by ep. 72hrs 
post ep cells were labeled with CMFDA and incubated with the following 
unlabeled target cells; Huh-7 Lunet parental cells and those transduced to 
express CD81. Anti-CD81 mAb (2.s131 at 5 µg/ml) or irrelevant control IgG 
was incubated with the Lunet cells for 1hr prior to addition of producer cells. 
Representative dot plots are shown displaying the percentage of infected 
target cells. (C) Infectious co-culture assay was repeated, stained for NS5A 
and imaged on a Zeiss META head confocal microscope with a 40x water 
immersion objective.  Cell nuclei (grey), producer cells (green), infected target 
cells (red), infected producer cells (orange), white arrows depict infected 
Lunet target cells. Scale bar represents 50µm. 
B 
10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 0 
20 
40 
60 
80 
100 
%
 o
f 
M
a
x
 
CD81 
Huh-7.5 Lunet Lunet CD81 A 
Lunet CD81   Lunet Lunet (+ anti-CD81) 
10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 
0 
10 1 
10 2 
10 3 
10 4 
10 0 
10 1 
10 2 
10 3 
10 4 
H
7
7
/J
F
H
 
S
A
1
3
 
N
S
5
A
 
14.1% 
 
81.3% 
 
0.9% 
2.3% 
0.4% 
 
10 0 10 1 10 2 10 3 10 4 
0.1% 
C 
S
A
1
3
 
H
7
7
 
Lunet Lunet CD81 Lunet (+anti-CD81) 
CMFDA 
174 
 
 
175 
A mutant virus defective in binding CD81 was previously reported to transmit 
in vitro using a CD81-independent route (515). To investigate this further 
transmission of the CD81 mutant virus (JFH1W529A) was compared to 
transmission of parental JFH virus in our co-culture system. The assay was 
carried out as previously described for the J6/JFH del B mutant virus. 
Comparable levels of NS5A expression were noted in the JFH and JFH1W529A 
expressing producer cells prior to co-culture (T=0hr). However, the mutant 
virus showed minimal evidence of transmission, supporting our previous data 
that CD81 is essential for co-culture transmission (Fig.5.9). As previously 
discussed we suspect the small percentage of infected cells observed by 
Witteveldt et al., was possibly due to cell aggregates.  
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Figure 5.9: Transmission of a CD81 negative mutant virus. 
JFH and JFH1W529A RNA was delivered into Huh-7.5 cells by ep. 72hrs post 
ep a standard co-culture assay was performed. NS5A expression was 
determined at 72hr post ep (0hr) and after co-culture transmission (48hr). No 
nAb was used in this assay. Representative dot plots are shown displaying 
(A) the percentage of infected producer cells at 0hr and (B) the percentage of 
infected target cells at the end of the assay. The assay was performed in 
duplicate. The data set is representative of two independent experiments. 
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5.4.2 Role of SR-BI in nAb resistant co-culture transmission  
 
SR-BI is a cell membrane protein involved in cholesterol metabolism; it 
functions as a receptor for high-density lipoproteins. It has also been shown to 
bind directly to HCV E2 glycoprotein and is believed to be important in the 
early stages of HCV attachment and entry (174, 418). To investigate the role 
of SR-BI in nAb resistant co-culture transmission the effect of anti-SR-BI 
antibody on transmission was investigated. As previously described the target 
cells were cultured in the presence of the anti-receptor antibody for 1hr prior 
to addition of H77/JFH infected producer cells and nAb 9/27.  Titration of the 
anti-SR-BI antibody revealed that nAb resistant transmission is preferentially 
inhibited at all concentrations (Fig.5.10A). To investigate whether this 
phenomenon was due to a potential synergy between 9/27, a neutralizing 
antibody specific for E2 HVR-1, and the anti-SR-BI antibody transmission in 
the presence of another epitope specific antibody 11/20 was determined 
(Fig.5.10B). 11/20 targets part of the E2 CD81 binding domain (208). A 
significant difference between anti-SR-BI inhibition of nAb resistant and 
sensitive transmission was observed in the presence of both epitope specific 
nAbs indicating the synergy is not specific to the HVR-1 targeting antibody.  
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Figure 5.10: Effect of anti-SR-BI antibody on HCV transmission. 
H77/JFH RNA was delivered into Huh-7.5 cells by ep. (A) 72hrs post ep target 
cells were incubated with titrated anti-SR-BI mAb (PF72) or control IgG for 1hr 
prior to addition of H77/JFH infected producer cells. The percentage inhibition 
of nAb sensitve () and nAb resistant () transmission plotted. (B) 72hrs 
post ep target cells were incubated with anti-SR-BI mAb at 1µg/ml or control 
IgG for 1hr. H77/JFH infected producer cells were then added in the presence 
of nAb 9/27 at 4µg/ml, nAb 11/20 at 10µg/ml or control IgG. Two tailed 
unpaired T-tests were performed to determine whether there was a significant 
difference between nAb resistant and sensitive transmission in the presence 
of nAb 9/27 or 11/20. A significant difference was determined P= 0.0013 and 
0.0003 respectively. For both assays cell free infection was determined in a 
standard infectious assay and >95% of cell free infection was neutralized in 
the presence of nAb. The treatments were performed in duplicate and the 
error bars indicate standard deviation from the mean. The data set is 
representative of three independent experiments.     
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To further examine the role of SR-BI in nAb resistant transmission, virus 
dissemination was determined to Huh-7.5 cells and those transduced to over 
express SR-BI. Our laboratory previously published that cell-free virus 
infection of these cells induced greater foci size indicative of increased cell-to-
cell transmission (175). nAb resistant transmission of virus to target cells over 
expressing SR-BI significantly increased however, SR-BI overexpression had 
no effect on nAb sensitive transmission (Fig.5.11A). This data indicates that 
SR-BI expression may be a limiting factor for efficient nAb resistant 
transmission.   
 
To further investigate the role of SR-BI in nAb resistant infection, SR-BI was 
silenced in Huh-7.5 cells and transmission compared to parental Huh-7.5 
cells. Receptor staining of parental and SR-BI silenced Huh-7.5 cells was 
carried out to determine efficacy of SR-BI silencing and to verify any off target 
effects (Fig.5.11B). SR-BI expression level was reduced and expression level 
of the other receptors remained with the exception of tetraspanin CD81 that 
was reduced; this was confirmed by flow cytometry (Fig.5.11C). Silencing SR-
BI significantly inhibited both routes of viral transmission and did not 
preferentially inhibit nAb resistant transmission as expected from previous 
results (Fig.5.11D). It has recently been published that silencing SR-BI 
reduced cholesterol levels and inhibited plasmodium infection of hepatocytes 
(523). A sample of SR-BI silenced cells were lysed at the start of the assay to 
determined cholesterol levels. This confirmed that indeed SR-BI silenced cells 
had reduced levels of total cholesterol (Fig.5.11E).  
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Figure 5.11: Effect of SR-BI expression levels on HCV transmission.  
H77/JFH RNA was delivered into Huh-7.5 cells by ep. (A) A standard co-
culture assay was performed with control target cells and those transduced to 
over express SR-BI. A significant difference in nAb resistant transmission to 
control and SR-BI over expressing cells was observed, (P=0.0007, two tailed 
unpaired T-test). No significant difference was observed in nAb sensitive 
transmission, (P=0.2430, two tailed unpaired T-test). Huh-7.5 target cells 
were transduced to express sh SR-BI RNA (SR-BI KD). (B) Receptor 
expression of SR-BI KD and control cells. Images taken on a Zeiss META 
head confocal microscope with a 60x water immersion objective, receptor 
expression visualized using alexa-fluor 488 secondary antibody (green) and 
DAPI (blue) show cell nuclei. Scale bar represents 10µm. (C) SR-BI and 
CD81 expression also determined by flow cytometry (Anti-SR-BI (PF72) and 
anti-CD81 (2.s131mAb) used). (D) A standard H77/JFH co-culture assay was 
performed with control and SR-BI KD cells as targets. Two tailed unpaired T-
tests were performed to determine whether there was a significant difference 
in nAb sensitive and resistant transmission between control and SR-BI KD 
cells. A significant difference was determined P= 0.0127 and 0.0045 
respectively. For both co-culture assays supernatants were collected to 
determine cell free infection and >95% of cell free infection was shown to be 
neutralized in the presence of nAb 9/27 at 4µg/ml. (E) Total cholesterol levels 
were determined in control and SR-BI KD cells using Invitrogen Amplex Red 
Cholesterol Assay Kit. Assays were performed in duplicate and the error bars 
indicate standard deviation from the mean. The data sets are representative 
of two independent experiments.  
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Our laboratory previously published that a cell culture adapted virus 
containing a single mutation G451R within E2 of JFH has a reduced SR-BI 
dependency and increased infectivity (175). Transmission of parental and 
G451R adapted virus was compared in our co-culture system using HCV + 
sera at 300µg/ml to neutralize all cell free infection. JFH-1 G451R transmitted 
more efficiently in co-culture compared to control although only a small 
proportion of this transmission was nAb resistant (Fig.5.12A). Suggesting that 
nAb resistant transmission is SR-BI dependent.  
 
To investigate SR-BI dependency of JFH-1 and JFH-1 G451R co-culture 
transmission we repeated the previous co-culture assay and included a pre-
incubation step with an anti-SR-BI antibody. The Anti-SR-BI antibody inhibited 
JFH-1 nAb resistant transmission to a significantly greater extent than nAb 
sensitive transmission as previously shown with HCV strain H77/JFH-1 in 
Figure 5.11 (Fig.5.12B). The anti-SR-BI antibody reduced both routes of JFH-
1 G451R co-culture transmission and there was no significant difference 
between the inhibition of nAb resistant and sensitive transmission. This data 
supports our previous findings that SR-BI is important for nAb resistant 
transmission and previous published data that JFH-1 G451R has reduced SR-
BI dependency (175).  
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Figure 5.12: Transmission of a cell culture adapted virus with reduced 
SR-BI dependency.  
JFH-1 and JFH-1 G451R RNA were delivered into Huh-7.5 cells by ep. (A) 
72hrs post ep a standard co-culture assay was performed. The stacked 
histogram displays nAb resistant (white bars) and nAb sensitive transmission 
(black bars). (B) Target cells were incubated with anti-SR-BI mAb (PF72) or 
IgG control at 1µg/ml for 1hr prior to addition of JFH-1 and JFH-1 G451R 
infected producer cells. The mAb was present throughout the duration of the 
assay. Results are represented as percentage inhibition of nAb resistant 
(white bars) and nAb sensitive (black bars) transmission. A significant 
difference between percentage inhibition of nAb resistant and sensitive 
transmission of JFH-1 virus was determined, (P=0.0092, two tailed unpaired 
T-test). No significant difference for JFH-1 G451R was observed, (P=0.2096, 
two tailed unpaired T-test).  For all assays cell free infection was determined 
in a standard infectious assay and >95% of cell free infection was neutralized 
in the presence of pooled patient IgG (300µg/ml). Assays were performed in 
duplicate and the error bars indicate standard deviation from the mean. The 
data set is representative of three independent experiments. 
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Syder and colleagues recently reported a number of small molecular inhibitors 
that target SR-BI as effective inhibitors of HCV entry (462). ITX5061 and 
ITX7650 have been reported to function by inhibiting HCV E2 glycoprotein-
SR-BI interaction and not by affecting overall SR-BI expression levels. We 
wanted to investigate their efficacy to inhibit nAb resistant and nAb sensitive 
transmission. An MTS assay (colorimetric test that measures metabolic 
function) was performed to ascertain the effect(s) of ITX compounds on 
hepatoma cell proliferation (Fig.5.13A). The inhibitors were then used in our 
standard co-culture assay (Fig.5.13B). These inhibitors were relatively 
ineffective at targeting cell free infection but as with antibodies targeting SR-BI 
they were able to efficiently inhibit nAb resistant transmission.  
 
 
184 
Figure 5.13: Effect of small molecular inhibitors of SR-BI on HCV 
transmission. 
(A) Huh-7.5 cells were treated with small molecular inhibitors of SR-BI 
ITX5061, ITX7650 and control at 3,1,0.3 and 0.1µM. 48hrs post treatment an 
MTS assay was performed to determine metabolic function, and the results 
presented as absorbance at 490nm (minus background). (B) H77/JFH RNA 
was delivered into Huh-7.5 cells by electroporation (ep). 72hrs post ep a 
standard H77/JFH co-culture assay was performed. Target cells were 
incubated with ITX5061 and ITX7650 at 0.1 µ1M for 1hr prior to addition of 
H77/JFH infected producer cells. Compounds were present throughout the 
duration of the assay.  Results are displayed as percentage inhibition of nAb 
resistant (white bars) and nAb sensitive transmission (black bars). For all 
assays cell free infection was determined in a standard infectious assay and 
>95% of cell free infection was neutralized in the presence of nAb 9/27 at 
4µg/ml. The treatments were performed in duplicate and the error bars 
indicate standard deviation from the mean. The data set is representative of 
three independent experiments. 
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5.4.3. Role of tight junction proteins CLDN-1 and Occludin in nAb 
resistant HCV transmission.  
 
The tight junction proteins Claudin-1 and Occludin have only recently been 
identified as co-receptors for HCV, as such there are limited tools available to 
study these receptors. Recent studies indicate that they are both important in 
the latter stages of HCV entry and as yet there is no evidence for a direct 
interaction of these proteins with the HCV glycoproteins (39, 133, 288, 385).  
 
To study the role of Claudin-1 in nAb resistant transmission a recently 
described polyclonal antiserum raised to Claudin-1 was used (255). Target 
cells were incubated with a pre-immune and a post-immune serum for 1hr 
prior to the addition of H77/JFH infected producer cells. A standard co-culture 
assay was then performed using nAb 9/27 at 4µg/ml to neutralize cell free 
infectivity. The polyclonal anti-Claudin-1 antibody inhibited approximately 50% 
of nAb sensitive transmission and approximately 30% of nAb resistant 
transmission, indicating both routes of transmission require Claudin-1 
(Fig.5.14A).  
 
Further to this we carried out a standard co-culture assay using Claudin-1 
silenced cells as targets. Receptor staining of control and silenced cells were 
carried out to determine the efficacy of silencing and to confirm expression of 
other HCV co-receptors. Immuno-fluorescence results revealed that Occludin 
expression was also reduced upon Claudin-1 silencing (Fig.5.14B). Claudin-1 
silencing reduced nAb sensitive and resistant transmission by 47 and 32 % 
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respectively supporting our previous data that both routes of transmission 
require Claudin-1 (Fig.5.14C).  
 
No antibodies to extra-cellular Occludin epitopes are available; we therefore 
silenced Occludin in the target cells and performed a standard co-culture 
assay as previously carried out for Claudin-1. Receptor staining of control and 
Occludin silenced cells was carried out to determine efficacy of silencing and 
to confirm expression of other HCV co-receptors. Occludin was efficiently 
silenced and no differences in co-receptor expression were observed 
(Fig.5.14A). Occludin silencing reduced nAb sensitive and nAb resistant 
transmission by 80% and 60% respectively (Fig.5.14B). Results indicate that 
both tight junction proteins Claudin-1 and Occludin are essential for both 
routes of transmission.  
 
 
 
 
187 
Figure 5.14: Claudin-1 is essential for nAb resistant transmission.  
H77/JFH RNA was delivered into Huh-7.5 cells by ep. (A) 72hrs post ep a 
standard co-culture assay was performed. Target cells were incubated with 
anti-Claudin-1 polyclonal antibody for 1hr prior to addition of producer cells. 
Percentage inhibition of nAb resistant (white bars) and nAb sensitive (black 
bars) transmission shown. A significant difference between inhibition of nAb 
sensitive and nAb resistant transmission by anti-Claudin-1 polyclonal antibody 
was determined, (P= 0.0062, two tailed unpaired T-test). Huh-7.5 target cells 
were transduced to express si Claudin-1 RNA. (B) Receptor expression of 
Claudin-1 silenced (Claudin-1 KD) and control cells. Images taken on a Zeiss 
META head confocal microscope with a 60x water immersion objective, 
receptor expression visualized using alexa-fluor 488 secondary antibody 
(green) and DAPI (blue) show cell nuclei. Scale bar represents 10µm. (C) 
Claudin-1 KD cells were used as targets in a standard H77/JFH co-culture 
assay and transmission was compared to control. Co-culture transmission 
displayed as stacked histograms, nAb resistant (white bars) and nAb sensitive 
(black bars) transmission. Two tailed unpaired T-tests were performed to 
determine whether there was a significant difference in nAb sensitive and 
resistant transmission between control and Claudin-1 KD cells. A significant 
difference was determined P= 0.0439 and 0.0079 respectively.  For all assays 
cell free infection was determined in a standard infectious assay and >95% of 
cell free infection was neutralized in the presence of nAb 9/27 at 4µg/ml. The 
treatments were performed in duplicate and the error bars indicate standard 
deviation from the mean. The data set is representative of two independent 
experiments.  
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Figure 5.15: Occludin is essential for nAb resistant transmission.  
Huh-7.5 target cells were transduced to express sh occludin RNA (Occludin 
KD). (A) Images display receptor expression of occludin KD cells and control 
cells. Images taken on a Zeiss META head confocal microscope with a 60x 
water immersion objective, receptor expression visualized using alexa-fluor 
488 secondary antibody (green) and DAPI (blue) show cell nuclei. Scale bar 
represents 10µm. (B) H77/JFH RNA was delivered into Huh-7.5 cells by ep. 
72h post ep a standard H77/JFH co-culture assay was performed with control 
and occludin KD cells as targets. Co-culture transmission displayed as 
stacked histograms, nAb resistant (white bars) and nAb sensitive (black bars) 
transmission. Two tailed unpaired T-tests were performed to determine 
whether there was a significant difference in nAb sensitive and resistant 
transmission between control and occludin KD cells. A significant difference 
was determined P= 0.0186 and 0.0051 respectively.  For all assays cell free 
infection was determined in a standard infectious assay and >95% of cell free 
infection was neutralized in the presence of nAb 9/27 at 4µg/ml. The 
treatments were performed in duplicate and the error bars indicate standard 
deviation from the mean. The data set is representative of two independent 
experiments.  
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5.4.4 Receptor dependency of nAb resistant transmission of multiple 
HCV genotypes.  
 
In this project so far, we have only studied the effect(s) of antibody 
antagonists on genotype 1a chimeric virus H77/JFH co-culture transmission. 
To strengthen our findings the effect(s) of these antagonists were determined 
for multiple HCV genotypes. A pooled patient sera at 300µg/ml was able to 
neutralize cell free infectivity of JFH chimera’s representative of genotypes 1a, 
1b, 3, 4, 5 and 6 in co-culture (Fig.5.4B). Therefore a standard co-culture 
assay was performed using patient IgG to neutralize cell free infectivity for all 
of the above genotypes.  Target cells were incubated for 1hr with the following 
inhibitors prior to co-culture; anti-CD81 (2.s131 at 5µg/ml), anti-CLDN-1 
(polyclonal antibody at 1in 100), anti-SR-BI (PF72 at 5µg/ml) and small 
molecular SR-BI inhibitors (ITX5061 and ITX7650 at 1µM) (Table 5.1). 
Sensitivity to anti-CD81 antibodies were similarly high for all genotypes and 
inhibited both nAb resistant and sensitive transmission equally with the 
exception of SA13/JFH.  The anti-CLDN-1 polyclonal antibody was not 
efficient at blocking co-culture transmission and in the majority of cases 
blocked nAb sensitive to a greater extent than nAb resistant transmission. 
Treatment with the anti-SR-BI antibody and SR-BI small molecule inhibitor 
ITX5061 had comparable effects on transmission and both antagonists 
preferentially blocked the nAb resistant route.  
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Table 5.1: Receptor dependency of multiple genotypes. 
 
 
 
 
 
 
Genotype JFH chimera Sensitive Resistant Sensitive Resistant  Sensitive  Resistant Sensitive Resistant
1a H77 88 (±1) 92 (±2) 43 (±1) 17 (±3)   7 (±6) 87 (±1)   7 (±12) 81 (±1)
1b J4 82 (±1) 88 (±1) 55 (±5) 32 (±1)   7 (±14) 79 (±1)   8 (±2) 73 (±1)
4a ED43 97 (±1) 94 (±2) 54 (±5) 36 (±4)   7 (±2)   75 (±2)   4 (±5) 69 (±1)
5a SA13 46 (±4) 92 (±1)   8 (±5) 22 (±2)   0 (±4) 44 (±2)   0 (±0) 41 (±2)
6a HK6a 94 (±1) 93 (±1) 10 (±1)   1 (±1) 10 (±2) 34 (±7) 15 (±1) 40 (±3)
% INHIBITION
Anti-CD81 Anti-CLDN1 Anti-SR-BI ITX5061
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5.5 Discussion 
 
In this study we developed a co-culture assay that allowed us to examine 
HCV transmission in vitro (Fig.5.2). Our results support previous observations 
made using standard infectious assays; cell free HCV particles are relatively 
sensitive to neutralizing antibodies in vitro (29, 359, 560). Importantly our 
results demonstrate that a proportion of co-culture transmission is highly 
insensitive to neutralization by antibodies targeting the viral glycoproteins. We 
envisage that the co-culture system used in this study demonstrates 
neutralizing antibody sensitivities that are more akin to the in vivo situation 
than standard infection assays.  
 
To investigate the sensitivity of HCV transmission to different antibodies 
targeting the viral glycoproteins, H77/JFH chimera (genotype 1a virus) was 
studied. Patient IgG isolated from HCV infected patients and eptiope specifc 
antibodies 11/20 and 9/27 targeting the CD81 binding domain and the HVR-1 
of E2 respectively neutralized > 95% of the infectivity of cell-free virus whilst 
still allowing new rounds of virus transmission to occur (Fig.5.3). Interestingly 
different levels of co-culture transmission were observed depending on the 
antibody studied. Importantly, once all cell free virus infectivity was 
neutralized, mAbs 11/20 and 9/27 were able to limit co-culture transmission 
although they were unable to completely abrogate all transmission at a final 
concentration of 30µg/ml. These results suggest that nAb resistant 
transmission does not occur through a sealed junction, that is impermeable to 
HCV glycoprotein targeting antibodies. Rather susceptibility to neutralization 
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is variable and dependent on the antibody in question, this maybe due to 
differences in antibody affinities or target epitope availability. The majority of 
HCV RNA is reported to associate with lipoproteins in vitro and in vivo, these 
are termed lipo-viro-particles (LVP) (14). It has previously been reported that 
lipoprotein association increases specific infectivity and decreases 
neutralization efficacy (175, 215). It is therefore interesting to postulate 
whether the associated lipoproteins may aid nAb resistant viral transmission.  
 
To further characterize co-culture transmission we defined nAb resistant cell-
to-cell transmission as the proportion of transmission that occurred in the 
presence of a anti-glycoprotein specific Ab capable of inhibiting between 90 
and 100% of all cell-free virus infectivity. For the majority of experiments we 
investigated H77/JFH transmission and used the most proficient epitope 
specific antibody 9/27 at 4µg/ml, a concentration able to effectively neutralize 
cell free infectivity. When it was not possible to use H77/JFH we used patient 
IgG isolated from HCV infected patients that was able to neutralize cell free 
infectivity at 300µg/ml. 
 
The proportion of nAb resistant transmission decreased when target and 
producer cell contacts were reduced (Fig.5.5A) and was ablated upon 
separation of the cells (Fig.5.5B). These findings suggest that cell contacts 
are essential for nAb resistant transmission and HCV can transmit via direct 
cell-to-cell route(s) as well as release of cell-free virus. A mutant virus (J6/JFH 
del B) that is un-able to assemble viral particles did not transmit infection in 
co-culture (Fig.5.6), demonstrating that viral particles are required for co-
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culture transmission. Furthermore, comparison of the levels of infectious virus 
released from the chimeric JFH viruses and the percentage of target cells 
infected in co-culture revealed an association between infectious cell-free 
virus and transmission, suggesting that particles are required to initiate both 
nAb resistant and sensitive forms of transmission (Fig 5.6). These findings do 
not support a recent hypothesis that HCV RNA directly transmits through cell-
to-cell fusion events via the exosomal excretory pathway (424).  
 
Importantly we demonstrated that diverse HCV genotypes can transmit via 
nAb resistant cell-to-cell route(s) using a panel of chimeric JFH viruses 
expressing the structural proteins that represent the major genotypes (166) 
(Fig.5.4). For 7 out of the 11 strains studied > 95% of cell-free infectivity was 
neutralized by IgG purified from the sera of HCV infected subjects (Fig.5.4B). 
We can be confident that these genotypes transmit in a nAb resistant manner. 
However the remaining genotypes were only partially neutralized by the 
patient IgG, therefore we cannot conclusively determine whether these 
viruses transmit in a nAb resistant manner.  
 
Four co-receptors are known to be essential for entry of cell-free virus, we 
were interested to investigate the receptor dependency nAb resistant cell-to-
cell transmission. Contradicting evidence exists as to whether the tetraspanin 
CD81 is essential for HCV co-culture transmission (229, 407, 480, 515). 
Timpe et al., 2008 reported that HCV could transmit to a CD81 negative 
HepG2 cell line. Witteveldt et al., 2009 supported these findings by showing 
that a mutant virus (JFH1W529A) that was un-able to interact with CD81 was 
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able to transmit in vitro. We believe these findings were a result of 
misinterpretation of flow cytometry data due to the formation of aggregates 
between labeled target cells and unlabelled infected producer cells (Fig. 5.1). 
We failed to observe any detectable transmission of infectivity of the 
JFH1W529A virus in our co-culture system (Fig.5.9), suggesting that HCV 
interaction with CD81 is indeed essential, as previously reported by Russel et 
al., 2008. A panel of anti-CD81 monoclonal antibodies were able to block 
greater than 85% of both routes of transmission for all HCV genotypes with 
the exception of genotype 5a virus SA13/JFH (Table 5.1). Suggesting that for 
the majority of genotypes CD81 is equally important for all routes of co-culture 
transmission. Transmission of H77/JFH and SA13/JFH was monitored to 
Lunet cells that express very low levels of CD81 (Fig.5.8B&C). Negligible 
transmission of H77/JFH was recorded to Lunet cells and this was rescued by 
ectopic CD81 expression, supporting our previous data that CD81 is essential 
for co-culture transmission. Notably a small population of SA13/JFH infected 
Lunet cells was observed, importantly both flow cytometry analysis and 
confocal imaging detected this transmission. To investigate whether this was 
evidence supporting CD81 independent transmission an anti-CD81 mAb was 
added to the co-culture. Anti-CD81 mAb completely abrogated SA13/JFH 
transmission to lunet cells demonstrating that the previous transmission 
observed was not evidence of CD81 independent transmission rather it was 
showing the efficiency of SA13/JFH transmission. Recent data from our 
laboratory revealed that SA13/JFH RNA level per infected cell is comparable 
to other genotypes indicating the difference in infectivity is unlikely to be due 
to an increase in replication efficacy (Un published data by Dr. P. Balfe and 
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Dr. N. Fletcher).  These results suggest that SA13/JFH is able to utilize a 
lower threshold of CD81 compared to other viruses. Koutsoudakis et al., 
reported that HCVcc needs a threshold level of CD81 to infect hepatoma cells 
(251). It would be interesting to see if the same threshold holds true for 
SA13/JFH. In summary we have demonstrated that CD81 is indispensable for 
HCV infection and transmission in co-culture.  
 
Our observations demonstrate that both tight junction proteins Claudin-1 and 
Occludin are required for HCV co-culture transmission. Previous studies using 
parental 293T cells and those transduced to express Claudin-1 reported that 
claudin-1 is essential for co-culture transmission of HCVcc but did not 
discriminate between nAb resistant and nAb sensitive transmission (480). We 
observed that nAb sensitive transmission was blocked to a greater extent than 
nAb resistant transmission by an anti-Claudin-1 polyclonal antibody for all 
genotypes tested (Table 5.1). Supporting this, nAb sensitive transmission was 
more sensitive to Claudin-1 expression than nAb resistant transmission 
(Fig.5.14C). Of note silencing Claudin-1 expression also reduced Occludin 
expression (Fig.5.14B). Therefore the observed reduction in transmission may 
have resulted from a reduction in both Claudin-1 and Occludin expression. To 
date no research has previously looked at the role of Occludin in HCV co-
culture transmission. No antibodies are available to block Occludin function in 
HCV entry; therefore to investigate the role of Occludin in co-culture 
transmission Occludin expression was silenced in the target cells. nAb 
resistant and nAb sensitive transmission to occludin silenced target cells 
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compared to parental cells was equally reduced, suggesting that Occludin is 
important for both routes of transmission (Fig.5.15).  
 
Our data suggests that SR-BI expression may be a limiting factor for nAb 
resistant cell-to-cell HCV transmission. A mutant virus, JFH-1 G451R, that 
was previously reported to be relatively SR-BI independent (175), 
demonstrated minimal nAb resistant compared to nAb sensitive transmission 
(Fig.5.12). Furthermore small molecular inhibitors targeting SR-BI and an anti-
SR-BI antibody blocked significantly greater levels of nAb resistant compared 
to nAb sensitive transmission (Table 5.1). This was demonstrated with a large 
panel of HCV genotypes and occurred in the presence of antibodies targeting 
different epitopes and polyclonal IgG purified from HCV infected patient sera. 
Suggesting these observations were not a result of a synergy between a 
specific anti-E2 antibody and a specific SR-BI targeting antibody or molecule.  
Further to this over expressing SR-BI in target cells promoted viral infection 
and specifically nAb resistant transmission (Fig.5.11A). Our laboratory 
previously published that over expression of SR-BI increased foci size of 
infection compared to control, further supporting our findings that SR-BI 
expression may be particularly important for nAb resistant cell-to-cell 
transmission (175).  We hypothesized that silencing SR-BI would specifically 
reduce nAb resistant transmission compared to nAb sensitive transmission. 
However silencing SR-BI expression in the target cell reduced both routes of 
transmission equally (Fig.5.11D). Silencing SR-BI has previously been shown 
to modulate membrane cholesterol levels and CD81 localisation reducing 
Plasmodium sporozite infection of hepatocytes (523). It is also reported that 
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cholesterol depletion reduces CD81 expression, perturbs CD81-Claudin-1 
association and reduces HCVpp and HCVcc entry (188, 235, 402). CD81 
directly associates with membrane cholesterol (78) it is therefore not 
surprising that cholesterol levels may modulate CD81 and its function in HCV 
entry. Cholesterol has also been shown to be important in other stages of the 
HCV life cycle including replication and particle assembly and release (209, 
236, 541). We found that total cholesterol levels were significantly reduced 
compared to control hepatoma cells following SR-BI silencing and CD81 cell 
surface expression was reduced (Fig.11.B,C&E). The cholesterol depletion 
may have altered CD81 localization in the plasma membrane, reducing 
epitope availability for the antibody and in turn lowering the detection level of 
cell surface CD81. Reduced cellular cholesterol may also increase CD81 
internalization as reported for tetraspanin CD82 (521).  It is therefore likely 
that silencing SR-BI may have numerous effects that reduce HCV 
transmission. Our results emphasize the important role SR-BI plays in Huh-
7.5 cells and that it is always important to consider indirect effects of silencing. 
We hypothesize that SR-BI may have an essential role in cell-to-cell spread of 
HCV in vivo and may be a good target for future therapeutics. Unlike other co-
receptors SR-BI is predominantly expressed in the liver, therefore reducing 
the opportunity for off-target effects.  
 
In conclusion we have observed in vitro the efficient transfer of HCV in the 
presence of neutralizing antibodies, indicating a possible mechanism by which 
HCV infection can persist in vivo. This has major consequences for the use of 
E2 specific antibodies as therapeutics and highlights receptors in particular 
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SR-BI as possible targets to inhibit nAb resistant transmission. Furthermore 
the co-culture system we have developed and used throughout this study may 
be a preferred system to use when determining efficacy of future therapeutics 
due to its high stringency compared to standard infectious assays. However it 
is important to remember that although HCV may transmit efficiently by a cell 
associated route within the host the release of cell free viral particles is 
essential for HCV to transmit from host to host.  
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6.0 Final Remarks 
 
 
Tetraspanin CD81 function in hepatoma biology: 
Actin polymerization dependent morphological changes were observed upon 
ligation of CD81 on the surface of hepatoma cells with immobilized IgG but 
not HCV sE2. This process was found to be highly dependent on cellular 
cholesterol levels, where both a decrease and an increase in total cholesterol 
perturbed anti-CD81 induced cell spread. Cholesterol interacts directly with 
CD81 and is reported to coordinate the localization of tetraspanins in TEMs 
(78, 402, 439, 521), suggesting that anti-CD81 induced spread is dependent 
on CD81 interactions with partner proteins. In chapter 3 we utilized the 
phenomenon of cell spread to investigate the involvement of different partner 
proteins and signaling pathways in CD81 function in hepatoma cells. Figure 
6.1 illustrates reported partner proteins of CD81. In chapter 4 functional 
assays were performed determining that CD81 does not play a role in 
hepatoma-ECM adhesion, however CD81 expression increases hepatoma 
cell migration and invasion. We postulate that our findings from chapter 3 may 
be useful for predicting possible mechanisms involved in CD81 induced 
hepatoma cell migration.  
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Figure 6.1: Schematic diagram of CD81 as part of a TEM.  
Diagram represents reported partner protein interactions of CD81 that may be 
occurring in TEM(s) present in hepatoma cell membranes. Image not drawn to 
scale.  
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Notably anti-CD81 induced hepatoma cell spread was dependent on the C 
terminus of CD81 (Fig.3.5), previously reported to contain a PDZ domain 
believed to permit association with actin-associated proteins Ezrin Radoxin 
Moesin (ERM) (95, 411).  Further to this CD81 co-localized with activated 
ERM proteins in hepatoma cells and anti-CD81 induced cell spread was 
dependent on ERM function (Fig.3.6). Our observations suggest the presence 
of a functional link between the CD81 C terminus and ERM proteins in 
hepatoma cells as illustrated in Figure 6.1. Importantly this association was 
not important for CD81 to function as an HCV co-receptor (data not shown). 
However we can speculate that the link between CD81 and the actin 
cytoskeleton through ERM proteins may be important for CD81 function in 
tumor cell migration. Indeed a number of reports have identified ERM protein 
Ezrin as an indicator of hepatoma cell metastasis potential (354, 543, 557).  
This has also been confirmed by in vivo studies of Ezrin expression in tumors 
of hepatitis B virus (HBV) infected HCC patients, where higher levels of Ezrin 
expression associate with a smaller tumour size and a higher frequency of 
metastasis (543).  
 
Immunoglobulin like proteins EWI-2 and EWI-F associate with CD81 and are 
reported to associate with ERM proteins. Interestingly their association with 
ERM proteins has been reported to negatively regulate cell migration (411). 
Our observations together with these reports suggest that the relationship 
between CD81, EWI-2, EWI-F and ERM is important in determining cellular-
migration potential.  
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Although previous reports have identified a number of different signaling 
cascades to be involved in CD81 function, inhibitors to these pathways had no 
observable effect on anti-CD81 induced cell spread (Fig.3.7-8). This may be 
explained by compensatory actions of different pathways. Interestingly 
inhibition of the large GTPase, dynamin, perturbed hepatoma cell spread 
suggesting an important role for dynamin in CD81 function (Fig.3.9). Dynamin 
is reported to play a role in HCV entry through its role in clathrin mediated 
endocytosis (287)(Farquar, submitted), however until now it has not been 
associated with tetraspanin function.  
 
A number of different integrin sub-units were detected on the surface of 
hepatoma cells, some of which have previously been identified to associate 
either directly or indirectly with CD81 (42, 75, 427, 481, 528). CD81 
expression or cell surface ligation did not modulate hepatma–ECM adhesion 
suggesting that CD81 is not involved in coordinating integrin function in 
hepatoma–ECM interactions (Fig.4.2). However, CD81 expression was 
observed to increase invasion of hepatoma cells (Fig.4.8), a process 
potentially coordinated through CD81’s association with integrins. Additional 
partner proteins not investigated in this study that could be involved in 
hepatoma invasion include the matrix metalloproteinase MT1-MMP. Lafleur et 
al., reported MT1-MMP to be stabilized by CD81 expression, promoting 
invasive potential (262).  
 
In summary, we have identified that CD81 expression increases hepatoma 
cell migration and invasion in vitro. We hypothesize that this may have 
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consequences for hepatoma carcinoma development in vivo, CD81 
expression levels could prove to be a useful marker for tumor progression. 
This is an area of research that has been paid little attention to in the past, our 
findings help justify this as an important area of research in the future.  CD81 
is ubiquitously expressed making it an unattractive target for therapeutics for 
fear of off target effects, and importantly we observed no inhibition of 
migration in response to ligation with soluble IgG (Fig.4.7). The later 
observation also makes it unlikely that HCV E2 binding to CD81 will modulate 
CD81 function in migration and invasion. Cholesterol levels, dynamin, ERM 
and CD81 C terminal function were all observed to be important in 
coordinating anti-CD81 induced hepatoma cell spread (Chapter 3) and may 
also be involved in CD81 function in hepatoma migration and invasion.  
 
HCV perturbation of anti-CD81 induced cell spread: 
Recombinant forms of truncated HCV E2 glycoprotein directly bind CD81 
(384), and HCV has been shown to bind sCD81 (30, 208) therefore we 
speculated as to whether HCV infection may modulate CD81 function in 
hepatoma cells. Interestingly HCV infection perturbed anti-CD81 induced 
hepatoma cell spread (Fig.3.11). CD81 expression levels were comparable for 
naïve and infected cells, eliminating this as a possible explanation for the 
attenuated spread (Fig.3.11). We hypothesized a number of possible 
mechanisms that could be responsible for this observation, illustrated in 
Figure 6.2. Firstly HCV engagement of CD81 may directly perturb CD81 
partner protein interactions (Fig.6.2A). Supporting this hypothesis viruses 
unable to associate with CD81 had no effect on anti-CD81 induced spread 
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(Fig.3.12). However the infection levels recorded for the cell populations 
expressing these viruses were relatively low, providing an alternative 
explanation for these results.  Secondly we hypothesized that modulation of 
CD81-ERM association/activation, or dynamin function including inhibition of 
down stream signaling pathways may be responsible (Fig.6.2B-D). For 
example HCV NS5A protein is reported to inhibit Syk kinase activity (220) and 
tyrosine phosphorylation of Ezrin upon CD81 ligation on B cells is dependent 
on Syk (95). Thus if this is also true for hepatoma cells, NS5A expression may 
be responsible for the observed perturbation. Lastly, we hypothesized that 
HCV modulation of cellular cholesterol levels may perturb anti-CD81 induced 
hepatoma cell spread (Fig.6.2E). Supporting this hypothesis an increase in 
total cellular cholesterol levels in HCV infected cells was recorded and 
elevated levels of cholesterol perturbed anti-CD81 induced cell spread 
(Fig.3.13).  
 
Given our earlier results implicating CD81 as a promoter for hepatoma cell 
migration and invasion we postulate that these findings might have 
consequences for HCV associated hepatoma carcinoma. 
 
 
205 
 
Figure 6.2: Possible mechanisms underlying HCV perturbation of CD81 
function in hepatoma cell spread.  
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HCV as a tumor promoter: 
An increase in hepatoma cell invasion was observed upon HCV infection in 
vitro, suggesting that HCV infection may directly increase the risk of 
developing HCC in vivo. As previously suggested this may be due to an 
alteration of CD81 function by HCV infection. However the processes involved 
in cell migration are extremely complex and are likely to be controlled through 
numerous mechanisms. Previous research in the HCV field has reported that 
expression of certain HCV proteins may be responsible for the development 
of HCC (17, 33, 89, 294, 330, 340), expression of HCV core protein for 
example was reported to increase HepG2 cell migration through modulation of 
E-cadherin levels (17). Until now no one has previously reported an increase 
in invasion potential of hepatoma cells upon expression of full-length 
replicating HCV virus.  
 
Stabilization of HIF-1α following HCV infection has been reported by a 
number of laboratories (191, 341, 400). The HIF transcription complex formed 
upon stabilization of HIF-1α is responsible for the transcription of numerous 
proteins involved in tumor cell progression and has recently been linked with 
the development of epithelial mesenchymal transition (EMT) (198, 534, 535). 
We postulated that stabilization of HIF-lα might be responsible for the 
observed increase in hepatoma cell invasion (Fig. 6.3). This was supported by 
our observations that HCV induced migration as well as hypoxia induced 
migration of Huh-7.5 cells was perturbed by HIF-1α inhibitor NSC-134754 
(Fig.4.11-12). A commonly known growth factor transcribed by the HIF 
transcription factor is VEGF. VEGF has previously been reported to be 
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responsible for increased angiogenesis, an extremely important process in 
tumor progression, as well as increased invasion potential of HepG2 cells 
(214, 423).  However our findings suggest that VEGF was not responsible for 
the increased invasion of HCV infected Huh-7.5 cells (Fig.4.10) and speculate 
that another HIF target gene may be responsible. Other target genes of the 
HIF transcription factor associated with migration and metastasis include the 
transcriptional factors TWIST and Snail, both of which have been 
demonstrated to be responsible for repressing E-cadherin expression and 
increasing invasion potential of cancer cells (309, 532, 533, 535). Chemokine 
receptor CXCR4 and matrix metalloproteinase’s including MMP2 are also 
reported to be targets of the HIF transcription factor and are implicated in 
mediating cancer cell invasion (19, 297, 379, 503). CXCR4 in particular is 
associated with hepatocellular carcinoma (44).  
 
We also observed inhibition of infection upon incubation with NSC-134754 
suggesting that HIF-1α stabilization may be fundamental for efficient HCV 
infection (Fig.3.13). In summary our research suggests that a HIF-1α inhibitor 
could be advantageous not only to prevent development of HCC but to also 
inhibit HCV infection.  
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Figure 6.3: Possible mechanism(s) for HCV induced hepatoma migration 
and tumor progression through stabilization of HIF-1α . 
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Neutralizing antibody resistant transmission of HCV: 
 
Finally we investigated nAb resistant transmission of HCV in vitro (Chapter 5). 
The results we obtained suggest that HCV transmits efficiently in co-culture 
via a cell contact and particle-dependent means of transmission that is highly 
insensitive to nAbs. This nAb resistant transmission is dependent on all co-
receptors previously shown to be essential for cell-free entry indicating the 
mechanism of entry is likely to be the same. Here we postulate possible 
mechanisms for this highly efficient neutralizing antibody resistant 
transmission.  
 
It is unlikely that HCV transmits through cell fusion events or formation of 
synctia, as demonstrated by many herpes viruses since this would negate the 
need for correct viral assembly and usage of viral co-receptors (415, 483). 
Huh-7.5 cells use in this study do not polarize (319). Consequently we were 
unable to determine whether tight junctions may be used to transmit virus as 
observed for other viruses such as Herpes Simplex Virus (HSV). HSV has 
been demonstrated to target virions to cell junctions of epithelial cells to 
promote transmission of infection (227). The liver is highly ordered and made 
up predominantly of hepatocytes that are highly polarized. HepG2 cells 
provide a model system to study hepatocyte polarity (319, 320). Unfortunately 
HepG2 cells have reduced permissivity to support HCV replication and are 
unsuitable for use in the co-culture assay (320). Future work is needed to 
investigate cell-to-cell transmission in a polarized cell line. In the current 
system with Huh-7.5 cells it is unlikely that HCV exploits cell junctions that are 
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impermeable to HCV glycoprotein targeting antibodies since we found 
differences in efficacy of antibodies able to inhibit co-culture HCV 
transmission. It is more likely that HCV transmits either through a virological 
synapse similar to those induced by HIV between T cells or through utilization 
of cellular protrusions for example filopodia, microvillus or nanotubes (337, 
415). See Figure 6.4 for illustrations of plausible routes of transmission.  
 
HIV and HTLV induce virological synapes between T-cells (216, 228, 362). 
These allow efficient transfer of virus but are still permeable to neutralizing 
antibodies (304). New techniques allowing visualization of virions have 
resulted in an increase in the number of viruses known to utilize cellular 
protrusions for intercellular transmission. Examples include HIV that has 
recently been shown to travel in nanotubes connecting T-cells allowing 
efficient transmission (452). This differs from murine leukemia virus (MLV) 
that attaches to receptors on filopodia of target cells where it then proceeds to 
travel along the surface using F-actin retrograde flow to reach the target cell 
body (432). A number of viruses including MLV remain associated with the 
cell surface once released and are directed to adjacent cells in a process 
called cell “surfing”, MLV has recently been shown to be assembled at sites of 
cell contact further increasing the efficiency of transmission (59, 304, 421, 
431). African Swine Fever virus and vaccinia viruses utilize cellular 
protrusions in a completely different way, actin tails propel the virions to 
neighbouring cells (106, 232). Interestingly vaccinia viruses use this system to 
propel themselves across infected cells until they reach naïve cells further 
increasing efficacy of transmission (116). 
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Filopodia are easily visible between our Huh-7.5 cells in co-culture (Fig.4.6) 
and have been shown to exist in vivo (202). A recent paper visualized HCV 
traveling along filopodia prior to endocytosis upon reaching the cell body (96). 
These findings support the theory that HCV may utilise a cell associated 
means of transmission including the use of filopodia to transmit effectively in 
co-culture and suggest that this may also be possible in vivo. We observed an 
apparent increase in dependence on co-receptor SR-BI during nAb resistant 
transmission (Fig.5.12-15). If filopodia or microvilli were indeed important for 
mediating nAb resistant transmission one would envisage that expression of 
SR-BI at these locations would be important. In support of this Peng et al., 
reported that SR-BI is found in clusters on microvili on a number of different 
cultured cell lines, and furthermore it is at these locations that SR-BI 
predominantly functions as a mediator for cholesterol trafficking between the 
cell and HDL particles (373).  
 
Transmission of viruses along cellular protrusions allows directed transfer of 
virions to neighbouring cells negating the rate limiting step of diffusion and in 
turn reducing exposure and time of exposure to neutralizing antibodies. These 
cell-associated routes may allow the highly neutralizing antibody resistant 
transmission we have observed for HCV in vitro. The crucial next step to 
further understand HCV cell-to-cell transmission is to visualize viral 
transmission in in vitro and in vivo studies.  
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Figure 6.4: Possible routes of HCV cell-to-cell transmission in co-
culture. 
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